Peptide inhibitors of interleukin-23 receptor

Abstract

The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease such as Crohn's disease or ulcerative colitis, psoriatic arthritis and psoriasis. The compounds have good physical and chemical stability in the gastrointestinal tract.

Description

[0001]PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR FIELD OF THE INVENTION The present invention relates to peptide inhibitors of interleukin-23 receptor (IL-23R), and to their medical use in the treatment and / or prevention of a variety of diseases, conditions or disorders, including inflammatory bowel disease (IBD), such as Crohn^s disease or ulcerative colitis, psoriasis, psoriatic arthritis, and other conditions and disorders described herein. BACKGROUND OF THE INVENTION Interleukin-23 (IL-23) is a heterodimeric cytokine composed of a unique p19 subunit and the p40 subunit of interleukin-12 (IL-12). IL-12 is a cytokine involved in the development of interferon-gamma (IFN- )-producing T helper 1 (Th1) cells. Although both IL-23 and IL- 12 contain the p40 subunit, they have different phenotypic properties. Animals deficient in IL-12 are susceptible to inflammatory autoimmune diseases, whereas IL-23 deficient animals are resistant. This is thought to be due to a reduced number of CD4+T cells producing interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor (TNF) in the central nervous system (CNS) of IL-23-deficient animals. Furthermore, in contrast to IL-12 which acts mainly on naive CD4+T cells, IL-23 preferentially acts on memory CD4+T cells. The receptor that binds IL-23 is the interleukin-23 receptor (IL-23R). IL-23R is a heterodimeric receptor composed of IL-12R 1 and IL-23R subunits. Binding of IL-23 to IL-23R activates the JAK-STAT signalling pathway: activating the Janus kinase (JAK) molecules JAK2 and tyrosine kinase 2 (TYK2), as well as the signal transducer and activator of transcription proteins (STATs) STAT1, STAT3, STAT4, and STAT5. STAT4 activation is substantially weaker and different DNA-binding STAT complexes form in response to IL-23 as compared with IL-12. IL-23R associates constitutively with JAK2 and in a ligand-dependent manner with STAT3. IL-23R is expressed on various adaptive and innate immune cells, including: T-helper 17 (Th17) cells, gamma-delta ( ) T cells, natural killer (NK) cells, dendritic cells, macrophages, and innate lymphoid cells. These cells are abundantly found in the intestine. In particular, the gene expression and protein levels of IL-23R at the intestine mucosal surface are found to be elevated in inflammatory bowel disease (IBD) patients. It is thought that IL-23 mediates this effect by promoting the development of a pathogenic CD4+T cell population that produces IL6, IL-17, and TNF. IL-23 production is enriched in the intestine, where it is believed to play a key role in regulating the balance between tolerance and immunity through both T-cell-dependent and independent pathways of intestinal inflammation through effects on Th1 and Th17- associated cytokines. IL-23 is also thought to restrain regulatory T-cell responses in the gut, favoring inflammation. Furthermore, IL-23R polymorphisms have been associated with susceptibility to inflammatory bowel diseases (IBDs), further establishing the critical role of the IL-23 pathway in intestinal homeostasis. Therefore, IL-23 is thought to play a crucial role in the pathogenesis of autoimmune inflammation and related diseases and disorders, such as multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel diseases (IBDs), e.g., ulcerative colitis and Crohn^s disease. Studies in acute and chronic mouse models of IBD have revealed a primary role of IL-23R and downstream effector cytokines in disease pathogenesis. The anti-IL-23 antibody Risankizumab (ABBV-006) has been approved for the treatment of inflammatory diseases, including psoriasis, psoriatic arthritis and Crohn^s disease, and is also being investigated for the treatment of ulcerative colitis. Protagonist Therapeutics, Inc. had the IL-23 antagonist peptide PTG-200 in Phase II clinical trials for Crohn's disease. Protagonist in collaboration with Janssen Biotech, Inc. also have two second generation IL-23 antagonist peptides in clinical trials: JNJ-77242113 (or JNJ-2113; formerly PN-235) for psoriasis; and PN-232. Protagonist have filed several patent applications in the area of IL-23R inhibitors: WO 2016 / 011208, WO 2017 / 011820, WO 2018 / 022937, WO 2018 / 136646, WO 2020 / 014646, WO 2021 / 007433, WO 2021 / 146441, WO 2021 / 146458, WO 2023 / 288017, WO 2023 / 288019, WO 2023 / 288028 and WO 2024 / 015958. Protagonist also disclose another peptide, Compound C, as an IL-23R inhibitor in WO 2016 / 011208, WO 2017 / 011820, and Sayago et al., 2018. Notably, only single bridging moieties are present in the peptides disclosed by the above Protagonist patent applications WO 2016 / 011208, WO 2017 / 011820, WO 2018 / 022937, WO 2018 / 136646, WO 2020 / 014646, WO 2021 / 007433, WO 2021 / 146441, WO 2021 / 146458, WO 2023 / 288028 and WO 2024 / 015958. None of these applications disclose the use of two bridging moieties to stabilise the peptide inhibitor of IL-23R. Kong et al., 2020 discloses the development of proteolytically resistant therapeutic peptides for oral administration. The authors generated peptides as inhibitors of coagulation Factor XIa and other peptides as gastrointestinal-protease resistant peptide antagonists of IL-23R. The peptides generated as antagonists of IL-23R comprised of two dithioether bridges (specifically 1,3-dithio-propan-2-one bridges) between two pairs of cysteine residues in the peptide chain. The authors identified peptide I5 as the most promising candidate for further development as an oral treatment of inflammatory disorders such as Crohn^s disease on the basis of IL-23R inhibition. WO 2023 / 288017 discloses bicyclic (and some tricyclic) peptide inhibitors of IL-23R. The peptides are up to 15 amino acid residues long, all of which have (at least) two bonds bridging between certain amino acid residues. WO 2023 / 288019 discloses lipidated peptide inhibitors of IL-23R. The peptides are up to 15 amino acid residues long, and either have one or two bonds bridging between certain amino acid residues. Of the peptides with two bridges, one is either a disulfide or dithioether bond and the other is an amide bond. Both applications propose the use of the inhibitors for the treatment of autoimmune inflammation and related diseases and disorders, including IBD, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. However, none of the bridges in the peptides disclosed in Kong et al., 2020, WO 2023 / 288017 and WO 2023 / 288019 ^ either by position, type of bond, and / or number of amino acid residues between the bridging amino acids ^ are the same as the present invention. Challenges still remain with respect to identifying stable and selective agents that preferentially target the IL-23 pathway, which can be used for the treatment of intestinal inflammation, such as intestinal bowel diseases, including Crohn^s disease, ulcerative colitis and related disorders. In particular, the inventors have identified the gastrointestinal stability and IL-23R potency of the peptides disclosed in Kong et al., 2020 could still be further improved for an orally dosed IL-23R peptide blocker. In particular, the most- promising candidate, peptide I5 from Kong et al., 2020, exhibited a lower stability under a simulated intestinal fluid (SIF) assay and a lower potency for IL-23R in comparison with Protagonist^s Compound C (Sayago et al., 2018). Therefore, there remains a need for new therapeutics targeting the IL-23 pathway, which may be used to treat and prevent IL-23-associated diseases, including those associated with autoimmune inflammation in the intestinal tract. Furthermore, compounds and methods for specific targeting of IL-23R from the luminal side of the gut may provide therapeutic benefit to IBD patients suffering from local inflammation of the intestinal tissue. The inventors have also filed WO 2023 / 099669 directed to peptide inhibitors of IL-23R. The present invention is directed to further peptide inhibitors with improved stability in the gastrointestinal tract and / or more potent inhibition of IL-23R than the peptides disclosed in WO 2023 / 099669. SUMMARY OF THE INVENTION The present invention relates to compounds which are peptide inhibitors of interleukin-23 receptor (IL-23R). These compounds exhibit a good combination of properties such as highly potent inhibition of IL-23R and / or high stability in the gastrointestinal tract. Furthermore, the compounds described herein may be useful in the treatment of various diseases, conditions and disorders related to IL-23R such as inflammatory bowel disease, Crohn^s disease, ulcerative colitis, and psoriasis. The compounds described herein may also exhibit improved properties as compared to the compounds disclosed in WO2023 / 099669. The present invention addresses these needs by providing novel peptide inhibitors that bind IL-23R to inhibit IL-23 mediated signalling. The novel peptide inhibitors are also suitable for oral administration due to their stability in the gastrointestinal tract. In a first aspect, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta-Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta- Dpr, (N3)-homo-Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D- beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, (N3)-Asp, D-(N3)-Asp, (N3)-beta-Asp, (N3)-D-beta- Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta-Glu, (N3)-homo-Glu, (N3)-D-homo-Glu, (N3)-beta-homo-Glu, 2-amino-6-carboxyhexanoyl and 3-aminopropanoyl; X3 is selected from any amino acid, -hydroxy-C2-6alkanoic acid or is absent; X4 is Val, D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo-Val, 2-Me-Val, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile or is absent; X5 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, and an optionally substituted beta- homotryptophan residue; X6 is selected from the group consisting of an optionally substituted Gln residue, an optionally substituted Lys residue, an optionally substituted Arg residue, an optionally substituted Dab residue, an optionally substituted Orn residue, an optionally substituted Phe residue, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N- Me-Ala, N-Me-homo-Ala, Cit, D-Cit, beta-Cit, D-beta-Cit, homo-Cit, D-homo-Cit, beta- homo-Cit, N-Me-Cit, N-Me-homo-Cit, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Tyr, D-Tyr, beta-Tyr, D-beta-Tyr, homo-Tyr, D-homo-Tyr, beta-homo-Tyr, N-Me-Tyr, N-Me-homo-Tyr, Val, D- Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo- Val or His, D-His, beta-His, D-beta-His, homo-His, D-homo-His, beta-homo-His, N-Me-His and N-Me-homo-His; X7 is selected from the group consisting of Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D- beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-Lys, iso-Lys, beta-Lys, D-iso-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Pra, D-Pra, beta-Pra, D-beta-Pra, homo-Pra, D-homo-Pra, beta-homo-Pra, N-Me-Pra, N- Me-homo-Pra, Hpg, D-Hpg, beta-Hpg, D-beta-Hpg, homo-Hpg, D-homo-Hpg, beta-homo-Hpg, N-Me-Hpg and N-Me-homo-Hpg; X8 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted beta- homotryptophan residue, an optionally substituted tyrosine residue, an optionally substituted phenylalanine residue, an optionally substituted homophenylalanine residue, and an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted; X9 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted alanine residue, an optionally substituted phenylalanine and an optionally substituted tyrosine residue; X10 is selected from the group consisting of, Val, D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N- Me-homo-Val, 2-Me-Val, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Aib, D-Aib, beta-Aib, D-beta-Aib, homo-Aib, D-homo-Aib, beta-homo-Aib, N-Me-Aib, N- Me-homo-Aib, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile, and a carbocyclic or heterocyclic ring having an amino substituent and a carbonyl substituent; X11 is selected from the group consisting of Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Lys(Me), Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of an optionally substituted Phe residue, an optionally substituted Tyr residue, an optionally substituted His residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo- Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, Gly, beta-Gly, homo-Gly, beta-homo- Gly, N-Me-Gly, N-Me-homo-Gly, Pro, 5-aminopentanoyl,4-aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, 3-aminopropanoyl, Gly-CF3, D-Gly-CF3, Nle, Gln, D-Gln, iso-Gln, D-iso-Gln, beta-Gln, D-beta-Gln, homo-Gln, D-homo-Gln, beta-homo-Gln, N-Me- Gln, N-Me-homo-Gln, THP, Ser, D-Ser, beta-Ser, D-beta-Ser, homo-Ser, D-homo-Ser, beta-homo-Ser, N-Me-Ser, N-Me-homo-Ser, Ser(OMe), 3-aminotetrahydrofuran-3- carbonyl, Arg, D-Arg, beta-Arg, D-beta-Arg, homo-Arg, D-homo-Arg, beta-homo-Arg, N- Me-Arg, N-Me-homo-Arg, , Thr, D-Thr, beta-Thr, D-beta-Thr, homo-Thr, D-homo-Thr, beta-homo-Thr, N-Me-Thr, N-Me-homo-Thr Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D- beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Asn, D- Asn, beta-Asn, D-beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me- homo-Asn, 4-aminobutanoyl, 2-(trimethyl-2-aminoethoxy)ethoxy]propyl and Lys wherein the side chain -NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of an optionally substituted His residue, an optionally substituted Phe residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Asn, D-Asn, beta-Asn, D- beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me-homo-Asn, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, and Dab, Orn or Lys wherein the side chain -NH K 2 is substituted with -C(=O)(CH2)nR wherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In a second aspect, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D- iso-Glu, Orn, D-Orn, Dpr, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, N-Me-3-aminopropanoyl, and Ser, or is absent; X4 is Val or is absent; X5 is selected from the group consisting of Trp, 1-Me-Trp, and beta-homo-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, D-Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, and Cyclopropyl-Ala; X9 is 2-Nal or Cyclopropyl-Ala; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, Lys, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, beta-homo-Glu, Dab, iso- Dab, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, 5-aminopentanoyl, 4- aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain - NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3- (3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound is of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Ia: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Ia) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Trp, Ile, 3-aminopropanoyl, 4- aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, 3- hydroxypropanoic acid or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln, Gln(Me), Dab(Ac-N-Me), Dab(Ac) or Gln(2Me); X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), Y(2- aminoethoxy)(N(Me)2), Y(nPentylamine)(N+(Me)3), Y(2-trimethyl-PEG2), F(4-Me), F(4- Bu), Cyclopropyl-Ala, F(4-morpholine), F(4-THP), Y(CH3-2-F), F(4-F), F(4-piperazine), F(4-imidazole), Y(CH3-3-F), F(4piperidine), 5-AzaTrp, Y(Ac-2-aminoethoxy), 7-AzaTrp, 6- AzaTrp, F(4-CONH2); X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, D-Ala, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, S(OCH3), D-His, His(1-Me), 3-(3- Quinolinyl)-Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound is of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Ia: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Ia) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4- Bu), and Cyclopropyl-Ala; X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(3-Quinolinyl)- Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the lactam bridge between X2 and X11 uses the side chain of the amino acid residue at X2, and the bridge between X2 and X7 uses the N-terminus of the amino acid residue at X2. In some embodiments, X2 is Lys. In some embodiments, X3 is selected from the group consisting of Thr, Ile, and 3- aminopropanoyl, or is absent. In some embodiments, X4 is absent. In some embodiments, X5 is Trp. In some embodiments, X7 is Glu. In some embodiments, X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me). In some embodiments, X8 is Y(2-aminoethoxy). In some embodiments, X9 is 2-Nal. In some embodiments, X10 is 2-Me-Leu or 2-Me-Val. In some embodiments, X10 is 2- Me-Leu. In some embodiments, X11 is Glu. In some embodiments, X12 is Dab. In some embodiments, X13 is 3-(3-Pyridyl)-Ala or is absent. In some embodiments, X13 is 3-(3-Pyridyl)-Ala. In some embodiments, R2is NHR3wherein R3is hydrogen or C1-6 alkyl. In some embodiments, R2is NH2. In some embodiments, R2is NHMe. In some embodiments, X2 is Lys; X5 is Trp; X9 is 2-Nal; and X10 is 2-Me-Leu. In some embodiments, X2 is Lys; X5 is Trp; X9 is 2-Nal; X10 is 2-Me-Leu; and R2is NH2or NHMe. In some embodiments, X2 is Lys; X5 is Trp; X9 is 2-Nal; X10 is 2-Me-Leu; X13 is 3-(3- Pyridyl)-Ala or is absent, and R2is NH2or NHMe. In some embodiments, X2 is Lys; X5 is Trp; X7 is Glu; X9 is 2-Nal; X10 is 2-Me-Leu; X13 is 3-(3-Pyridyl)-Ala or is absent, and R2is NH2or NHMe. In some embodiments, Z is an amino acid sequence selected from the group consisting of a sequence listed in Table 1-1a. In some embodiments, the compound is selected from a compound from Table 1-1, or a pharmaceutically acceptable salt or solvate thereof. The invention further provides a composition comprising a compound as described above. The composition may be a pharmaceutical composition, and may comprise a pharmaceutically acceptable carrier, excipient or vehicle. The invention further provides a method for the synthesis of a compound as described above. The method may comprise the steps of synthesising the peptide by solid-phase or liquid-phase methodology, and optionally isolating and / or purifying the final product, and optionally further comprising the step of forming an amide bond between the amino acid residues at positions X2 and X11, and optionally further comprising the step of forming an amide bond, or forming a triazole between the amino acid residues at positions X2 and X7, and optionally further comprising the step of forming an amide bond between the amino acid residues at positions X10 and X13. The invention further provides a compound of the invention, or a pharmaceutical composition comprising said compound, for use in a method of medical treatment. The invention also provides a compound of the invention, or a pharmaceutical composition comprising said compound, for use in a method of prevention or treatment of inflammatory bowel disease (IBD) such as Crohn^s Disease or ulcerative colitis, psoriasis, psoriatic arthritis, and combinations thereof. In some embodiments, the condition is inflammatory bowel disease (IBD) and / or psoriasis. The invention also provides use of a compound of the invention, or the pharmaceutical composition comprising said compound, in the manufacture of a medicament for the prevention or treatment of inflammatory bowel disease (IBD) such as Crohn^s Disease or ulcerative colitis, psoriasis, psoriatic arthritis, and combinations thereof. In some embodiments, the condition is inflammatory bowel disease (IBD) and / or psoriasis. The invention also provides a method of prevention or treatment of inflammatory bowel disease (IBD) such as Crohn^s Disease or ulcerative colitis, psoriasis, psoriatic arthritis, and combinations thereof; which comprises administering to the subject a therapeutically effective amount of the compound of the invention, or the pharmaceutical composition comprising said compound. In some embodiments, the condition is inflammatory bowel disease (IBD) and / or psoriasis. Further aspects and embodiments of the present invention will become apparent from the disclosure below. DETAILED DESCRIPTION OF THE INVENTION Definitions Unless otherwise defined herein, scientific and technical terms used herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature employed herein in connection with techniques of chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry, described herein, is that well known and commonly used in the art. All publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control. Throughout this specification, the word ^comprise^ or variations such as ^comprises^ or ^comprising^ will be understood to imply the inclusion of a stated integer or component, or of a stated group of integers or components, but not the exclusion of any other integer or component or group of integers or components. The singular forms ^a^, ^an^, and ^the^ include the plurals unless the context clearly dictates otherwise. The term ^including^ is used to mean ^including but not limited to^. ^Including^ and ^including but not limited to^ are used interchangeably. The terms ^patient^, ^subject^, and ^individual^ may be used interchangeably and may refer to either a human or a non-human animal. Subjects are typically mammals, including humans, non-human primates (including great apes, Old World monkeys and New World monkeys), livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats). As used herein, the term ^pharmaceutically acceptable salt^ is intended to indicate a salt which is not harmful to a patient or subject to which the salt in question is administered. It may suitably be a salt chosen, e.g., among acid addition salts and basic salts. Examples of acid addition salts include chloride salts, citrate salts and acetate salts. Examples of basic salts include salts where the cation is selected among alkali metal cations, such as sodium or potassium ions, alkaline earth metal cations, such as calcium or magnesium ions, as well as substituted ammonium ions, such as ions of the type N(R1)(R2)(R3)(R4)+, where R1, R2, R3and R4independently will typically designate hydrogen, optionally substituted C1-6-alkyl or optionally substituted C2-6-alkenyl. Examples of relevant C1-6-alkyl groups include methyl, ethyl, 1-propyl and 2-propyl groups. Examples of C2-6-alkenyl groups of possible relevance include ethenyl, 1-propenyl and 2-propenyl. Other examples of pharmaceutically acceptable salts are described in ^Remington^s Pharmaceutical Sciences^, 17thedition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, PA, USA, 1985 (and more recent editions thereof), in the ^Encyclopaedia of Pharmaceutical Technology^, 3rdedition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY, USA, 2007, and in J. Pharm. Sci.66: 2 (1977). The term ^solvate^ in the context of the present invention refers to a complex of defined stoichiometry formed between a solute (in casu, a peptide or pharmaceutically acceptable salt thereof according to the invention) and a solvent. The solvent in this connection may, for example, be water, ethanol or another pharmaceutically acceptable - typically small- molecular - organic species, such as, but not limited to, acetic acid or lactic acid. When the solvent in question is water, such a solvate is normally referred to as a hydrate. The terms ^antagonist^ and ^inhibitor^ as employed in the context of the invention refers to a substance that inhibits the receptor type in question, typically by binding to it (i.e. as a ligand) and blocking it. Each embodiment of the invention described herein may be taken alone or in combination with one or more other embodiments of the invention. The term ^therapeutically effective amount^ or ^effective amount^ as used herein in the context of the above-described methods of treatment or other therapeutic interventions according to the invention refers to an amount that is sufficient to cure, ameliorate, alleviate or partially arrest the clinical manifestations of the particular disease, disorder or condition that is the object of the treatment or other therapeutic intervention in question e.g. as measured by established clinical endpoints or other biomarkers (established or experimental). A therapeutically relevant amount may be determined empirically by one skilled in the art based on the indication being treated or prevented and the subject to whom the therapeutically relevant amount is being administered. For example, the skilled worker may measure one or more of the clinically relevant indicators of bioactivity described herein, e.g. myeloperoxidase (MPO), interleukin-1 (IL-1 ), interleukin-6 (IL-6), interleukin-22 (IL-22), interleukin-17A (IL-17A), interleukin-17F (IL-17F), lipocalin 2 (LCN2), matrix metallopeptidase 9 (MMP9), S100 calcium-binding protein A8 (S100A8), microRNA-223-3p (miR223-3p), Claudin 8 (CLDN8), and phosphorylated signal transducer and activator of transcription 3 (pSTAT3) proteins, polynucleotides encoding any of the proteins, and polynucleotides comprising a region complementary to microRNA-223-3p or any of the polynucleotides that encode any of the proteins, as described in WO 2018 / 089693. The skilled worker may determine a clinically relevant amount through in vitro or in vivo measurements. An amount adequate to accomplish any or all of these effects is defined as a therapeutically effective amount. The administered amount and the method of administration can be tailored to achieve optimal efficacy. An amount effective for a given purpose will depend, inter alia, on the severity of the disease, disorder or condition that is the object of the particular treatment or other therapeutic intervention, on the body weight and general condition of the subject in question, on diet, on possible concurrent medication, and on other factors well known to those skilled in the medical arts. Determination of an appropriate dosage size and dosing regimen most appropriate for administration of a peptide or pharmaceutically acceptable salt or solvate thereof according to the invention to a human may be guided by the results obtained by the present invention, and may be confirmed in properly designed clinical trials. An effective dosage and treatment protocol may be determined by conventional means, starting with a low dose in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well. Numerous factors may be taken into consideration by a clinician when determining an optimal dosage for a given subject. Such considerations are well known to the skilled person. The terms "treatment" and grammatical variants thereof (e.g. ^treated^, ^treating^, ^treat^) as employed in the present context refer to an approach for obtaining beneficial or desired clinical results. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilization (i.e. not worsening) of state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival relative to expected survival time if not receiving treatment. A subject (e.g. a human) in need of treatment may thus be a subject already afflicted with the disease or disorder in question. The term ^treatment^ includes inhibition or reduction of an increase in severity of a pathological state or symptoms (e.g. inflammation) relative to the absence of treatment, and is not necessarily meant to imply complete cessation of the relevant disease, disorder or condition. The terms "prevention" and grammatical variants thereof (e.g., ^prevented^, ^preventing^, ^prevent^) as employed in the present context refer to an approach for hindering or preventing the development of, or altering the pathology of, a condition, disease or disorder. Accordingly, "prevention" may refer to prophylactic or preventive measures. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, prevention or slowing of symptoms, progression or development of a disease, whether detectable or undetectable. A subject (e.g. a human) in need of ^prevention^ may thus be a subject not yet afflicted with the disease or disorder in question. The term ^prevention^ thus includes inhibiting or slowing the onset of disease relative to the absence of treatment, and is not necessarily meant to imply permanent prevention of the relevant disease, disorder or condition. Amino acids nomenclature The term ^amino acid^ is an organic compound that, in isolation, contains an amino or amine group (-NH2 or -NHR) and a carboxylic acid (-COOH) group. As is known to the person skilled in the art, the amine and carboxylic acid groups of amino acid residues react together to form peptides having an amide bond, also referred to as a peptide linkage, of the formula ^NH-C(=O)- or ^NR-C(=O)-. The term ^amino acid^ is thus not limited to including natural and unnatural alpha and beta amino-acids but also includes (when forming part of a peptide) residues such as 3- aminopropanoyl and 4-aminobutanoyl. The term also includes cyclic structures such as carbocyclic and heterocyclic structures, having an amine and a carboxylic acid functionality. The amine group of the amino acid may be further functionalised, such as an azide group (-N3), for example in (N3)-Lys or D-(N3)-Lys. Some amino acids described herein have the amine and carboxylic acid groups attached to the same carbon, called alpha ( ) amino acids. Some amino acids described herein have the amine and carboxylic acid groups 1, 2, 3, 4, 5, or 6 carbon atoms away. For example, beta-Lys and D-beta-Lys have the amine and the carboxylic acid groups are 1 carbon away from each other, such that the carbon connected to the amine group and the carbon connected to the carboxylic acid group are adjacent to one another. Some amino acids described herein have a side chain specific to each amino acid. The side chain may also be further functionalised. Throughout the present specification, unless naturally occurring amino acids are referred to by their full name (e.g. alanine, arginine, etc.), they are designated by their conventional three-letter or single-letter abbreviations (e.g. Ala or A for alanine, Arg or R for arginine, etc.). In the case of certain less common or non-naturally occurring amino acids (i.e. amino acids other than the 20 encoded by the standard mammalian genetic code), unless they are referred to by their full name (e.g. ornithine, etc.), frequently employed three- or four-character codes are employed for residues thereof, including 2-Nal (3-(2-naphthyl)- alanine). Unless otherwise indicated, reference is made to both the L and D-isomeric forms of the amino acids in question. In one embodiment, unless otherwise stated, the amino acids referred to herein are in their L isomeric form. In one embodiment, unless otherwise stated, the amino acids referred to herein are in their D isomeric form. In a preferred embodiment, unless otherwise stated, the amino acids referred to herein are in their L isomeric form. Unless otherwise indicated, reference is made to both the homo and non-homo forms of the amino acids in question. As evident from Table A below, the prefix ^homo^ to the name of an amino acid indicates the addition of a methylene group to the -carbon of an amino acid. In one embodiment, unless otherwise stated, the amino acids referred to herein are in their non-homo form. In one embodiment, unless otherwise stated, the amino acids referred to herein are in their homo-form. In a preferred embodiment, unless otherwise stated, the amino acids referred to herein are in their non-form. Unless otherwise indicated, reference is made to both the alpha and beta forms of the amino acids in question. As evident from Table A below, the prefix ^beta^ to the name of an amino acid indicates that the carbon skeleton has been lengthened by insertion of one carbon atom immediately after the acid group of the amino acid backbone. In one embodiment, unless otherwise stated, the amino acids referred to herein are in their alpha form. In one embodiment, unless otherwise stated, the amino acids referred to herein are in their beta-form. In a preferred embodiment, unless otherwise stated, the amino acids referred to herein are in their alpha form. Amino acid residues are amino acid moieties within a peptide chain. Unnatural amino acid residues may be identified as the fragment of the unnatural amino acid defined in a peptide chain (for example, the unnatural amino acid 3-aminopropanoic acid may be identified as the unnatural amino acid residue 3-aminopropanoyl in a peptide chain). Additional exemplary abbreviations for amino acid residues are described in Table A. Table A Amino Acid Residue Structure D-Lys or {d}K also known as: D-lysine or (2R)-2,6-diaminohexanoic acid beta-Lys or bLys also known as: L-beta-lysine or (3S)-3,6-diaminohexanoic acid D-beta-Lys or {d}bLys also known as: D-beta-lysine or (3R)-3,6-diaminohexanoic acid homo-Lys or hLys also known as: L-homolysine or (2S)-2-amino-7-amino- heptanoic acid D-homo-Lys or {d}hLys also known as: D-homolysine or (2R)-2-amino-7-amino- heptanoic acid beta-homo-Lys or beta-hLys H2N OH also known as: NH2O L-beta-homolysine, L- -homolysine, or (3S)-3,7-diaminoheptanoic acid N-Me-Lys also known as: N2-methyl-L-lysine or (2S)-6-amino-2-(methylamino)hexanoic acid Amino Acid Residue Structure Dab (also iso-Dab ^ see Table B) also known as: (2S)-2,4-diaminobutanoic acid D-Dab Also known as {d}Dab or D-2,4-diaminobutanoic acid or (2R)-2,4-diaminobutanoic acid D-Glu (also D-iso-Glu ^ see Table B) also known as: D-glutamic acid Orn also known as: L-ornithine or (2S)-2,5-diaminopentanoic acid D-Orn also known as: D-ornithine or (2R)-2,5-diaminopentanoic acid Dpr also known as: 3-amino-L-alanine or (2S)-2,3- diaminopropanoic acid Cit Also known as: Citrulline 2-Amino-5-(carbamoylamino)pentanoic acid Amino Acid Residue Structure Lys(Gly) or K(G) also known as: (2S)-2-amino-6-[(2- aminoacetyl)amino]hexanoic acid (N3)-Lys or (N3)-K also known as: (2S)-6-amino-2-azido-hexanoic acid D-(N3)-Lys or {d}(N3)-K also known as: (2R)-6-amino-2-azido-hexanoic acid 3-aminopropanoic acid 4-aminobutanoic acid Also known as: GABA, Gamma-aminobutyric acid beta-homo-Ile or beta-hIle also known as: L-beta-homoisoleucine, L- - homoisoleucine, or (3R,4S)-3-amino-4-methyl-hexanoic acid beta-homo-Thr or beta-hThr also known as: L-beta-homothreonine, L- - homothreonine, or (3R,4R)-3-amino-4-hydroxy-pentanoic acid N-Me-3-aminopropanoic acid Amino Acid Residue Structure 1-Me-Trp also known as: 1-methyl-L-tryptophan or (2S)-2-amino-3-(1-methylindol-3- yl)propanoic acid beta-homo-Trp or beta-hTrp also known as: L-beta-homotryptophan, L- - homotryptophan, or (3S)-3-amino-4-(1H-indol-3-yl)butanoic acid homo-Glu or hGlu also known as: L-homoglutamic acid or (2S)-2- aminohexanedioic acid Pra also known as: L-propargylglycine or (2S)-2-aminopent-4- ynoic acid Hpg also known as: L-homopropargylglycine or (2S)-2- aminohex-5-ynoic acid Y(2-aminoethoxy) also known as: (2S)-2-amino-3-[4-(2- aminoethoxy)phenyl]propanoic acid Amino Acid Residue Structure Y(Me) also known as: 4-methoxy-L-phenylalanine, or (2S)-2-amino-3-(4- methoxyphenyl)propanoic acid Y(nPr) also known as: (2S)-2-amino-3-(4- propoxyphenyl)propanoic acid Y(Bn) also known as: (2S)-2-amino-3-(4- benzyloxyphenyl)propanoic acid D-Phe or {d}F also known as: D-phenylalanine or (2R)-2-amino-3- phenyl-propanoic acid 2-Me-Phe also known as: alpha-methyl-L-phenylalanine, -methyl-L- phenylalanine, or (2S)-2-amino-2-methyl-3-phenylpropanoic acid F(4-Me) also known as: 4-methyl-L-phenylalanine or (2S)-2-amino-3-(p-tolyl)propanoic acid Amino Acid Residue Structure F(4-Bu) also known as: butyl-L-phenylalanine, 4-butyl-L- phenylalanine, or (2S)-2-amino-3-(4-butylphenyl)propanoic acid 3-(2-Pyridyl)-Ala also known as: 3-(2-pyridyl)-L-alanine, or (2S)-2-amino-3-(pyridin-2-yl)propanoic acid 3-(3-Pyridyl)-Ala also known as: 3-(3-pyridyl)-L-alanine, 3-Pal, or (2S)-2-amino-3-(pyridin-3-yl)propanoic acid 3-(4-Pyridyl)-Ala also known as: 3-(4-pyridyl)-L-alanine, or (2S)-2-amino-3-(pyridin-4-yl)propanoic acid Cyclopropyl-Ala also known as: cyclopropyl-L-alanine or (2S)-2-amino-3-cyclopropyl-propanoic acid 2-Nal also known as: 3-(2-naphthyl)-L-alanine or (2S)-2-amino-3-(2-naphthyl)propanoic acid Amino Acid Residue Structure 2-Me-Leu also known as: 2-methyl-L-leucine, alpha-methylleucine, -methylleucine, or (2S)-2-amino-2,4-dimethylpentanoic acid 2-Me-Val also known as: 2-methyl-L-valine, alpha-methylvaline, - methylvaline, or (2S)-2-amino-2,3-dimethylbutanoic acid Aib also known as: 2-aminoisobutyric acid, alpha- methylalanine, 2-methylalanine, or 2-amino-2-methyl- propanoic acid beta-homo-Glu or beta-hGlu also known as: L-beta-homoglutamic acid, L- - homoglutamic acid, or (3S)-3-aminohexanedioic acid Lys(Me) or K(Me) also known as: N6-methyl-L-lysine or (2S)-2-amino-6-(methylamino)hexanoic acid 2-amino-6-carboxyhexanoic acid Amino Acid Residue Structure D-His or {d}H also known as: D-histidine or (2R)-2-amino-3-(1H-imidazol-4- yl)propanoic acid His(1-Me) or H(1-Me) or His(Me) or H(Me) also known as: 1-methyl-L-histidine or (2S)-2-amino-3-(1-methylimidazol-4- yl)propanoic acid 3-(3-Quinolinyl)-Ala also known as: 3-(3-quinolinyl)-L-alanine or (2S)-2-amino-3-(3-quinolyl)propanoic acid 5-aminopentanoic acid 4-aminopiperidin-4-carboxylic acid (R,S)-Imidazolidin-2-carboxylic acid K(piconilate) also known as: (2S)-2-amino-6-(pyridine-2- carbonylamino)hexanoic acid Amino Acid Residue Structure K(2-pyridylacetyl) also known as: (2S)-2-amino-6-[[2-(2- pyridyl)acetyl]amino]hexanoic acid K(2-pyridylpropionyl) also known as: (2S)-2-amino-6-[3-(2- pyridyl)propanoylamino]hexanoic acid K(nicotinate) also known as: (2S)-2-amino-6-(pyridine-3- carbonylamino)hexanoic acid K(3-pyridylacetyl) also known as: (2S)-2-amino-6-[[2-(3- pyridyl)acetyl]amino]hexanoic acid K(3-pyridylpropionyl) also known as: (2S)-2-amino-6-[3-(3- pyridyl)propanoylamino]hexanoic acid K(isonicotinyl) also known as: (2S)-2-amino-6-(pyridine-4- carbonylamino)hexanoic acid Amino Acid Residue Structure K(4-pyridylacetyl) also known as: (2S)-2-amino-6-[[2-(4- pyridyl)acetyl]amino]hexanoic acid K(4-pyridylpropionyl) also known as: (2S)-2-amino-6-[3-(4- pyridyl)propanoylamino]hexanoic acid K(3,5-pyrimidine) also known as: (2S)-2-amino-6-(pyrimidine-5- carbonylamino)hexanoic acid K(4-pyridyl-3-fluoroacetyl) also known as: (2S)-2-amino-6-[[2-(2-fluoro-4- pyridyl)acetyl]amino]hexanoic acid K(Imidazoleacetyl) also known as: (2S)-2-amino-6-[[2-(2H-imidazol-2- yl)acetyl]amino]hexanoic acid K(Imidazolepropanoyl) also known as: (2S)-2-amino-6-[3-(2H-imidazol-2- yl)propanoylamino]hexanoic acid Amino Acid Residue Structure D-3-(3-Pyridyl)-Ala or {d}3-(3-Pyridyl)-Ala also known as: 3-(3-pyridyl)-D-alanine, D-3-Pal, or (2R)-2-amino-3-(pyridin-3-yl)propanoic acid 3-(3,5-Pyrimidyl)-Ala also known as: (2S)-2-amino-3-pyrimidin-5-yl-propanoic acid Q(Me) Also known as: N5-L-Methylglutamine, or (2S)-2-amino-5- (methylamino)-5-oxopentanoic acid F(4-morpholine) also known as: 4-morpholine-L-phenylalanine or (2S)-2-Amino-3-(4-morpholin-4- ylphenyl)propanoic Acid Dab(Ac-N-Me) Dab(Ac) D-Ala or {d}A Also known as: (R)-2-Aminopropionic acid Amino Acid Residue Structure F(4-THP) Also known also 4-tetrahydropyran-L-phenylalanine (2S)-2-Amino-3-(4-tetrahydropyranyl-4- ylphenyl)propanoic Acid S(Me) Also known as: O-Methyl-L-serine Y(CH3-2-F) Also known as: 4-methoxy-2-fluoro-L-phenylalanine, or (2S)-2-amino-3-(4-methoxy-2- fluorophenyl)propanoic acid F(4-F) Also known as: 4-fluoro-L-phenylalanine, or (2S)-2-amino-3-(4 fluorophenyl)propanoic acid F(4-piperazine) also known as: 4-piperazine-L-phenylalanine or (2S)-2-Amino-3-(4-piperazin-4- ylphenyl)propanoic Acid F(4-imidazole) O also known as: OH 4-imidazole-L-phenylalanine or NH N2(2S)-2-Amino-3-(4- N imidazolylphenyl)propanoic Acid Amino Acid Residue Structure Y(CH3-3-F) Also known as: 4-methoxy-3-fluoro-L-phenylalanine, or (2S)-2-amino-3-(4-methoxy-3- fluorophenyl)propanoic acid F(4-piperidine) also known as: 4-piperidine-L-phenylalanine or (2S)-2-Amino-3-(4-piperidin-4- ylphenyl)propanoic Acid 5-AzaTrp Also known as: 5-Aza-L-tryptophan (S)-2-amino-3-(1H-pyrrolo[3,2-c]pyridin-3- yl)propanoic acid O H N Y(Ac-2-aminoethoxy) OH O NH O27-AzaTrp Also known as: 7-Aza-L-tryptophan (S)-2-Amino-3-(1H-pyrrolo[2,3-b]pyridin-3- yl)-propionic acid 6-AzaTrp Also known as: 6-Aza-L-tryptophan 3-hydroxy propanoic acid Amino Acid Residue Structure O F(4-CONH2) OH H2N NH2O D-Trp or {d}W Also known as: D-Tryptophan (R)-2-Amino-3-(3-indolyl)propionic acid, D- -Amino-3-indolepropionic acid Q(2Me) Also known as: N,N, dimethyl--L-glutamine ((2S)-2-amino-5-(dimethylamino)-5- oxopentanoic acid Y(2-aminoethoxy)(N(Me)2) Y(nPentylamine)(N+(Me)3) Y(2-trimethyl-PEG2) (S)-2-(2-(2-(4-(2-amino-2- carboxyethyl)phenoxy)ethoxy)ethoxy)- N,N,N-trimethylethan-1-aminium Using the above Table A and the below Table A1, the skilled person would be able to derive the structure of any D, beta, homo, homo-beta, N-Me and N3 analogues (and combinations thereof) of the amino acid residues disclosed herein. In particular, Table A1 outlines the relevant analogues for a lysine amino acid, which can subsequently be applied to derive the corresponding structures for any equivalent amino acid analogue disclosed herein. Table A1 Amino Acid Residue Structure Lys Also known as L-lysine or (2S)-2,6-Diaminohexanoic acid (L-lysine) D-Lys or {d}K also known as: D-lysine or (2R)-2,6-diaminohexanoic acid beta-Lys or bLys also known as: L-beta-lysine or (3S)-3,6-diaminohexanoic acid D-beta-Lys or {d}bLys also known as: D-beta-lysine or (3R)-3,6-diaminohexanoic acid homo-Lys or hLys also known as: L-homolysine or (2S)-2-amino-7-amino-heptanoic acid D-homo-Lys or {d}hLys also known as: D-homolysine or (2R)-2-amino-7-amino-heptanoic acid beta-homo-Lys or beta-hLys H2N OH also known as: NH2O L-beta-homolysine, L- -homolysine, or (3S)-3,7-diaminoheptanoic acid Amino Acid Residue Structure N-Me-Lys also known as: N2-methyl-L-lysine or (2S)-6-amino-2-(methylamino)hexanoic acid N-Me-homo-Lys also known as: N2-methyl-L-homolysine (N3)-Lys or (N3)-K also known as: (2S)-6-amino-2-azido-hexanoic acid D-(N3)-Lys or {d}(N3)-K also known as: (2R)-6-amino-2-azido-hexanoic acid Linear peptides are written from N-terminus to C-terminus, left to right. Unnatural (or non-naturally occurring) amino acids and unnatural (or non-naturally occurring) amino acid residues are amino acids and amino acid residues that do not naturally occur in peptide chains. Unnatural amino acids may be formed as secondary metabolites in bacteria, fungi, plants, or marine organisms, or they can be synthesised chemically. Unless otherwise stated, the peptide backbone (that is, the amide bonds ^-^ between X2- X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 in the peptide chain) is formed by the amino acid residues joined by amide bonds via their terminal -NH2and -COOH groups. That is, the ^terminal -NH2group^ is the alpha-amine group for alpha amino acids or beta-amine group for beta amino acids such as bLys, {d}bLys and beta-hLys; and the ^terminal - COOH group^ is the alpha-carboxylic acid group for the alpha amino acids. The skilled person thus understands that the amino acids within the peptide chains (i.e., those specified for at least X3, X4, X5, X6, X7, X8, X9, X10, X11 and X12) will be in the form ^ NH-X-C(=O)-, wherein X represents the amino acid structure between the amine and carboxylic acids residues that form the amide backbone of the peptide chain. Where the amino acid residue comprises two or more amine groups (-NH2, such as Lys and Dab) or carboxylic acid groups (-COOH, such as Glu and D-Glu), the peptide backbone may instead be formed using the side chain of the amino acid residue. For example, the following nomenclature is used to distinguish the use of the terminal and the side chain -NH2 and -COOH groups: Table B Amino Acid Residue Residue in peptide chain Iso-residue in peptide chain Lys / iso-Lys Lysiso-LysSide chain: -CH2CH2CH2CH2NH2 Dab / iso-Dab Dab iso-Dab Side chain: -CH2CH2NH2 Glu / iso-Glu Glu iso-Glu Side chain: -CH2CH2COOH D-Glu / D-iso-Glu D-Glu D-iso-Glu Side chain: -CH2CH2COOH It will be understood that the above Table B taken in conjunction with Table A and Table A1 can be used to derive the structures of any corresponding iso analogue disclosed herein. The C-terminus of the peptide may be derivatised with an alkyl group substituted with a pyridyl group to improve gastrointestinal stability (see Example 2). The following C- terminal derivatives are disclosed in Table C: Table C C-terminal Derivatisation (R2group) Structure 3-pyridylpropionyl 6-(3-pyridyl)hexanoyl NH-(2-(pyridin-3-yl)ethyl) NH-(4-(pyridin-3-yl)butanyl) NH-(6-(pyridin-3-yl)hexanyl) NH-(3-(pyridin-3-yl)propyl) For the NH-(2-(pyridin-3-yl)ethyl), NH-(4-(pyridin-3-yl)butanyl), NH-(6-(pyridin-3- yl)hexanyl), and NH-(3-(pyridin-3-yl)propyl) groups, these are attached to carbonyl carbon of the carboxylic acid group of the C-terminal amino acid residue, such as at Glu, beta- homo-Glu, and Dab. The attachment forms an amide bond. For the 3-pyridylpropionyl and 6-(3-pyridyl)hexanoyl groups, these are attached to amine group of the C-terminal amino acid residue, such as iso-Dab. The attachment forms an amide bond. Lactam A lactam is cyclic amide of formula cyclo(R-NH-C(=O)-R) wherein each R may be any other suitable functional group that joins to the other R. Each R may the the same or different. Thioether and dithioether A thioether is a functional group of the formula R-S-R, wherein R may be any other suitable functional group. A dithioether is a functional group comprising two thioether groups linked together by a linker, such as R-S-L-Y-L-S-R wherein the linker is -L-Y-L-. Head-to-tail cyclisation The term ^head-to-tail cyclisation^ is cyclisation of the N-terminal amine (or derivative thereof) and the C-terminal carboxylic acid to form a cyclic peptide. Typically, this cyclisation forms an amide bond. Alkyl The term "alkyl" refers to a monoradical of a saturated straight or branched hydrocarbon. Preferably, the alkyl group comprises from 1 to 40, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, carbon atoms, such as 1 to 30, such as 1 to 20 carbon atoms, such as 1 to 12 carbon atoms, such as 1 to 10 carbon atoms, such as 1 to 8 carbon atoms, such as 1 to 6 or 1 to 4 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, iso- propyl (also called 2-propyl or 1 methylethyl), butyl, iso-butyl, tert-butyl, n-pentyl, iso- pentyl, sec-pentyl, neo-pentyl, 1,2-dimethylpropyl, iso-amyl, n-hexyl, iso-hexyl, sec-hexyl, n-heptyl, iso-heptyl, n-octyl, 2-ethyl-hexyl, n-nonyl, ndecyl, n-undecyl, n-dodecyl, n- undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n- octadecyl, n-nonadecyl, n-icosyl, n-triacontyl, n-tetracontyl, and the like. A "substituted alkyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an alkyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the alkyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the alkyl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A. Examples of a substituted alkyl include chloromethyl, dichloromethyl, fluoromethyl, and difluoromethyl. C1-6 alkyl groups C1-6 alkyl groups that may be present as a group R2in the context of compounds of the present invention include, but are not limited to, C6 alkyl groups such as hexanyl (- CH2CH2CH2CH2CH2CH3), C5 alkyl groups such as pentanyl (-CH2CH2CH2CH2CH3), or C1-4 alkyl groups. C1-4 alkyl groups C1-4alkyl groups that may be present as a group R2in the context of compounds of the present invention include, but are not limited to, C4alkyl groups such as butyl (n-Bu or - CH2CH2CH2CH3), or C1-3alkyl groups, such as methyl (Me or -CH3, that is a C1alkyl group), ethyl (-CH2CH3, that is a C2alkyl group), 1-propyl (-CH2CH2CH3, that is a C3alkyl group), or 2-propyl (-CH(CH3)2, that is a C3alkyl group). C1-3alkyl groups C1-3alkyl groups that may be present as a group R2in the context of compounds of the present invention include methyl (Me or -CH3, that is a C1alkyl group), ethyl (-CH2CH3, that is a C2alkyl group), 1-propyl (-CH2CH2CH3, that is a C3alkyl group), and 2-propyl (- CH(CH3)2, that is a C3alkyl group). C1-2alkyl groups C1-2alkyl groups that may be present as a group R2in the context of compounds of the present invention include methyl (Me or -CH3, that is a C1alkyl group) and ethyl (-CH2CH3, that is a C2alkyl group). -hydroxy-C2-6alkanoic acid The residue at the X3 position herein may be a -hydroxy-C2-6 alkanoic acid. This residue can be represented by the following structure: wherein n is 1, 2, 3, 4 or 5. In some embodiments, n is selected from 1, 2 or 3, such that the -hydroxy-C2-6alkanoic acid is a -hydroxy-C2-4alkanoic acid. In some embodiments, n is 2 such that the - hydroxy-C2-6alkanoic acid is a -hydroxy-C3alkanoic acid such as 3-hydroxypropanoic acid. The term "alkylene" refers to a diradical of a saturated straight or branched hydrocarbon. Preferably, the alkylene group comprises from 1 to 40, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, carbon atoms, such as 1 to 30, such as 1 to 20 carbon atoms, such as 1 to 12 carbon atoms, such as 1 to 10 carbon atoms, such as 1 to 8 carbon atoms, such as 1 to 6 or 1 to 4 carbon atoms. Exemplary alkylene groups include methylene, ethylene (i.e., 1,1-ethylene, 1,2-ethylene), propylene (i.e., 1,1-propylene, 1,2-propylene (- CH(CH3)CH2-), 2,2-propylene (-C(CH3)2-), and 1,3-propylene), the butylene isomers (e.g., 1,1-butylene, 1,2-butylene, 2,2-butylene, 1,3-butylene, 2,3-butylene (cis or trans or a mixture thereof), 1,4-butylene, 1,1-iso-butylene, 1,2-iso-butylene, and 1,3-iso-butylene), the pentylene isomers (e.g., 1,1-pentylene, 1,2-pentylene, 1,3-pentylene, 1,4-pentylene, 1,5-pentylene, 1,1-iso-pentylene, 1,1-sec-pentyl, 1,1-neo-pentyl), the hexylene isomers (e.g., 1,1-hexylene, 1,2-hexylene, 1,3-hexylene, 1,4-hexylene, 1,5-hexylene, 1,6- hexylene, and 1,1-isohexylene), the heptylene isomers (e.g., 1,1-heptylene, 1,2- heptylene, 1,3-heptylene, 1,4-heptylene, 1,5-heptylene, 1,6-heptylene, 1,7-heptylene, and 1,1-isoheptylene), the octylene isomers (e.g., 1,1-octylene, 1,2-octylene, 1,3-octylene, 1,4-octylene, 1,5-octylene, 1,6-octylene, 1,7-octylene, 1,8-octylene, and 1,1-isooctylene), and the like. In one embodiment, alkylene is C1-20alkylene. In one embodiment, alkylene is C2-14alkylene. In one embodiment, alkylene is C3-9alkylene. In one embodiment, alkylene is C7-9alkylene. The straight alkylene moieties having at least 3 carbon atoms and a free valence at each end can also be designated as a multiple of methylene (e.g., 1,4-butylene can also be called tetramethylene). Generally, instead of using the ending "ylene" for alkylene moieties as specified above, one can also use the ending "diyl" (e.g., 1,2-butylene can also be called butan-1,2-diyl). A "substituted alkylene" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an alkylene group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the alkylene group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituent may be the same or different). In one embodiment, the alkylene is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A. C1-4 alkylene groups C1-4 alkylene groups that may be present as a group L of the dithioether bridge in the context of compounds of the present invention include, but are not limited to, C1-2alkylene groups, such as methylene (-CH2-, that is a C1alkylene group) and ethylene (-CH2CH2-, that is a C2alkylene group). Alkyleneoxy The term ^alkyleneoxy^ ^ means ^alkylene-O-^, wherein alkylene is defined and exemplified above. In one embodiment, alkyleneoxy means (C2-3)alkyleneoxy. In one embodiment, alkyleneoxy means (C2)alkyleneoxy (ethyleneoxy). In one embodiment, alkyleneoxy means (C3)alkyleneoxy (propyleneoxy). Carbocyclic and Heterocyclic Groups ^ Cycloalkyl, cycloalkylene, cycloalkenyl, cycloalkenylene, heterocyclyl The terms "cycloalkyl" and ^cycloalkenyl^ represents cyclic non-aromatic versions of "alkyl" and "alkenyl" with preferably 3 to 40, such as 3 to 30, such as 3 to 20, such as 3 to 14 carbon atoms, such as 3 to 12 or 3 to 10 carbon atoms, i.e., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms (such as 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms), more preferably 3 to 7 carbon atoms. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, and adamantyl. Exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl. The cycloalkyl or cycloalkenyl group may consist of one ring (monocyclic), two rings (bicyclic), or more than two rings (polycyclic). A "substituted cycloalkyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to a cycloalkyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the cycloalkyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the cycloalkyl or cycloalkenyl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituent selected from List A. The terms "cycloalkylene" and ^cycloalkenylene^ represents cyclic non-aromatic versions of "alkylene" and "alkenylene" with preferably 3 to 40, such as 3 to 30, such as 3 to 20, such as 3 to 14 carbon atoms, such as 3 to 12 or 3 to 10 carbon atoms, i.e., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms (such as 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms), more preferably 3 to 10 carbon atoms, such as 5 to 10 carbon atoms. In one embodiment, cycloalkylene is (C5-10)cycloalkylene. In one embodiment, cycloalkylene is (C3-10)cycloalkylene. In one embodiment, cycloalkenylene is (C3-10)cycloalkenylene. In one embodiment, cycloalkenylene is (C5-10)cycloalkenylene. Exemplary cycloalkylene groups include; cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, cyclooctylene, cyclononylene, and cyclodecylene. Exemplary cycloalkenylene groups include cyclopentenylene and cyclohexenylene. In one embodiment, the cycloalkylene or cycloalkenylene is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituent selected from List A. The term "heterocyclyl" or "heterocyclic ring" means a cycloalkyl group as defined above in which from 1, 2, 3, or 4 carbon atoms in the cycloalkyl group are replaced by heteroatoms of oxygen, nitrogen, silicon, selenium, phosphorus, or sulfur, preferably O, S, or N. A heterocyclyl group has preferably 1 or 2 rings containing from 3 to 10, such as 3, 4, 5, 6, or 7, ring atoms. Preferably, in each ring of the heterocyclyl group the maximum number of O atoms is 1, the 5 maximum number of S atoms is 1, and the maximum total number of O and S atoms is 2. The term "heterocyclyl" is also meant to encompass partially or completely hydrogenated forms (such as dihydro, tetrahydro or perhydro forms) of the above-mentioned heteroaryl groups. Exemplary heterocyclyl groups include morpholinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl (also called piperidyl), piperazinyl, di- and tetrahydrofuranyl, di- and tetrahydrothienyl, di- and tetrahydropyranyl, urotropinyl, lactones, lactams, cyclic imides, and cyclic anhydrides. A "substituted heterocyclyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to a heterocyclyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the heterocyclyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the heterocyclyl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A. Aromatic Groups ^ Aryl, heteroaryl, arylene, heteroarylene The term "aryl" refers to a monoradical of an aromatic cyclic hydrocarbon. Preferably, the aryl group contains 3 to 14 (e.g., 5, 6, 7, 8, 9, or 10, such as 5, 6, or 10) carbon atoms which can be arranged in one ring (e.g., phenyl) or two or more condensed rings (e.g., naphthyl). Exemplary aryl groups include cyclopropenylium, cyclopentadienyl, phenyl, indenyl, naphthyl, azulenyl, fluorenyl, anthryl, and phenanthryl. Preferably, "aryl" refers to a monocyclic ring containing 6 carbon atoms or an aromatic bicyclic ring system containing 10 carbon atoms. Preferred examples are phenyl and naphthyl. Aryl does not encompass fullerenes. A "substituted aryl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an aryl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 5 or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the aryl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the aryl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituent selected from List A. Examples of a substituted aryl include biphenyl, 2-fluorophenyl, 2-chloro-6-methylphenyl, anilinyl, 4-hydroxyphenyl, and methoxyphenyl (i.e., 2-, 3-, or 4-methoxyphenyl). The term "heteroaryl" or "heteroaromatic ring" means an aryl group as defined above in which one or more carbon atoms in the aryl group are replaced by heteroatoms of O, S, or N. Preferably, heteroaryl refers to a five or six-membered aromatic monocyclic ring wherein 1, 2, or 3 carbon atoms are replaced by the same or different heteroatoms of O, N, or S. Alternatively, it means an aromatic bicyclic or tricyclic ring system wherein 1, 2, 3, 4, or 5 carbon atoms are replaced with the same or different heteroatoms of O, N, or S. Preferably, in each ring of the heteroaryl group the maximum number of O atoms is 1, the maximum number of S atoms is 1, and the maximum total number of O and S atoms is 2. Exemplary heteroaryl groups include furanyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, 1H- indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, benzodiazinyl, quinoxalinyl, quinazolinyl, benzotriazinyl, pyridazinyl, phenoxazinyl, thiazolopyridinyl, pyrrolothiazolyl, phenothiazinyl, isobenzofuranyl, chromenyl, xanthenyl, pyrrolizinyl, indolizinyl, indazolyl, purinyl, quinolizinyl, phthalazinyl, naphthyridinyl, cinnolinyl, pteridinyl, carbazolyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, and phenazinyl. Exemplary 5- or 6-memered heteroaryl groups include furanyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, imidazolyl (e.g., 2-imidazolyl), pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl (e.g., 4-pyridyl), pyrimidinyl, pyrazinyl, triazinyl, and pyridazinyl. A "substituted heteroaryl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to a heteroaryl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the heteroaryl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the heteroaryl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A. The term "arylene" refers to a diradical of an aromatic cyclic hydrocarbon. Preferably, the aryl group contains 3 to 14 (e.g., 5, 6, 7, 8, 9, or 10, such as 5, 6, or 10) carbon atoms which can be arranged in one ring (e.g., phenyl) or two or more condensed rings (e.g., naphthyl). Preferably, "arylene" is C5-14arylene. More preferably, "arylene" is C6-14arylene. Even more preferably "arylene" is C6-10arylene, which refers to a monocyclic ring containing 6 carbon atoms or an aromatic bicyclic ring system containing 10 carbon atoms. Preferably, "arylene" refers to a monocyclic ring containing 6 carbon atoms or an aromatic bicyclic ring system containing 10 carbon atoms. Preferred examples are phenylene (which may be 1,2-phenylene, 1,3-phenylene or 1,4-phenylene) and naphthylene (which may be 1,2-naphthylene, 1,3-naphthylene, 1,4-naphthylene, 1,5- naphthylene, 1,6-naphthylene, 1,7-naphthylene or 1,8-naphthylene). Optional substituents A number of the amino acid residues described herein may be optionally substituted. In some embodiments, the substituent is selected from the group defined by List A below. In some embodiments, the substituent is selected from the group defined by List A1 below. In some embodiments, the substituent is selected from the group defined by List A2 below. ^List A^ substituents are selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 6- to 14-membered (such as 6- to 10-membered) aryl, 3- to 14-membered (such as 5- or 6- membered) heteroaryl, 3- to 14-membered (such as 3- to 7-membered) cycloalkyl, 3- to 14-membered (such as 3- to 7-membered) heterocyclyl, halogen, -CN, azido, -NO2, -OR^, -N(R^)2, -S(O)0-2R^, -S(O)1-2OR^, -OS(O)1-2R^, -OS(O)1-2OR^, -S(O)1- 2N(R^)2, -OS(O)1-2N(R^)2, -N(R^)S(O)1-2R^, -N(R^)S(O)1-2OR^, -C(=X1)R^, -C(=X1)X1R^, - X1C(=X1)R^, and -X1C(=X1)X1R^, wherein X1is independently selected from O, S, NH and N(CH3); and each R^ is independently selected from the group consisting of H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, 5- or 6-membered cycloalkyl, 5- or 6-membered aryl, 5- or 6- membered heteroaryl, and 5- or 6-membered heterocyclyl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl groups is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-3 alkyl, halogen, -CF3, -CN, azido, -NO2, -OH, -O(C1-3 alkyl), -S(C1-3 alkyl), -NH2, -NH(C1-3 alkyl), -N(C1-3 alkyl)2, -N+(C1-3 alkyl)3, -NHS(O)2(C1-3 alkyl), -S(O)2NH2-z(C1-3 alkyl)z, -C(=O)OH, -C(=O)O(C1-3 alkyl), -C(=O)NH2-z(C1-3 alkyl)z, -NHC(=O)(C1-3 alkyl), - NHC(=NH)NHz-2(C1-3 alkyl)z, and -N(C1-3 alkyl)C(=NH)NH2-z(C1-3 alkyl)z, wherein each z is independently 0, 1, or 2 and each C1-3alkyl is independently methyl, ethyl or propyl, In some embodiments, List A substituents are selected from List A1, consisting of C1-3alkyl, phenyl, halogen, -CF3, -OH, -OCH3, -SCH3, -NH2-z(CH3)z, -C(=O)OH, C(=O)OCH3and -C(=O)CH3, wherein z is 0, 1, or 2 and C1-3alkyl is methyl, ethyl, propyl or isopropyl. In some embodiments, List A substituents are selected from List A2, consisting of C(=O)CH3, methyl, ethyl, propyl, isopropyl, halogen (such as F, Cl, or Br), and -CF3. Bridging moieties The sequences disclosed herein containing bridging moieties noted in the rounded brackets (e.g., (1a), (2a), etc.). These represent chemical bridges between the specific residue pairs. Each rounded bracket will appear twice in the sequence as a pair to indicate a single bridging moiety. Most of the sequences have two bridging moieties, indicated by 4 sets of rounded brackets meaning two bridging moiety pairs. The number in the rounded bracket indicates a specific bridging moiety pair (e.g. ^1^ indicates a bridge between amino acid residues at positions 2 and 11, which is also indicated by the square bracket notation defining the specific chemical bridge). The letter indicates the type of chemical bridge (e.g. ^a^ indicates a 1,3-dithio-propan-2-one bridge whilst ^c^ indicates a lactam bridge). The specific chemical bridge is defined at the end of the tables, using a square bracket (e.g. [2,11], [2,7], [10,13] etc.) to indicate the amino acid residues using in the bridging moiety as compared to the original starting peptide (the I3 peptide (isomer 3) as described in Example 2 of WO2023 / 099669), so these may not line-up specifically with the actual amino acid numbering of the SEQ ID NO: (as in some of these sequences for example, the first amino acid residue had been deleted as compared to the original starting peptide). The residue directly preceding the rounded bracket notation indicates that specific residue is used in the bridging moiety. The ^^^ notation directly after the rounded bracket notation indicates that the alpha-amine (-NH2) group (or beta-amine group for bLys, {d}bLys and beta-hLys, or the alpha-amine has been converted into an azide group for (N3)-K and {d}(N3)-K) is used to form the bridge. The notation directly after the rounded bracket notation indicates that the alpha- carboxylic acid (-COOH) group is used to form the bridge. Both the alpha-amine (-NH2) group (or beta-amine group for bLys, {d}bLys and beta-hLys) and the alpha-carboxylic acid (-COOH) group is conventionally used to form the peptide backbone (see, e.g., Table B). The ^*^ notation directly after the rounded bracket notation indicates that the terminal -NH2 (if at the start of the sequence i.e. the N-terminus) or -COOH (if at the end of the sequence i.e. the C-terminus) is used to form the bridge. When the bridging moiety is a triazole and the ^*^ notation is used on the N-terminus, the terminal -NH2has been converted to an azide (-N3) of the N-terminal amino acid residue. SMILES strings The Simplified Molecular-Input Line-Entry System (SMILES) strings are provided below the structures described by the amino acid sequence for each of the compounds disclosed herein. A SMILES string is a line notation for describing the structure of chemical species using short American Standard Code for Information Interchange (ASCII) strings. SMILES strings can be imported by most molecule editors (e.g. ChemDraw®, BIOVIA Draw) for conversion back into two-dimensional or three- dimensional drawings of the chemical structure. Where there is a discrepancy between the structure of the amino acid sequence and the structure provided by the SMILES string, the SMILES string prevails. Compounds The invention provides compounds which are peptide inhibitors of IL-23R. These compounds exhibit a good combination of properties such as highly potent inhibition of IL- 23R and / or high stability in the gastrointestinal tract (see Example 3). Furthermore, the compounds described herein may be useful in the treatment of various diseases, conditions and disorders related to IL-23R such as inflammatory bowel disease, such as Crohn^s disease or ulcerative colitis, psoriasis and psoriatic arthritis. The compounds described herein exhibit improved properties (such as more potent inhibition and / or higher gastrointestinal tract stability) as compared to the compounds disclosed in WO2023 / 099669. The invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta-Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta- Dpr, (N3)-homo-Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D- beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, (N3)-Asp, D-(N3)-Asp, (N3)-beta-Asp, (N3)-D-beta- Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta-Glu, (N3)-homo-Glu, (N3)-D-homo-Glu, (N3)-beta-homo-Glu, 2-amino-6-carboxyhexanoyl and 3-aminopropanoyl; X3 is selected from any amino acid, -hydroxy-C2-6alkanoic acid or is absent; X4 is Val D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo-Val, 2-Me-Val, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile or is absent; X5 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, and an optionally substituted beta- homotryptophan residue; X6 is selected from the group consisting of an optionally substituted Gln residue, an optionally substituted Lys residue, an optionally substituted Arg residue, an optionally substituted Dab residue, an optionally substituted Orn residue, an optionally substituted Phe residue, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N- Me-Ala, N-Me-homo-Ala, Cit, D-Cit, beta-Cit, D-beta-Cit, homo-Cit, D-homo-Cit, beta- homo-Cit, N-Me-Cit, N-Me-homo-Cit, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Tyr, D-Tyr, beta-Tyr, D-beta-Tyr, homo-Tyr, D-homo-Tyr, beta-homo-Tyr, N-Me-Tyr, N-Me-homo-Tyr, Val, D- Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo- Val or His, D-His, beta-His, D-beta-His, homo-His, D-homo-His, beta-homo-His, N-Me-His and N-Me-homo-His; X7 is selected from the group consisting of Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D- beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-Lys, iso-Lys, beta-Lys, D-iso-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Pra, D-Pra, beta-Pra, D-beta-Pra, homo-Pra, D-homo-Pra, beta-homo-Pra, N-Me-Pra, N- Me-homo-Pra, Hpg, D-Hpg, beta-Hpg, D-beta-Hpg, homo-Hpg, D-homo-Hpg, beta-homo-Hpg, N-Me-Hpg and N-Me-homo-Hpg; X8 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted beta- homotryptophan residue, an optionally substituted tyrosine residue, an optionally substituted phenylalanine residue, an optionally substituted homophenylalanine residue, and an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted; X9 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted alanine residue, an optionally substituted phenylalanine and an optionally substituted tyrosine residue; X10 is selected from the group consisting of, Val, D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N- Me-homo-Val, 2-Me-Val, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Aib, D-Aib, beta-Aib, D-beta-Aib, homo-Aib, D-homo-Aib, beta-homo-Aib, N-Me-Aib, N- Me-homo-Aib, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile, and a carbocyclic or heterocyclic ring having an amino substituent and a carbonyl substituent; X11 is selected from the group consisting of Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Lys(Me), Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of an optionally substituted Phe residue, an optionally substituted Tyr residue, an optionally substituted His residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo- Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, Gly, beta-Gly, homo-Gly, beta-homo- Gly, N-Me-Gly, N-Me-homo-Gly, Pro, 5-aminopentanoyl,4-aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, 3-aminopropanoyl, Gly-CF3, D-Gly-CF3, Nle, Gln, D-Gln, iso-Gln, D-iso-Gln, beta-Gln, D-beta-Gln, homo-Gln, D-homo-Gln, beta-homo-Gln, N-Me- Gln, N-Me-homo-Gln, THP, Ser, D-Ser, beta-Ser, D-beta-Ser, homo-Ser, D-homo-Ser, beta-homo-Ser, N-Me-Ser, N-Me-homo-Ser, Ser(OMe), 3-aminotetrahydrofuran-3- carbonyl, Arg, D-Arg, beta-Arg, D-beta-Arg, homo-Arg, D-homo-Arg, beta-homo-Arg, N- Me-Arg, N-Me-homo-Arg, , Thr, D-Thr, beta-Thr, D-beta-Thr, homo-Thr, D-homo-Thr, beta-homo-Thr, N-Me-Thr, N-Me-homo-Thr Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D- beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Asn, D- Asn, beta-Asn, D-beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me- homo-Asn, 4-aminobutanoyl, 2-(trimethyl-2-aminoethoxy)ethoxy]propyl and Lys wherein the side chain -NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of an optionally substituted His residue, an optionally substituted Phe residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Asn, D-Asn, beta-Asn, D- beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me-homo-Asn, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, and Dab, Orn or Lys wherein the side chain -NH2 is substituted with -C(=O)(CH2)nRK wherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Ia: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Ia) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Trp, Ile, 3-aminopropanoyl, 4- aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, 3- hydroxypropanoic acid or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln, Gln(Me), Dab(Ac-N-Me), Dab(Ac) or Gln(2Me); X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4- Bu), Cyclopropyl-Ala, F(4-morpholine), F(4-THP), Y(CH3-2-F), F(4-F), F(4-piperazine), F(4-imidazole), Y(CH3-3-F), F(4piperidine), 5-AzaTrp, Y(Ac-2-aminoethoxy), 7-AzaTrp, 6- AzaTrp, F(4-CONH2); X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, D-Ala, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, S(OCH3), D-His, His(1-Me), 3-(3- Quinolinyl)-Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D- iso-Glu, Orn, D-Orn, Dpr, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, N-Me-3-aminopropanoyl, and Ser, or is absent; X4 is Val or is absent; X5 is selected from the group consisting of Trp, 1-Me-Trp, and beta-homo-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, D-Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, and Cyclopropyl-Ala; X9 is 2-Nal or Cyclopropyl-Ala; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, Lys, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, beta-homo-Glu, Dab, iso- Dab, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, 5-aminopentanoyl, 4- aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain - NH2 of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3- (3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. The invention also provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Ia: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Ia) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4- Bu), and Cyclopropyl-Ala; X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(3-Quinolinyl)- Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. The invention also provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula II: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (II) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D- iso-Glu, Orn, D-Orn, Dpr, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, N-Me-3-aminopropanoyl, and Ser, or is absent; X4 is Val or is absent; X5 is selected from the group consisting of Trp, 1-Me-Trp, and beta-homo-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, D-Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, and Cyclopropyl-Ala; X9 is 2-Nal or Cyclopropyl-Ala; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, Lys, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, beta-homo-Glu, Dab, iso- Dab, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, 5-aminopentanoyl, 4- aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain - NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3- (3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention also provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula IIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IIa) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4- Bu), and Cyclopropyl-Ala; X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(3-Quinolinyl)- Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the above formulae wherein Z is an amino acid sequence of any one of the above formulae I, Ia, II, and IIa, wherein the lactam bridge between X2 and X11 uses the side chain of the amino acid residue at X2, and the bridge between X2 and X7 uses the N-terminus of the amino acid residue at X2. In such embodiments, X2 is selected from the group consisting of Lys, D-Lys, beta- Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, Orn, D-Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula III: [Lys]-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (III) wherein X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula IIIa: [Lys]-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IIIa) wherein X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula IV: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IV) wherein X3 is selected from the group consisting of Thr, Ile, and 3-aminopropanoyl, or is absent; X2, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula IVa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IVa) wherein X3 is selected from the group consisting of Thr, Ile, and 3-aminopropanoyl, or is absent; X2, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula V: X2-X3-X5-X6-X7-X8-X9-X10-X11-X12-X13 (V) wherein X2, X3, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Va: X2-X3-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Va) wherein X2, X3, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula VI: X2-X3-X4-[Trp]-X6-X7-X8-X9-X10-X11-X12-X13 (VI) wherein X2, X3, X4, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula VIa: X2-X3-X4-[Trp]-X6-X7-X8-X9-X10-X11-X12-X13 (VIa) wherein X2, X3, X4, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula VII: X2-X3-X4-X5-X6-[Glu]-X8-X9-X10-X11-X12-X13 (VII) wherein X2, X3, X4, X5, X6, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) the Glu at X7 forms a lactam bridge with the amino acid residue at X2; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula VIIa: X2-X3-X4-X5-X6-[Glu]-X8-X9-X10-X11-X12-X13 (VIIa) wherein X2, X3, X4, X5, X6, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) the Glu at X7 forms a lactam bridge with the amino acid residue at X2; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula VIII: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (VIII) wherein X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me); X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula VIIIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (VIIIa) wherein X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me); X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula IX: X2-X3-X4-X5-X6-X7-[Y(2-aminoethoxy)]-X9-X10-X11-X12-X13 (IX) wherein X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula IX: X2-X3-X4-X5-X6-X7-[Y(2-aminoethoxy)]-X9-X10-X11-X12-X13 (IX) wherein X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula X: X2-X3-X4-X5-X6-X7-X8-[2-Nal]-X10-X11-X12-X13 (X) wherein X2, X3, X4, X5, X6, X7, X8, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Xa: X2-X3-X4-X5-X6-X7-X8-[2-Nal]-X10-X11-X12-X13 (Xa) wherein X2, X3, X4, X5, X6, X7, X8, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XI: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (XI) wherein X10 is 2-Me-Leu or 2-Me-Val; X2, X3, X4, X5, X6, X7, X8, X9, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XI as defined above; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XII: X2-X3-X4-X5-X6-X7-X8-X9-[2-Me-Leu]-X11-X12-X13 (XII) wherein X2, X3, X4, X5, X6, X7, X8, X9, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XII as defined above; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XIII: X2-X3-X4-X5-X6-X7-X8-X9-X10-[Glu]-X12-X13 (XIII) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Glu at X11 forms a lactam bridge with the amino acid residue at X2; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XIIIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-[Glu]-X12-X13 (XIIIa) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Glu at X11 forms a lactam bridge with the amino acid residue at X2; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XIV: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-[Dab]-X13 (XIV) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XIVa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-[Dab]-X13 (XIVa) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XV: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (XV) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XVa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (XVa) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XVI: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-[3-(3-Pyridyl)-Ala] (XVI) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, the 3-(3-Pyridyl)-Ala at X13 forms a lactam bridge with the amino acid residue at X10; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XVIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-[3-(3-Pyridyl)-Ala] (XVIa) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XVII: [Lys]-X3-X4-[Trp]-X6-X7-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XVII) wherein X3, X4, X6, X7, X8, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula XVIIa: [Lys]-X3-X4-[Trp]-X6-X7-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XVIIa) wherein X3, X4, X6, X7, X8, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-NH2 or Z-NHMe wherein Z is an amino acid sequence of any one of the formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa, VIII, VIIIa, IX, IXa, X, Xa, XI, XII, XIII, XIIIa, XIV, XIVa, XV, XVa, XVI, XVIa, XVII, and XVIIa as defined above; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-NH2or Z-NHMe wherein Z is an amino acid sequence of formula XVIII: [Lys]-X3-X4-[Trp]-X6-X7-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XVIII) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X3, X4, X6, X7, X8, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound of the formula: Z-NH2 or Z-NHMe wherein Z is an amino acid sequence of formula XIX: [Lys]-X3-X4-[Trp]-X6-[Glu]-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XIX) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X3, X4, X6, X8, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 and the Glu at X7 together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the invention provides a compound selected from a compound in Table 1-1, or a pharmaceutically acceptable salt or solvate thereof. In previously disclosed compounds that are inhibitors of IL-23R, such as those disclosed in WO2023 / 099669, any internal truncation, that is deletion of amino acid residues, between X2 and X11 led to inactive compounds (see reference compounds Ref 5, Ref 6, and Ref 7 in Example 2 of WO2023 / 099669). However, the inventors have now observed that certain deletions between X2 and X11 of the presently disclosed compounds, such as at X3 and / or X4, is tolerated and may even improve the potency and / or gastrointestinal stability and / or bioavailability of the compounds disclosed herein (see Example 2 below). It will be understood that the invention encompasses salts and solvates of the compounds. Suitable salts and solvates of peptides are known in the art. It will also be understood any of the following references to embodiments may be applicable and are combinable with any of the formulae described herein. R2R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent. In some embodiments, R2is absent. In some such embodiments, X13 is present and forms a lactam bridge with the amino acid residue at X10. In some embodiments, R2is NHR3wherein R3is hydrogen or C1-6alkyl. In some embodiments, R2is NHR3wherein R3is hydrogen or C1-5alkyl. In some embodiments, R2 is NHR3wherein R3is hydrogen or C1-4alkyl. In some embodiments, R2is NHR3wherein R3is hydrogen or C1-3alkyl. In some embodiments, R2is NHR3wherein R3is hydrogen or C1-2alkyl. In some embodiments, R2is NHR3wherein R3is hydrogen or C1alkyl (methyl or Me). In some embodiments, R2is NHR3wherein R3is C1-6alkyl optionally substituted with a pyridyl ring. In some such embodiments, the R2group is attached to carbonyl carbon of the carboxylic acid group of the C-terminal amino acid residue. The C-terminal amino acid may be Glu, beta-homo-Glu, or Dab. In some embodiments, R2is NHR3wherein R3is C1-6 alkyl optionally substituted with a pyridyl ring. In some embodiments, R2is NHR3wherein R3is C1-6 alkyl optionally substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is C1-6 alkyl substituted with a pyridyl ring. In some embodiments, R2is NHR3wherein R3is C1-6 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is C6 alkyl substituted with a pyridyl ring. In some embodiments, R2is NHR3wherein R3is C6 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is hexanyl (that is, -CH2CH2CH2CH2CH2CH3) substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is -CH2CH2CH2CH2CH2CH2(pyrid-3-yl). That is, NHCH2CH2CH2CH2CH2CH2(pyrid-3-yl) or NH-(6-(pyridin-3-yl)hexanyl). The group NH-(6- (pyridin-3-yl)hexanyl) has the structure: . In some embodiments, R2is NHR3wherein R3is C4 alkyl substituted with a pyridyl ring. In some embodiments, R2is NHR3wherein R3is C4 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is n-Bu substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is -CH2CH2CH2CH2(pyrid-3-yl). That is, NHCH2CH2CH2CH2(pyrid-3-yl) or NH-(4-(pyridin-3-yl)butanyl). The group NH-(4-(pyridin- 3-yl)butanyl) has the structure: . In some embodiments, R2is NHR3wherein R3is C3 alkyl substituted with a pyridyl ring. In some embodiments, R2is NHR3wherein R3is C3 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is n-Pr substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is -CH2CH2CH2(pyrid-3-yl). That is, NHCH2CH2CH2(pyrid-3-yl) or NH-(3-(pyridin-3-yl)propyl). The group NH-(3-(pyridin-3- yl)propyl) has the structure: . In some embodiments, R2is NHR3wherein R3is C2 alkyl substituted with a pyridyl ring. In some embodiments, R2is NHR3wherein R3is C2 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is ethyl (Et) substituted with a pyrid-3-yl ring. In some embodiments, R2is NHR3wherein R3is -CH2CH2(pyrid-3-yl). That is, NHCH2CH2(pyrid-3-yl) or NH-(2-(pyridin-3-yl)ethyl). The group NH-(2-(pyridin-3-yl)ethyl) has the structure: . In some embodiments, R2is C(=O)R3, wherein R3is C1-6 alkyl optionally substituted with a pyridyl ring. In some embodiments, R2is C(=O)R3, wherein R3is C1-6alkyl optionally substituted with a pyrid-3-yl ring. In some such emdodiments, the R2group is attached to amine group of the C-terminal amino acid residue. The C-terminal amino acid may be iso- Dab. In some embodiments, R2is C(=O)R3wherein R3is C1-6alkyl optionally substituted with a pyridyl ring. In some embodiments, R2is C(=O)R3wherein R3is C1-6alkyl optionally substituted with a pyrid-3-yl ring. In some embodiments, R2is C(=O)R3wherein R3is C1-6alkyl substituted with a pyridyl ring. In some embodiments, R2is C(=O)R3wherein R3is C1-6alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is C(=O)R3wherein R3is C5alkyl substituted with a pyridyl ring. In some embodiments, R2is C(=O)R3wherein R3is C5 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is C(=O)R3wherein R3is pentanyl substituted with a pyrid- 3-yl ring. In some embodiments, R2is C(=O)R3wherein R3is -CH2CH2CH2CH2CH2(pyrid- 3-yl). That is, C(=O)CH2CH2CH2CH2CH2(pyrid-3-yl) or 6-(3-pyridyl)hexanoyl. The group 6-(3-pyridyl)hexanoyl has the structure: . In some embodiments, R2is C(=O)R3wherein R3is C2 alkyl substituted with a pyridyl ring. In some embodiments, R2is C(=O)R3wherein R3is C2 alkyl substituted with a pyrid-3-yl ring. In some embodiments, R2is C(=O)R3wherein R3is ethyl (Et) substituted with a pyrid-3-yl ring. In some embodiments, R2is C(=O)R3wherein R3is -CH2CH2(pyrid-3-yl). That is, C(=O)CH2CH2(pyrid-3-yl) or 3-pyridylpropionyl. The group 3-pyridylpropionyl has the structure: . In some embodiments, R2is NHMe, NH2, NH-(6-(pyridin-3-yl)hexanyl) [that is, NHCH2CH2CH2CH2CH2CH2(pyrid-3-yl)], NHCH2CH2CH2CH2(pyrid-3-yl) [that is, NH-(4- (pyridin-3-yl)butanyl)], NH-(3-(pyridin-3-yl)propyl) [that is, NHCH2CH2CH2(pyrid-3-yl)], NHCH2CH2(pyrid-3-yl) [that is, NH-(2-(pyridin-3-yl)ethyl)], C(=O)CH2CH2CH2CH2CH2(pyrid-3-yl) [that is, 6-(3-pyridyl)hexanoyl], or C(=O)CH2CH2(pyrid-3-yl) [that is, 3-pyridylpropionyl].. In some embodiments, R2is absent. In some embodiments, R2is NHMe. In some embodiments, R2is NH2. In some embodiments, R2is NHCH2CH2CH2CH2CH2CH2(pyrid- 3-yl), that is NH-(6-(pyridin-3-yl)hexanyl). In some embodiments, R2is NHCH2CH2CH2CH2(pyrid-3-yl), that is NH-(4-(pyridin-3-yl)butanyl). In some embodiments, R2is NHCH2CH2CH2(pyrid-3-yl), that is NH-(3-(pyridin-3-yl)propyl). In some embodiments, R2is NHCH2CH2(pyrid-3-yl), that is NH-(2-(pyridin-3-yl)ethyl). In some embodiments, R2is C(=O)CH2CH2CH2CH2CH2(pyrid-3-yl), that is, 6-(3- pyridyl)hexanoyl. In some embodiments, R2is C(=O)CH2CH2(pyrid-3-yl), that is, 3- pyridylpropionyl. Preferably, R2is NHMe or NH2. Even more preferably, R2is NHMe. Z Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta-Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta- Dpr, (N3)-homo-Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D- beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, (N3)-Asp, D-(N3)-Asp, (N3)-beta-Asp, (N3)-D-beta- Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta-Glu, (N3)-homo-Glu, (N3)-D-homo-Glu, (N3)-beta-homo-Glu, 2-amino-6-carboxyhexanoyl and 3-aminopropanoyl; X3 is selected from any amino acid, -hydroxy-C2-6alkanoic acid or is absent; X4 is selected from the group consisting of Val D-Val, beta-Val, D-beta-Val, homo-Val, D- homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo-Val, 2-Me-Val, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Gly, beta-Gly, , homo-Gly, , beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile or is absent; X5 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, and an optionally substituted beta- homotryptophan residue; X6 is selected from the group consisting of an optionally substituted Gln residue, an optionally substituted Lys residue, an optionally substituted Arg residue, an optionally substituted Dab residue, an optionally substituted Orn residue, an optionally substituted Phe residue, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N- Me-Ala, N-Me-homo-Ala, Cit, D-Cit, beta-Cit, D-beta-Cit, homo-Cit, D-homo-Cit, beta- homo-Cit, N-Me-Cit, N-Me-homo-Cit, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Tyr, D-Tyr, beta-Tyr, D-beta-Tyr, homo-Tyr, D-homo-Tyr, beta-homo-Tyr, N-Me-Tyr, N-Me-homo-Tyr, Val, D- Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo- Val or His, D-His, beta-His, D-beta-His, homo-His, D-homo-His, beta-homo-His, N-Me-His and N-Me-homo-His ; X7 is selected from the group consisting of Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D- beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-Lys, iso-Lys, beta-Lys, D-iso-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Pra, D-Pra, beta-Pra, D-beta-Pra, homo-Pra, D-homo-Pra, beta-homo-Pra, N-Me-Pra, N- Me-homo-Pra, Hpg, D-Hpg, beta-Hpg, D-beta-Hpg, homo-Hpg, D-homo-Hpg, beta-homo-Hpg, N-Me-Hpg and N-Me-homo-Hpg; X8 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted beta- homotryptophan residue, an optionally substituted tyrosine residue, an optionally substituted phenylalanine residue, an optionally substituted homophenylalanine residue, and an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted; X9 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted alanine residue, an optionally substituted phenylalanine and an optionally substituted tyrosine residue; X10 is selected from the group consisting of, Val, D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N- Me-homo-Val, 2-Me-Val, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Aib, D-Aib, beta-Aib, D-beta-Aib, homo-Aib, D-homo-Aib, beta-homo-Aib, N-Me-Aib, N- Me-homo-Aib, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile, and a carbocyclic or heterocyclic ring having an amino substituent and a carbonyl substituent; X11 is selected from the group consisting of Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Lys(Me), Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of an optionally substituted Phe residue, an optionally substituted Tyr residue, an optionally substituted His residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo- Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, Gly, beta-Gly, homo-Gly, beta-homo- Gly, N-Me-Gly, N-Me-homo-Gly, Pro, 5-aminopentanoyl,4-aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, 3-aminopropanoyl, Gly-CF3, D-Gly-CF3, Nle, Gln, D-Gln, iso-Gln, D-iso-Gln, beta-Gln, D-beta-Gln, homo-Gln, D-homo-Gln, beta-homo-Gln, N-Me- Gln, N-Me-homo-Gln, THP, Ser, D-Ser, beta-Ser, D-beta-Ser, homo-Ser, D-homo-Ser, beta-homo-Ser, N-Me-Ser, N-Me-homo-Ser, Ser(OMe), 3-aminotetrahydrofuran-3- carbonyl, Arg, D-Arg, beta-Arg, D-beta-Arg, homo-Arg, D-homo-Arg, beta-homo-Arg, N- Me-Arg, N-Me-homo-Arg, , Thr, D-Thr, beta-Thr, D-beta-Thr, homo-Thr, D-homo-Thr, beta-homo-Thr, N-Me-Thr, N-Me-homo-Thr Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D- beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Asn, D- Asn, beta-Asn, D-beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me- homo-Asn, 4-aminobutanoyl, 2-(trimethyl-2-aminoethoxy)ethoxy]propyl and Lys wherein the side chain -NH2 of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of an optionally substituted His residue, an optionally substituted Phe residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Asn, D-Asn, beta-Asn, D- beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me-homo-Asn, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, and Dab, Orn or Lys wherein the side chain -NH2 is substituted with -C(=O)(CH2)nRK wherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof In some embodiments, Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D- iso-Glu, Orn, D-Orn, Dpr, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, N-Me-3-aminopropanoyl, and Ser, or is absent; X4 is Val or is absent; X5 is selected from the group consisting of Trp, 1-Me-Trp, and beta-homo-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, D-Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, and Cyclopropyl-Ala; X9 is 2-Nal or Cyclopropyl-Ala; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, Lys, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, beta-homo-Glu, Dab, iso- Dab, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, 5-aminopentanoyl, 4- aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain - NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3- (3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula Ia: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Ia) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4- Bu), and Cyclopropyl-Ala; X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(3-Quinolinyl)- Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula II: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (II) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D- iso-Glu, Orn, D-Orn, Dpr, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, N-Me-3-aminopropanoyl, and Ser, or is absent; X4 is Val or is absent; X5 is selected from the group consisting of Trp, 1-Me-Trp, and beta-homo-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, D-Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, and Cyclopropyl-Ala; X9 is 2-Nal or Cyclopropyl-Ala; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, Lys, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, beta-homo-Glu, Dab, iso- Dab, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, 5-aminopentanoyl, 4- aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain - NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3- (3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula IIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IIa) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp; X6 is Gln; X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4- Bu), and Cyclopropyl-Ala; X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(3-Quinolinyl)- Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula III: [Lys]-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (III) wherein X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula IIIa: [Lys]-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IIIa) wherein X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7. In some embodiments, Z is an amino acid sequence of formula IV: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IV) wherein X3 is selected from the group consisting of Thr, Ile, and 3-aminopropanoyl, or is absent; X2, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula IVa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (IVa) wherein X3 is selected from the group consisting of Thr, Ile, and 3-aminopropanoyl, or is absent; X2, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula V: X2-X3-X5-X6-X7-X8-X9-X10-X11-X12-X13 (V) wherein X2, X3, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula Va: X2-X3-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Va) wherein X2, X3, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula VI: X2-X3-X4-[Trp]-X6-X7-X8-X9-X10-X11-X12-X13 (VI) wherein X2, X3, X4, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula VIa: X2-X3-X4-[Trp]-X6-X7-X8-X9-X10-X11-X12-X13 (VIa) wherein X2, X3, X4, X6, X7, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula VII: X2-X3-X4-X5-X6-[Glu]-X8-X9-X10-X11-X12-X13 (VII) wherein X2, X3, X4, X5, X6, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) the Glu at X7 forms a lactam bridge with the amino acid residue at X2; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula VIIa: X2-X3-X4-X5-X6-[Glu]-X8-X9-X10-X11-X12-X13 (VIIa) wherein X2, X3, X4, X5, X6, X8, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) the Glu at X7 forms a lactam bridge with the amino acid residue at X2. In some embodiments, Z is an amino acid sequence of formula VIII: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (VIII) wherein X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me); X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula VIIIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (VIIIa) wherein X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me); X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula IX: X2-X3-X4-X5-X6-X7-[Y(2-aminoethoxy)]-X9-X10-X11-X12-X13 (IX) wherein X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula IX: X2-X3-X4-X5-X6-X7-[Y(2-aminoethoxy)]-X9-X10-X11-X12-X13 (IX) wherein X2, X3, X4, X5, X6, X7, X9, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula X: X2-X3-X4-X5-X6-X7-X8-[2-Nal]-X10-X11-X12-X13 (X) wherein X2, X3, X4, X5, X6, X7, X8, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula Xa: X2-X3-X4-X5-X6-X7-X8-[2-Nal]-X10-X11-X12-X13 (Xa) wherein X2, X3, X4, X5, X6, X7, X8, X10, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XI: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (XI) wherein X10 is 2-Me-Leu or 2-Me-Val; X2, X3, X4, X5, X6, X7, X8, X9, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XII: X2-X3-X4-X5-X6-X7-X8-X9-[2-Me-Leu]-X11-X12-X13 (XII) wherein X2, X3, X4, X5, X6, X7, X8, X9, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XIII: X2-X3-X4-X5-X6-X7-X8-X9-X10-[Glu]-X12-X13 (XIII) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Glu at X11 forms a lactam bridge with the amino acid residue at X2; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula XIIIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-[Glu]-X12-X13 (XIIIa) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Glu at X11 forms a lactam bridge with the amino acid residue at X2; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XIV: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-[Dab]-X13 (XIV) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula XIVa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-[Dab]-X13 (XIVa) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XV: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (XV) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge. In some embodiments, Z is an amino acid sequence of formula XVa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (XVa) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XVI: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-[3-(3-Pyridyl)-Ala] (XVI) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, the 3-(3-Pyridyl)-Ala at X13 forms a lactam bridge with the amino acid residue at X10. In some embodiments, Z is an amino acid sequence of formula XVIa: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-[3-(3-Pyridyl)-Ala] (XVIa) wherein X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; and (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring. In some embodiments, Z is an amino acid sequence of formula XVII: [Lys]-X3-X4-[Trp]-X6-X7-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XVII) wherein X3, X4, X6, X7, X8, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7. In some embodiments, Z is an amino acid sequence of formula XVIIa: [Lys]-X3-X4-[Trp]-X6-X7-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XVIIa) wherein X3, X4, X6, X7, X8, X11, X12, and X13 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7. In some embodiments, Z is an amino acid sequence of formula XVIII: [Lys]-X3-X4-[Trp]-X6-X7-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XVIII) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X3, X4, X6, X7, X8, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 forms a lactam bridge with the amino acid residue at X7. In some embodiments, Z is an amino acid sequence of formula XIX: [Lys]-X3-X4-[Trp]-X6-[Glu]-X8-[2-Nal]-[2-Me-Leu]-X11-X12-X13 (XIX) wherein X13 is 3-(3-Pyridyl)-Ala or is absent; X3, X4, X6, X8, X11, and X12 are as defined in any one of the above formulae I, Ia, II, and IIa; and wherein (i) the Lys at X2 forms a lactam bridge with the amino acid residue at X11; and (ii) the Lys at X2 and the Glu at X7 together form a lactam bridge. In some embodiments, Z is an amino acid sequence selected from the group consisting of a sequence listed in Table 1-1a. X2 X2 is selected from the group consisting of: Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta-Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta- Dpr, (N3)-homo-Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D- beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, (N3)-Asp, D-(N3)-Asp, (N3)-beta-Asp, (N3)-D-beta- Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta-Glu, (N3)-homo-Glu, (N3)-D-homo-Glu, (N3)-beta-homo-Glu, and 2-amino-6-carboxyhexanoyl and 3-aminopropanoyl. In some embodiments, X2 is selected from the group consiting of Dab, D-Dab, iso-Dab, Lys, iso-Lys, D-beta-Lys, N-Me-Lys, homo-Lys, D-Lys, D-homo-Lys, beta-Lys, beta-homo- Lys, Lys(Gly), (N3)-Lys, D-(N3)-Lys, D-iso-Glu, iso-Glu, Glu, Orn, D-Orn, Dpr and Lys(Gly). In some embodiments, X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D-iso-Glu, Orn, D-Orn, Dpr, Lys(Gly), (N3)-Lys and D-(N3)-Lys. The amino acid residue at X2 forms a (first) lactam bridge with the amino acid residue at X11, and a (second) lactam bridge or bridge containing a triazole ring with the amino acid residue at X7. Preferably, the lactam bridge between X2 and X11 uses the side chain of the amino acid residue at X2, and the bridge between X2 and X7 uses the N-terminus of the amino acid residue at X2. In some embodiments where the amino acid residue at X2 forms a (first) lactam bridge with the amino acid residue at X11 and a (second) lactam bridge with the amino acid residue at X7, X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D-iso-Glu, Orn, D-Orn, Dpr, and Lys(Gly). In some embodiments where the amino acid residue at X2 forms a (first) lactam bridge with the amino acid residue at X11 and a (second) bridge containing a triazole ring with the amino acid residue at X7, X2 is (N3)-Lys or D-(N3)-Lys. In some embodiments, X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D-Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys. In some embodiments, X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, D- beta-Lys, homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Glu, iso-Glu, D-iso- Glu, Orn, and D-Orn. In some embodiments, X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, D- beta-Lys, homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, and D-Orn. In some embodiments, X2 is Lys. In some embodiments, X2 is D-Lys. In some embodiments, X2 is iso-Lys. In some embodiments, X2 is beta-Lys. In some embodiments, X2 is D-beta-Lys. In some embodiments, X2 is homo-Lys. In some embodiments, X2 is D-homo-Lys. In some embodiments, X2 is beta-homo-Lys. In some embodiments, X2 is N-Me-Lys. In some embodiments, X2 is Dab. In some embodiments, X2 is D-Dab. In some embodiments, X2 is iso-Dab. In some embodiments, X2 is Glu. In some embodiments, X2 is iso-Glu. In some embodiments, X2 is D-iso-Glu. In some embodiments, X2 is Orn. In some embodiments, X2 is D-Orn. In some embodiments, X2 is Dpr. In some embodiments, X2 is Lys(Gly). In some embodiments, X2 is (N3)-Lys. In some embodiments, X2 is D-(N3)-Lys. Preferably, X2 is Lys. X3 X3 is selected from any amino acid, -hydroxy-C2-6 alkanoic acid or is absent. In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, beta-homo-Trp, Gly, N- Me-3-aminopropanoyl, Ser, Trp, Phe, N-Me-Ser, N-Me-Ala, 3-hydroxypropanoic acid or is absent. In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, N-Me-3- aminopropanoyl, and Ser, or is absent. X3 may be absent in the compounds disclosed herein without loss of activity (see Example 2 below). Any internal truncation, that is deletion of amino acid residues, between X2 and X11 (such as X3) in other peptide inhibitors of IL-23R had previously been reported to lead to inactive compounds (see reference compounds Ref 5, Ref 6, and Ref 7 in the Examples of WO2023 / 099669). In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3- aminopropanoyl, or is absent. In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, and Gly, or is absent. In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, Gly, and Ser, or is absent. In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, Gly, or is absent. In some embodiments, X3 is selected from the group consisting of Thr, Ile, 3- aminopropanoyl, or is absent. In some embodiments, X3 is Thr, Ile, or is absent. In some embodiments, X3 is Thr. In some embodiments, X3 is Ile. In some embodiments, X3 is 3-aminopropanoyl. In some embodiments, X3 is 4-aminobutanoyl. In some embodiments, X3 is beta-homo-Ile. In some embodiments, X3 is beta-homo-Thr. In some embodiments, X3 is Gly. In some embodiments, X3 is N-Me-3-aminopropanoyl. In some embodiments, X3 is Ser. In some embodiments, X3 is absent. Preferably, X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, or is absent. Evern more preferably, X3 is Thr, Ile, or is absent. X4 X4 is selected from the group consisting of Val, D-Val, beta-Val, D-beta-Val, homo-Val, D- homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo-Val, 2-Me-Val, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile or is absent. In some embodiments, X4 is Val or is absent. In some embodiments, X4 is Val. In some embodiments, X4 is absent. X4 may be absent in the compounds disclosed herein without loss of activity (see Example 2 below). Any internal truncation, that is deletion of amino acid residues, between X2 and X11 (such as X4) in other peptide inhibitors of IL-23R had previously been reported to lead to inactive compounds (see reference compounds Ref 5, Ref 6, and Ref 7 in the Examples of WO2023 / 099669). Preferably, X4 is absent. X5 X5 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, and an optionally substituted beta- homotryptophan residue. In some embodiments, X5 is selected from the group consisting of Trp, 1-Me-Trp, 7-Aza- Trp, 7-Me-Trp and beta-homo-Trp. In some embodiments, X5 is selected from the group consisting of Trp, 1-Me-Trp, and beta-homo-Trp. In some embodiments, X5 is Trp or 1-Me-Trp. In some embodiments, X5 is Trp. In some embodiments, X5 is 1-Me-Trp. In some embodiments, X5 is beta-homo-Trp. Preferably, X5 is Trp. X6 X6 is selected from the group consisting of an optionally substituted Gln residue, an optionally substituted Lys residue, an optionally substituted Arg residue, an optionally substituted Dab residue, an optionally substituted Orn residue, an optionally substituted Phe residue, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N- Me-Ala, N-Me-homo-Ala, Cit, D-Cit, beta-Cit, D-beta-Cit, homo-Cit, D-homo-Cit, beta- homo-Cit, N-Me-Cit, N-Me-homo-Cit, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Tyr, D-Tyr, beta-Tyr, D-beta-Tyr, homo-Tyr, D-homo-Tyr, beta-homo-Tyr, N-Me-Tyr, N-Me-homo-Tyr, Val, D- Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo- Val or His, D-His, beta-His, D-beta-His, homo-His, D-homo-His, beta-homo-His, N-Me-His and N-Me-homo-His. In some embodiments, X6 is selected from the group consisting of Dab(Ac), Dab(Ac-N- Me), Gln, Gln(2Me), K(NMePEG3) and Gln(Me). In some embodiments, X6 is Gln. X7 X7 is selected from the group consisting of Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D- beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-Lys, iso-Lys, beta-Lys, D-iso-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Pra, D-Pra, beta-Pra, D-beta-Pra, homo-Pra, D-homo-Pra, beta-homo-Pra, N-Me-Pra, N- Me-homo-Pra, Hpg, D-Hpg, beta-Hpg, D-beta-Hpg, homo-Hpg, D-homo-Hpg, beta-homo-Hpg, N-Me-Hpg and N-Me-homo-Hpg. In some embodiments, X7 is selected from the group consisting of Asp, D-Glu, Glu, Pra, Hpg and homo-Glu. In some embodiments, X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg. The amino acid residue at X7 forms a lactam bridge or bridge containing a triazole ring with the amino acid residue at X2. In some embodiments where the amino acid residue at X7 forms a lactam bridge with the amino acid residue at X2, X7 is selected from the group consisting of Glu, homo-Glu, and Asp. In embodiments where the amino acid residue at X7 forms a bridge containing a triazole ring with the amino acid residue at X2, X7 is Pra or Hpg. In some embodiments, X7 is Glu or Asp. In some embodiments, X7 is Glu. In some embodiments, X7 is homo-Glu. In some embodiments, X7 is Asp. In some embodiments, X7 is Pra. In some embodiments, X7 is Hpg. Preferably, X7 is Glu. The inventors postulate that X7 is Glu is advantageous over X7 is Asp from a synthetic point of view as Asp in amide bridges is more prone to potential isomerism compared to Glu. X8 X8 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted beta- homotryptophan residue, an optionally substituted tyrosine residue, an optionally substituted phenylalanine residue, an optionally substituted homophenylalanine residue, and an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted. In some embodiments, X8 is selected from the group consisting of Y(2-aminoethoxy), Y(2- aminoethoxy)(N(Me)2), Y(nPentylamine)(N+(Me)3), Y(2-trimethyl-PEG2), homo-Phe, 7- AzaTrp, beta-homo-Trp, 7-F-Trp, F(4-morpholine), 3-quinolinylalanine, Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4- Pyridyl)-Ala, Cyclopropyl-Ala, F(4-THP), Y(CH3-2-F), F(4-F), F(4-piperazine), F(4- imidazole), F(piperidine), Y(CH3-3-F), 5-AzaTrp, Y(Ac-2-aminoethoxy), 6-AzaTrp and F(4- CONH2). In some embodiments, X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3- Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, and Cyclopropyl-Ala. In some embodiments, X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), F(4-Me), F(4-Bu), and Cyclopropyl-Ala. In some embodiments, X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), F(4-Me), and Cyclopropyl-Ala. In some embodiments, X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), and F(4-Me). In some embodiments, X8 is Y(2-aminoethoxy) or Y(Me). In some embodiments, X8 is Y(2-aminoethoxy). In some embodiments, X8 is Y(Me). In some embodiments, X8 is Y(nPr). In some embodiments, X8 is Y(Bn). In some embodiments, X8 is Trp. In some embodiments, X8 is D-Phe. In some embodiments, X8 is 2-Me-Phe. In some embodiments, X8 is F(4-Me). In some embodiments, X8 is F(4- Bu). In some embodiments, X8 is 3-(2-Pyridyl)-Ala. In some embodiments, X8 is 3-(3- Pyridyl)-Ala. In some embodiments, X8 is 3-(4-Pyridyl)-Ala. In some embodiments, X8 is Cyclopropyl-Ala, Preferably, X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me). More preferably, X8 is Y(2- aminoethoxy) or Y(Me). Even more preferably, X8 is Y(2-aminoethoxy). X9 X9 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted alanine residue, an optionally substituted phenylalanine and an optionally substituted tyrosine residue.In some embodiments, X9 is 2-Nal or Cyclopropyl-Ala. In some embodiments, X9 is 2-Nal. In some embodiments, X9 is Cyclopropyl-Ala. Preferably, X9 is 2-Nal. X10 X10 is selected from the group consisting of Val, D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N- Me-homo-Val, 2-Me-Val, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Aib, D-Aib, beta-Aib, D-beta-Aib, homo-Aib, D-homo-Aib, beta-homo-Aib, N-Me-Aib, N- Me-homo-Aib, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile, and a carbocyclic or heterocyclic ring having an amino substituent and a carbonyl substituent. In some embodiments, X10 is selected from the group consisting of Dab, 2-Me-Leu, 2-Me- Val, Aib, D-Ala, Gly and Lys. In some embodiments, X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, Lys, and Aib. When X13 is present, the amino acid residue at X10 may form a lactam bridge with the amino acid residue at X13. In some embodiments where X13 is present and the amino acid residue at X10 forms a lactam bridge with the amino acid residue at X13, X10 is selected from the group consisting of Dab or Lys. In some embodiments where X13 is present and the amino acid residue at X10 forms a lactam bridge with the amino acid residue at X13, X10 is Dab. In some embodiments, X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, Dab, Gly, and Aib. In some embodiments, X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, and Gly. In some embodiments, X10 is 2-Me-Leu. In some embodiments, X10 is 2-Me-Val. In some embodiments, X10 is Dab. In some embodiments, X10 is Gly. In some embodiments, X10 is Lys. In some embodiments, X10 is Aib. Preferably, X10 is 2-Me-Leu or 2-Me-Val. More preferably, X10 is 2-Me-Leu. X11 X11 is selected from the group consisting of: Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Lys(Me), Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, or 2-amino-6-carboxyhexanoyl. In some embodiments, X11 is selected from the group consisting of Glu, homo-Glu, beta- homo-Glu, Dab, iso-Dab, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl. The amino acid residue at X11 forms a lactam bridge with the amino acid residue at X2. In some embodiments, X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2-amino-6-carboxyhexanoyl. In some embodiments, X11 is selected from the group consisting of Glu, homo-Glu, Lys, and 2-amino-6-carboxyhexanoyl. In some embodiments, X11 is Glu or 2-amino-6-carboxyhexanoyl. In some embodiments, X11 is Glu. In some embodiments, X11 is homo-Glu. In some embodiments, X11 is beta-homo-Glu. In some embodiments, X11 is Dab. In some embodiments, X11 is iso-Dab. In some embodiments, X11 is Lys. In some embodiments, X11 is Lys(Me). In some embodiments, X11 is Orn. In some embodiments, X11 is 2- amino-6-carboxyhexanoyl. Preferably, X11 is Glu. X12 X12 is selected from the group consisting of an optionally substituted Phe residue, an optionally substituted Tyr residue, an optionally substituted His residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo- Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, Gly, beta-Gly, homo-Gly, beta-homo- Gly, N-Me-Gly, N-Me-homo-Gly, Pro, 5-aminopentanoyl,4-aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, 3-aminopropanoyl, Gly-CF3, D-Gly-CF3, Nle, Gln, D-Gln, iso-Gln, D-iso-Gln, beta-Gln, D-beta-Gln, homo-Gln, D-homo-Gln, beta-homo-Gln, N-Me- Gln, N-Me-homo-Gln, THP, Ser, D-Ser, beta-Ser, D-beta-Ser, homo-Ser, D-homo-Ser, beta-homo-Ser, N-Me-Ser, N-Me-homo-Ser, Ser(OMe), 3-aminotetrahydrofuran-3- carbonyl, Arg, D-Arg, beta-Arg, D-beta-Arg, homo-Arg, D-homo-Arg, beta-homo-Arg, N- Me-Arg, N-Me-homo-Arg, , Thr, D-Thr, beta-Thr, D-beta-Thr, homo-Thr, D-homo-Thr, beta-homo-Thr, N-Me-Thr, N-Me-homo-Thr Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D- beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Asn, D- Asn, beta-Asn, D-beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me- homo-Asn, 4-aminobutanoyl, 2-(trimethyl-2-aminoethoxy)ethoxy]propyl and Lys wherein the side chain -NH2 of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent. In some embodiments, X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, Ser(OCH3), 5-aminopentanoyl, 4-aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2- carbonyl, and Lys wherein the side chain -NH2 of the Lys is substituted with - C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent. In some embodiments, X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, 5-aminopentanoyl, 4-aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain -NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent. In embodiments where X12 is Lys wherein the side chain -NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, X12 may be selected from the group consisting of K(piconilate), K(2- pyridylacetyl), K(2-pyridylpropionyl), K(nicotinate), K(3-pyridylacetyl), K(3- pyridylpropionyl), K(isonicotinyl), K(4-pyridylacetyl), K(4-pyridylpropionyl), K(3,5- pyrimidine), K(4-pyridyl-3-fluoroacetyl), K(Imidazoleacetyl), and K(Imidazolepropanoyl). That is, K(piconilate) is when n is 0 and RKis pyrid-2-yl; K(2-pyridylacetyl) is when n is 1 and RKis pyrid-2-yl; K(2-pyridylpropionyl) is when n is 2 and RKis pyrid-2-yl; K(nicotinate) is when n is 0 and RKis pyrid-3-yl; K(3-pyridylacetyl) is when n is 1 and RKis pyrid-3-yl; K(3-pyridylpropionyl) is when n is 2 and RKis pyrid-3-yl; K(isonicotinyl) is when n is 0 and RKis pyrid-4-yl; K(4-pyridylacetyl) is when n is 1 and RKis pyrid-4-yl; K(4-pyridylpropionyl) is when n is 2 and RKis pyrid-4-yl; K(3,5-pyrimidine) is when n is 0 and RKis 3,5- pyrimidinyl; K(4-pyridyl-3-fluoroacetyl) is when n is 1 and RKis pyrid-4-yl substituted with F at position 2; K(Imidazoleacetyl) is when n is 1 and RKis 1H-imidazol-2-yl; and K(Imidazolepropanoyl) is when n is 2 and RKis 1H-imidazol-2-yl. In some embodiments, X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(3-Quinolinyl)-Ala, and 4-aminopiperidin-4-carbonyl. In some embodiments, X12 is selected from the group consisting of Dab, His, Gly, or is absent. In some embodiments, X12 is selected from the group consisting of Dab or is absent. In some embodiments, X12 is Dab. In some embodiments, X12 is His. In some embodiments, X12 is D-His. In some embodiments, X12 is His(1-Me). In some embodiments, X12 is 3-(2-Pyridyl)-Ala. In some embodiments, X12 is 3-(3-Pyridyl)-Ala. In some embodiments, X12 is 3-(4-Pyridyl)-Ala. In some embodiments, X12 is 3-(3- Quinolinyl)-Ala. In some embodiments, X12 is Gly. In some embodiments, X12 is Pro. In some embodiments, X12 is 5-aminopentanoyl. In some embodiments, X12 is 4- aminopiperidin-4-carbonyl. In some embodiments, X12 is (R,S)-Imidazolidin-2-carbonyl. In some embodiments, X12 is K(piconilate). In some embodiments, X12 is K(2- pyridylacetyl). In some embodiments, X12 is K(2-pyridylpropionyl). In some embodiments, X12 is K(nicotinate). In some embodiments, X12 is K(3-pyridylacetyl). In some embodiments, X12 is K(3-pyridylpropionyl). In some embodiments, X12 is K(isonicotinyl). In some embodiments, X12 is K(4-pyridylacetyl). In some embodiments, X12 is K(4-pyridylpropionyl). In some embodiments, X12 is K(3,5-pyrimidine). In some embodiments, X12 is K(4-pyridyl-3-fluoroacetyl). In some embodiments, X12 is K(Imidazoleacetyl). In some embodiments, X12 is K(Imidazolepropanoyl). In some embodiments, X12 is absent. Preferably, X12 is Dab. X13 X13 is selected from the group consisting of an optionally substituted His residue, an optionally substituted Phe residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Asn, D-Asn, beta-Asn, D- beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me-homo-Asn, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, and Dab, Orn or Lys wherein the side chain -NH2is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or is absent.In some embodiments, X13 is selected from the group consisting of 3-(3- Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3-(3,5-Pyrimidyl)-Ala, or is absent. When X13 is present, the amino acid residue at X13 may form a lactam bridge with the amino acid residue at X10. In embodiments where X13 is present and the amino acid residue at X13 forms a lactam bridge with the amino acid residue at X10, X13 may be 3-(3-Pyridyl)-Ala. In some embodiments, X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3- (3-Pyridyl)-Ala, or is absent. In some embodiments, X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent. In some embodiments, X13 is 3-(3-Pyridyl)-Ala or is absent. In some embodiments, X13 is 3-(3-Pyridyl)-Ala. In some embodiments, X13 is D-3-(3- Pyridyl)-Ala. In some embodiments, X13 is 3-(3,5-Pyrimidyl)-Ala. In some embodiments, X13 is absent. Preferably, X13 is 3-(3-Pyridyl)-Ala or is absent. More preferably, X13 is 3-(3-Pyridyl)-Ala. Lactam bridge A lactam bridge is formed of one amino acid residue comprising an amine group and another amino acid residue comprising a carboxylic acid group. The amine and / or carboxylic acid group of the amino acid residue may be on the side chain of the amino acid residue, such as Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Lys(Me), Lys(Gly), Dab, D-Dab, iso-Dab, Orn, D-Orn, Dpr, Glu, D-Glu, iso-Glu, D-iso-Glu, homo-Glu, beta-homo-Glu, and Asp. Alternatively, the amine and / or carboxylic acid group of the amino acid residue may be the N- or C-terminus of the peptide chain, such as the amine or carboxylic acid of the peptide backbone of any amino acid, or such as Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta- homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Orn, D-Orn, Dpr, Lys(Gly), Glu, iso-Glu, D- iso-Glu, 3-(3-Pyridyl)-Ala, and 2-amino-6-carboxyhexanoyl. For simplicity, the amino acid residues who together form a lactam bridge will be discussed by reference to the residues nominally present before lactam formation. Suitable amino acid residues who together form a lactam bridge may be selected from: Amino acid residues comprising an amine group: Lys, D-Lys, iso-Lys, beta-Lys, D- beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Lys(Me), Lys(Gly), Dab, D-Dab, iso-Dab, Orn, D-Orn, Dpr, 3-(3-Pyridyl)-Ala, (N3)-Lys, and D-(N3)-Lys. Amino acid residues comprising a carboxylic acid group: Glu, D-Glu, iso-Glu, D- iso-Glu, homo-Glu, beta-homo-Glu, Asp, 2-amino-6-carboxyhexanoyl, and iso- Dab. The inventors have found that replacing a dithioether bridge with a lactam bridge can lead to increased potency of the IL-23R peptide inhibitor, as previously described in Example 2 of WO2023 / 099669. First lactam bridge ^ X2 and X11 A first lactam bridge is formed between the amino acid residues at X2 and at X11. One of the residues at positions X2 and X11 is an amino acid residue comprising an amine group and the other is an amino acid residue comprising a carboxylic acid group, wherein a lactam (cyclic amide) is formed between the amine and carboxylic acid groups. In some embodiments, the amino acid residue comprising amine group is at X2, and the amino acid residue comprising a carboxylic acid group at X11. In some such embodiments: X2 is selected from Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D- homo-Lys, beta-homo-Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta- Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta-homo-Dpr, N-Me- Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta-Dpr, (N3)-homo- Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, beta-Dab, D-beta-Dab, homo- Dab, D-homo-Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D-beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, , and Lys(Gly). In some such embodiments, X2 is selected from the group consiting of Dab, D-Dab, Lys, iso-Lys, D-beta-Lys, N-Me-Lys, homo-Lys, D-Lys, D-homo-Lys, beta-Lys, beta-homo-Lys, Lys(Gly), (N3)-Lys, D-(N3)-Lys, Orn, D-Orn, Dpr and Lys(Gly). In some such embodiments, X2 is selected from Lys, D-Lys, iso-Lys, beta-Lys, D-beta- Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Orn, D- Orn, Dpr, Lys(Gly), (N3)-Lys, and D-(N3)-Lys. In some such embodiments, X11 is selected from Asp, D-Asp, iso-Asp, D-iso-Asp, beta- Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, 2-amino-6-carboxyhexanoyl and iso-dab. In some such embodiments, X11 is selected from the group consisting of Glu, homo-Glu, beta-homo-Glu, 2-amino-6-carboxyhexanoyl, and iso-Dab. That is, in embodiments where the amino acid residue comprising amine group is at X2, and the amino acid residue comprising a carboxylic acid group at X11, the following are suitable combinations of X2 and X11: X2 is D-Lys and X11 is Glu; X2 is Lys and X11 is Glu; X2 is homo-Lys and X11 is Glu; X2 is D-homo-Lys and X11 is Glu; X2 is D-Orn and X11 is homo-Glu; X2 is D-Dab and X11 is 2-amino-6-carboxyhexanoyl; X2 is D-Orn and X11 is Glu; X2 is D-Dab and X11 is Glu; X2 is beta-Lys and X11 is Glu; X2 is D-beta-Lys and X11 is Glu; X2 is Lys and X11 is iso-Dab; X2 is Dab and X11 is Glu; X2 is Lys(Gly) and X11 is Glu; X2 is Lys and X11 is beta-homo-Glu; X2 is Ne-Me-Lys and X11 is Glu; X2 is Orn and X11 is Glu; X2 is Dpr and X11 is Glu; X2 is beta-homo-Lys and X11 is Glu; X2 is iso-Lys and X11 is Glu; X2 is iso-Dab and X11 is Glu; X2 is (N3)-Lys and X11 is Glu; and X2 is D-(N3)-Lys and X11 is Glu. In embodiments, the amino acid residue comprising amine group is at X11, and the amino acid residue comprising a carboxylic acid group at X2. In some such embodiments: X2 is selected from, Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D- homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp, (N3)-Asp, D-(N3)-Asp, (N3)-beta- Asp, (N3)-D-beta-Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me- Glu, N-Me-homo-Glu, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta-Glu, (N3)-homo- Glu, (N3)-D-homo-Glu, (N3)-beta-homo-Glu, and 2-amino-6-carboxyhexanoyl and 3- aminopropanoyl. In some such embodiments, X2 is selected from Glu, iso-Glu, and D-iso-Glu. In some such embodiments, X11 is selected from Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta- Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta-homo-Dpr, N-Me-Dpr and N-Me-homo- Dpr., Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta-homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, N-Me-homo-Lys, Lys(Me), In some such embodiments, X11 is selected from the group consisting of Dab, Lys, Lys(Me), and Orn. That is, in embodiments where the amino acid residue comprising amine group is at X2, and the amino acid residue comprising a carboxylic acid group at X11, the following are suitable combinations of X2 and X11: X2 is Glu and X11 is Orn; X2 is Glu and X11 is Lys(Me); X2 is Glu and X11 is Lys; X2 is iso-Glu and X11 is Lys; X2 is iso-Glu and X11 is Dab; X2 is D-iso-Glu and X11 is Lys; and X2 is D-iso-Glu and X11 is Dab. Second lactam bridge ^ X2 and X7 A second lactam bridge may be formed between the amino acid residues at X2 and X7. Preferably, the bridge between the amino acid residues at X2 and X7 is a lactam bridge. One of the residues at positions X2 and X7 is an amino acid residue comprising an amine group and the other is an amino acid residue comprising a carboxylic acid group, wherein a lactam (cyclic amide) is formed between the amine and carboxylic acid groups. In some embodiments, the amino acid residue comprising amine group is at X2, and the amino acid residue comprising a carboxylic acid group at X7. In some such embodiments: X2 is selected from Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D- homo-Lys, beta-homo-Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta- Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta-homo-Dpr, N-Me- Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta-Dpr, (N3)-homo- Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, beta-Dab, D-beta-Dab, homo- Dab, D-homo-Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D-beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, and Lys(Gly). In some such embodiments, X2 is selected from the group consiting of Dab, D-Dab, Lys, iso-Lys, D-beta-Lys, N-Me-Lys, homo-Lys, D-Lys, D-homo-Lys, beta-Lys, beta-homo-Lys, Lys(Gly), (N3)-Lys, D-(N3)-Lys, Orn, D-Orn, Dpr and Lys(Gly).In some such embodiments, X2 is selected from Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo-Lys, N-Me-Lys, Dab, D-Dab, iso-Dab, Orn, D-Orn, Dpr, Lys(Gly), iso-Glu, and D-iso-Glu. In some such embodiments, X7 is selected from the group consisting of Asp, D-Asp, iso- Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me- Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D- homo-Glu, beta-homo-Glu, N-Me-Glu and N-Me-homo-Glu. In some such embodiments, X7 is selected from the group consisting of Glu, D-Glu, homo-Glu, and Asp. That is, in embodiments where the amino acid residue comprising amine group is at X2, and the amino acid residue comprising a carboxylic acid group at X7, the following are suitable combinations of X2 and X7: X2 is D-Lys and X7 is Glu; X2 is Lys and X7 is Glu; X2 is D-Lys and X7 is Asp; X2 is homo-Lys and X7 is Glu; X2 is D-homo-Lys and X7 is Glu; X2 is D-Orn and X7 is Glu; X2 is D-Dab and X7 is Glu; X2 is D-Orn and X7 is Asp; X2 is D-Dab and X7 is Asp; X2 is beta-Lys and X7 is Glu; X2 is D-beta-Lys and X7 is Asp; X2 is D-beta-Lys and X7 is Glu; X2 is Lys and X7 is D-Glu; X2 is Dab and X7 is Glu; X2 is Lys and X7 is homo-Glu; X2 is Glu and X7 is Glu; X2 is Lys(Gly) and X7 is Glu; X2 is Ne-Me-Lys and X7 is Glu; X2 is Orn and X7 is Glu; X2 is Dpr and X7 is Glu; X2 is beta-homo-Lys and X7 is Glu; X2 is iso-Lys and X7 is Glu; X2 is iso-Dab and X7 is Glu; X2 is iso-Glu and X7 is Glu; and X2 is D-iso-Glu and X7 is Glu. Alternatively, the amino acid residue comprising amine group is at X7, and the amino acid residue comprising a carboxylic acid group at X2. Preferably, the amino acid residue comprising amine group is at X2, and the amino acid residue comprising a carboxylic acid group at X7. Optional third lactam bridge ^ X10 and X13 When X13 is present, an optional third lactam bridge may be formed between the amino acid residues at X10 and X13. In some such embodiments, one of the residues at positions X10 and X13 is an amino acid residue comprising an amine group and the other is an amino acid residue comprising a carboxylic acid group, wherein a lactam (cyclic amide) is formed between the amine and carboxylic acid groups. In some embodiments, the amino acid residue comprising amine group is at X13, and the amino acid residue comprising a carboxylic acid group at X10. In some such embodiments: In some such embodiments, X10 is selected from Dab, D-Dab, iso-Dab, D-iso-Dab, beta- Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo- Dab, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta- homo-Lys, N-Me-Lys and N-Me-homo-Lys. In some such embodiments, X10 is Dab or Lys. In some such embodiments, D13 is an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted and Dab, Orn or Lys wherein the side chain -NH2is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F In some such embodiments, X13 is 3-(3-Pyridyl)-Ala. That is, in embodiments where the amino acid residue comprising amine group is at X13, and the amino acid residue comprising a carboxylic acid group at X10, the following are suitable combinations of X13 and X10: X10 is Dab and X13 is 3-(3-Pyridyl)-Ala; and X10 is Lys and X13 is 3-(3-Pyridyl)-Ala. Alternatively, the amino acid residue comprising amine group is at X10, and the amino acid residue comprising a carboxylic acid group at X13. Preferably, the amino acid residue comprising amine group is at X13, and the amino acid residue comprising a carboxylic acid group at X10. Bridge containing a triazole ring A bridge containing a triazole ring is formed of one amino acid residue comprising an azide (-N3) group and another amino acid residue comprising an alkyne group. In some embodiments, the azide and / or alkyne groups of the amino acid residue is on the side chain of the amino acid residue. Suitable amino acid residues who together form a bridge containing a triazole ring may be selected from: Amino acid residues comprising an azide group: (N3)-Lys and D-(N3)-Lys. Amino acid residues compirising an alkyne group: Pra and Hpg. The compound of the invention may comprise a bridge containing a triazole ring formed between the amino acid residues at positions X2 and X7 (instead of a lactam bridge). One of the residues at positions X2 and X7 is an amino acid residue comprising an azide (-N3) group and the other is an amino acid residue comprising an alkyne group, wherein a triazole (such as a 1,2,3-triazole) is formed between the azide and the alkyne groups. The reaction for the formation of the triazole ring is a Huisgen azide-alkyne 1,3-dipolar cycloaddition. Typically, this reaction forms the 1,4-disubstituted 1,2,3-triazole ring (as opposed to the 1,5-disubstitued 1,2,3-triazole ring) as the major isomer. The 1,5- dibsubstituted 1,2,3-triazole ring may also be isolated, usually as the minor isomer. The azide and / or alkyne group may be present on the side chain of the amino acid residue. The alkyne is preferably a terminal alkyne (-C CH). Suitable amino acid residues whose side chains can participate in the formation of the triazole ring (such as 1,2,3-triazole ring) include Pra and Hpg (having side chains comprising alkyne groups). Alternatively, the azide and / or alkyne group of the amino acid residue may be the N- or C- terminus of the peptide chain. For example, the azide group may be derived from the amine group of the peptide backbone of any amino acid, such as (N3)-Lys and D-(N3)-Lys, and may be the N-terminus of the peptide chain. In some embodiments, the amino acid residue comprising azide group is at X2, and the amino acid residue comprising an alkyne group at X7. In some such embodiments: X2 is selected from (N3)-Lys, D-(N3)-Lys, (N3)-beta-Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta- Dpr, (N3)-homo-Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, (N3)-Dab, D-(N3)-Dab, (N3)- beta-Dab, (N3)-D-beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, (N3)- Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta-Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)- beta-homo-Orn, (N3)-Asp, D-(N3)-Asp, (N3)-beta-Asp, (N3)-D-beta-Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta- Glu, (N3)-homo-Glu, (N3)-D-homo-Glu and (N3)-beta-homo-Glu. In some such embodiments, X2 is (N3)-Lys and D-(N3)-Lys In some such embodiments, X7 is Pra and Hpg. That is, in embodiments where the amino acid residue comprising azide group is at X2, and the amino acid residue comprising an alkyne group at X7, the following are suitable combinations of X2 and X7: X2 is (N3)-Lys and X7 is Pra; and X2 is D-(N3)-Lys and X7 is Hpg. Alternatively, the amino acid residue comprising azide group is at X7, and the amino acid residue comprising an alkyne group at X2. Preferably, the amino acid residue comprising azide group is at X2, and the amino acid residue comprising an alkyne group at X7. Bridge length The length of the bridge is counted as the number of atoms in a linear chain from the first atom attached to the atom (carbon) adjacent to the carboxylic acid moiety of the amino acid of the first residue (X2 for the bridge between X2 and X11; X2 for the bridge between X2 and X7; or X10 for the bridge between X10 and X13), i.e. attached to the alpha carbon of the relevant residue for most amino acids, up to the first atom attached to the atom (carbon) adjacent to the carboxylic acid moiety of the amino acid of the second residue (X11 for the bridge between X2 and X11; X7 for the bridge between X2 and X7; or X13 for the bridge between X10 and X13). The contribution to the length of the bridge for amino acid residues and the type of bridge is described below. In some embodiments, the length of the bridge between X2 and X11 is at least 3 atoms long. In some embodiments, the length of the bridge between X2 and X11 is no longer than 11 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 3 to 11 atoms long, such as 3, 4, 5, 6, 7, 8, 9, 10, or 11 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 4 to 11 atoms long, such as 4, 5, 6, 7, 8, 9, 10, or 11 atoms long, such as 4, 5, 6, 7, 8, 9, or 11 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 4 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 5 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 6 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 7 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 8 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 9 atoms long. In some embodiments, the length of the bridge between X2 and X11 is 11 atoms long. In some embodiments, the length of the bridge between X2 and X7 is at least 3 atoms long. In some embodiments, the length of the bridge between X2 and X7 is no longer than 11 atoms long. In some embodiments, the length of the bridge between X2 and X7 is 3 to 11 atoms long, such as 3, 4, 5, 6, 7, 8, 9, 10, or 11 atoms long. In some embodiments, the length of the bridge between X2 and X7 is 3 to 6 atoms long, such as 3, 4, 5, 6 atoms long, such as 3, 4, or 6 atoms long. In some embodiments, the length of the bridge between X2 and X7 is 3 atoms long. In some embodiments, the length of the bridge between X2 and X7 is 4 atoms long. In some embodiments, the length of the bridge between X2 and X7 is 6 atoms long. In some embodiments, the length of the bridge between X10 and X13 is at least 3 atoms long. In some embodiments, the length of the bridge between X10 and X13 is no longer than 11 atoms long. In some embodiments, the length of the bridge between X10 and X13 is 3 to 11 atoms long, such as 3, 4, 5, 6, 7, 8, 9, 10, or 11 atoms long. In some embodiments, the length of the bridge between X10 and X13 is 4 to 6 atoms long, such as 4, 5, 6 atoms long, such as 4 or 6 atoms long. In some embodiments, the length of the bridge between X10 and X13 is 4 atoms long. In some embodiments, the length of the bridge between X10 and X13 is 6 atoms long. Lactam bridge The contribution of the side chain to the length of the lactam bridge is counted as the number of atoms in a linear chain from the first atom of the side chain (which is bonded to an atom of the peptide backbone, i.e. to the alpha carbon of the relevant residue for most amino acids) up to and including the atom which participates in the amide bond of the lactam bridge (i.e. the carbon atom of the carboxylic acid functional group or the nitrogen atom of the amine group). Thus common acid- and amine-containing side chains are considered to have the following side chain lengths. It will be understood that the following can be used to decipher the bridge length for any amino acid residue disclosed herein. Amine-containing side chains: 5 3 1 Lys / iso-Lys 5 atoms 4 2 5 3 1 D-Lys 5 atoms 4 2 3 1 beta-Lys 4 atoms 4 2 3 1 D-beta-Lys 4 atoms 4 2 5 31homo-Lys 6 atoms 6 4 2 5 31D-homo-Lys 6 atoms 6 4 2 5 3 1 beta-homo-Lys 5 atoms 4 2 5 3 1 N-Me-Lys 5 atoms 4 2 3 1 Dab / iso-Dab 3 atoms 2 3 1 D-Dab 3 atoms 2 3 1 Orn 4 atoms 4 2 3 1 D-Orn 4 atoms 4 2 1 Dpr 2 atoms 2 7 31Lys(Gly) 8 atoms 6 5 8 4 2 5 3 1 (N3)-Lys 5 atoms 4 2 5 3 1 D-(N3)-Lys 5 atoms 4 2 3 1 Lys(Me) 5 atoms 5 4 2 Carboxylic acid-containing side chains: 1 Glu / iso-Glu 3 atoms 3 2 1 D-Glu / D-iso-Glu 3 atoms 3 2 1 homo-Glu 3 atoms 3 2 1 Asp 2 atoms 2 1 beta-homo-Glu 3 atoms 3 2 3 1 2-amino-6-carboxyhexanoyl 5 atoms 5 4 2 Similarly, the contribution of the length of the lactam bridge from the use of the amine or carboxylic acid of the amino acid residue that is conventionally used in the amide bonds of the peptide backbone (that is, the alpha-amine group (or beta-amine group for bLys, {d}bLys and beta-hLys, or the alpha-amine converted into an azide group for (N3)-K and {d}(N3)-K), or the alpha carboxylic acid group) is counted as the number of atoms in a linear chain from the first atom attached to the atom (carbon) adjacent to the carboxylic acid moiety of the amino acid residue (i.e. the first atom attached to the alpha carbon of the relevant residue for most amino acids), up to and including the atoms which participate in the amide bond of the lactam bridge (i.e. the carbon atom of the carboxylic acid functional group or the nitrogen atom of the amine group). Thus the following amino acid residues are considered to have the following lengths: Using the alpha-amine group (or beta-amine group for bLys, {d}bLys and beta-hLys, or the alpha-amine converted into an azide group for (N3)-K and {d}(N3)-K) that is conventionally used in the peptide backbone in the lactam bridge: 5-aminopentanoyl 4 atoms 2 4 1 3 3-(3-Pyridyl)-Ala 1 atom 1 D-3-(3-Pyridyl)-Ala 1 atom 1 3-(3,5-Pyrimidyl)-Ala 1 atom 1 Lys / iso-Lys 1 atom 1 D-Lys 1 atom 1 beta-Lys 1 atom 1 D-beta-Lys 1 atom 1 homo-Lys 1 atom 1 D-homo-Lys 1 atom 1 beta-homo-Lys 1 atom 1 N-Me-Lys 1 atom 1 Dab / iso-Dab 1 atom 1 D-Dab 1 atom 1 Orn 1 atom 1 D-Orn 1 atom 1 Dpr 1 atom 1 Lys(Gly) 1 atom 1 Using the alpha-carboxylic acid group that is conventionally used in the peptide backbone in the lactam bridge: 1 Dab / iso-Dab 1 atom 1 3-(3-Pyridyl)-Ala 1 atom 1 Glu / iso-Glu 1 atom 1 D-Glu / D-iso-Glu 1 atom The location of the amide bond in the lactam bridge may affect the potency of the compound. The inventors observed that the compound was more active when the amide bond was closer to position 11 (X11) and less active when closer to position 2 (X2) (see Example 2 and Table 2-3b of WO2023 / 099669). Suitable pairings of residues at positions X2 and X11 in which the location of the amide bond in the lactam bridge is closer to position X11 than position X2 once formed include: X2 is D-Lys and X11 is Glu; X2 is Lys and X11 is Glu; X2 is homo-Lys and X11 is Glu; X2 is D-homo-Lys and X11 is Glu; X2 is D-Orn and X11 is homo-Glu; X2 is D-Orn and X11 is Glu; X2 is beta-Lys and X11 is Glu; X2 is D-beta-Lys and X11 is Glu; X2 is Lys and X11 is iso-Dab; X2 is Lys(Gly) and X11 is Glu; X2 is Lys and X11 is beta-homo-Glu; X2 is Ne-Me-Lys and X11 is Glu; X2 is Orn and X11 is Glu; X2 is beta-homo-Lys and X11 is Glu; X2 is (N3)-Lys and X11 is Glu; X2 is D-(N3)-Lys and X11 is Glu; X2 is Glu and X11 is Orn; X2 is Glu and X11 is Lys(Me); and X2 is Glu and X11 is Lys. Alternatively, suitable pairings of residues at positions X2 and X11 in which location of the amide bond in the lactam bridge is closer to position X2 than position X11 include: X2 is D-Dab and X11 is 2-amino-6-carboxyhexanoyl; X2 is Dpr and X11 is Glu; X2 is iso-Lys^and X11 is Glu; and X2 is iso-Dab^and X11 is Glu; X2 is iso-Glu^and X11 is Lys; X2 is iso-Glu^and X11 is Dab; X2 is D-iso-Glu^and X11 is Lys; and X2 is D-iso-Glu^and X11 is Dab. Wherein^denotes that the alpha-amine group (or beta-amine group for bLys, {d}bLys and beta-hLys) that is conventionally used in the peptide backbone is used in the bridge; and^denotes that the alpha-carboxylic acid group that is conventionally used in the peptide backbone is used in the bridge. Alternatively, suitable pairings of residues at positions X2 and X11 in which location of the amide bond in the lactam bridge is in the middle (that is, equal distant or equidistant) of positions X2 and X11 include: X2 is D-Dab and X11 is Glu; and X2 is Dab and X11 is Glu. The location of the amide bond in the lactam bridge between position 2 (X2) and position 7 (X7) may be be closer to position X7 than position X2. Suitable pairings of residues at positions X2 and X7 in which the location of the amide bond in the lactam bridge is closer to position X7 than position X2 once formed include: X2 is iso-Lys and X7 is Glu; and X2 is iso-Dab and X7 is Glu. Alternatively, suitable pairings of residues at positions X2 and X7 in which location of the amide bond in the lactam bridge is closer to position X2 than position X7 include: X2 is D-Lys^and X7 is Glu; X2 is Lys^and X7 is Glu; X2 is D-Lys^and X7 is Asp; X2 is homo-Lys^and X7 is Glu; X2 is D-homo-Lys^and X7 is Glu; X2 is D-Orn^and X7 is Glu; X2 is D-Dab^and X7 is Glu; X2 is D-Orn^and X7 is Asp; X2 is D-Dab^and X7 is Asp; X2 is beta-Lys^and X7 is Glu; X2 is D-beta-Lys^and X7 is Asp; X2 is D-beta-Lys^and X7 is Glu; X2 is Lys^and X7 is D-Glu; X2 is Dab^and X7 is Glu; X2 is Lys^and X7 is homo-Glu; X2 is Glu^and X7 is Glu; X2 is Lys(Gly)^and X7 is Glu; X2 is Ne-Me-Lys^and X7 is Glu; X2 is Orn^and X7 is Glu; X2 is Dpr^and X7 is Glu; X2 is beta-homo-Lys^and X7 is Glu; X2 is iso-Glu^and X7 is Glu; and X2 is D-iso-Glu^and X7 is Glu. Wherein^denotes that the alpha-amine group (or beta-amine group for bLys, {d}bLys and beta-hLys) that is conventionally used in the peptide backbone is used in the bridge; and^denotes that the alpha-carboxylic acid group that is conventionally used in the peptide backbone is used in the bridge. The location of the amide bond in the optional lactam bridge between position 10 (X10) and position 13 (X13) may be be closer to position X13 than position X10. Suitable pairings of residues at positions X10 and X13 in which the location of the amide bond in the lactam bridge is closer to position X13 than position X10 once formed include: X10 is Dab and X13 is 3-(3-Pyridyl)-Ala; and X10 is Lys and X13 is 3-(3-Pyridyl)-Ala. Alternatively, suitable pairings of residues at positions X10 and X13 in which location of the amide bond in the optional lactam bridge is closer to position X10 than position X13. Preferably the location of the amide bond in the optional lactam bridge between position 10 (X10) and position 13 (X13) may be be closer to position X13 than position X10. Desirably, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 5, 6, 7, 8, 9, or 10 atoms; such as 6, 7, 8, or 9 atoms; such as 7 or 8 atoms. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 3 atoms. Suitable pairings of residues at positions X2 and X7 in which the lactam bridge has a length of 3 atoms include: X2 is D-Lys^and X7 is Asp; X2 is D-Orn^and X7 is Asp; X2 is D-Dab^and X7 is Asp; and X2 is D-beta-Lys^and X7 is Asp. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 4 atoms. Suitable pairings of residues at positions X2 and X11 in which the lactam bridge has a length of 4 atoms include: X2 is iso-Lys^and X11 is Glu; X2 is iso-Dab^and X11 is Glu; X2 is iso-Glu^and X11 is Dab; and X2 is D-iso-Glu^and X11 is Dab. Suitable pairings of residues at positions X2 and X7 in which the lactam bridge has a length of 4 atoms include: X2 is D- Lys^and X7 is Glu; X2 is Lys^and X7 is Glu; X2 is homo-Lys^and X7 is Glu; X2 is D- homo-Lys^and X7 is Glu; X2 is D-Orn^and X7 is Glu; X2 is D-Dab^and X7 is Glu; X2 is beta-Lys^and X7 is Glu; X2 is D-beta-Lys^and X7 is Dab^and X7 is Glu; X2 is Lys^and X7 is homo- Lys(Gly)^and X7 is Glu; X2 is Ne-Me-Lys^and X7 is Glu; X2 is Orn^and X7 is Glu; X2 is Dpr^and X7 is Glu; X2 is beta-homo-Lys^and X7 is Glu; X2 is iso-Glu^and X7 is Glu; and X2 is D-iso-Glu^and X7 is Glu. A suitable pairing of residues at positions X10 and X13 in which the lactam bridge has a length of 4 atoms include: X10 is Dab and X13 is 3-(3- Pyridyl)-Ala. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 5 atoms. A suitable pairing of residues at positions X2 and X11 in which the lactam bridge has a length of 5 atoms include: X2 is Dpr and X11 is Glu. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 6 atoms. Suitable pairings of residues at positions X2 and X11 in which the lactam bridge has a length of 6 atoms include: X2 is iso-Glu^and X11 is Lys; X2 is D-iso-Glu^and X11 is Lys; X2 is D-Dab and X11 is Glu; and X2 is Dab and X11 is Glu. A suitable pairing of residues at positions X2 and X7 in which the lactam bridge has a length of 6 atoms include: X2 is iso-Dab and X7 is Glu. A suitable pairing of residues at positions X10 and X13 in which the lactam bridge has a length of 6 atoms include: X10 is Lys and X13 is 3-(3-Pyridyl)-Ala. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 7 atoms. Suitable pairings of residues at positions X2 and X11 in which the lactam bridge has a length of 7 atoms include: X2 is D-Orn and X11 is homo-Glu; X2 is D-Orn and X11 is Glu; X2 is beta-Lys and X11 is Glu; X2 is D-beta-Lys and X11 is Glu; X2 is Orn and X11 is Glu; X2 is Glu and X11 is Orn; and X2 is Glu and X11 is Lys(Me). Preferably, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 8 atoms. Suitable pairings of residues at positions X2 and X11 in which the lactam bridge has a length of 8 atoms include: X2 is D-Lys and X11 is Glu; X2 is Lys and X11 is Glu; X2 is Lys and X11 is iso-Dab; X2 is Lys and X11 is beta-homo-Glu; X2 is Ne-Me-Lys and X11 is Glu; X2 is beta-homo-Lys and X11 is Glu; X2 is (N3)-Lys and X11 is Glu; X2 is D-(N3)-Lys and X11 is Glu; X2 is Glu and X11 is Lys; and X2 is D-Dab and X11 is 2-amino-6-carboxyhexanoyl. A suitable pairing of residues at positions X2 and X7 in which the lactam bridge has a length of 8 atoms include: X2 is iso- Lys and X7 is Glu. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 9 atoms. Suitable pairings of residues at positions X2 and X11 in which the lactam bridge has a length of 9 atoms include: X2 is homo-Lys and X11 is Glu; and X2 is D-homo-Lys and X11 is Glu. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 10 atoms. In some embodiments, the length of the lactam bridge after formation of the amide bond (not including any atoms in the peptide backbone) is 11 atoms. A suitable pairing of residues at positions X2 and X11 in which the lactam bridge has a length of 11 atoms include: X2 is Lys(Gly) and X11 is Glu. Wherein^denotes that the alpha-amine group (or beta-amine group for bLys, {d}bLys and beta-hLys) that is conventionally used in the peptide backbone is used in the bridge; and^ denotes that the alpha-carboxylic acid group that is conventionally used in the peptide backbone is used in the bridge. Bridge containing a triazole ring The contribution of the side chain to the length of the bridge containing a triazole ring is counted as the number of atoms in a linear chain from the first atom of the side chain (which is bonded to an atom of the peptide backbone, i.e. to the alpha carbon of the relevant residue for most amino acids) up to and including the atoms which participate in the formation of the triazole ring (i.e. the first nitrogen atom of the azide group attached to the side chain (i.e. -N=N+=N ) for both 1,4-disubstituted 1,2,3-triazoles and 1,5- disubstituted 1,2,3-triazoles; or the two carbon atoms of the alkyne group for 1,4- disubstituted 1,2,3-triazoles or one carbon atom (i.e. -C CH) of the alkyne group for 1,5- disubstituted triazoles). Thus common alkyne-containing side chains are considered to have the following side chain lengths. It will be understood that the following can be used to decipher the bridge length for any amino acid residue disclosed herein. Alkyne-containing side chains (for 1,4-disubstituted 1,2,3-triazoles): 1 Pra 3 atoms 2 3 1 Hpg 4 atoms 4 3 2 Similarly, the contribution of the length of the bridge containing a triazole ring from the azide or alkyne thart is converted from the amine or carboxylic acid of the amino acid residue is counted as the number of atoms in a linear chain from the first atom attached to the atom (carbon) adjacent to the carboxylic acid moiety of the amino acid residue (i.e. the first atom attached to the alpha carbon of the relevant residue for most amino acids), up to and including the atoms which participate in the formation of the triazole ring (i.e. the first nitrogen atom of the azide group attached to the side chain (i.e. -N=N+=N ) for both 1,4- disubstituted 1,2,3-triazoles and 1,5-disubstituted 1,2,3-triazoles; or the two carbon atoms of the alkyne group for 1,4-disubstituted 1,2,3-triazoles or one carbon atom (i.e. -C CH) of the alkyne group for 1,5-disubstituted triazoles). Thus the following amino acid residues are considered to have the following lengths. It will be understood that the following can be used to decipher the bridge length for any amino acid residue disclosed herein. Using the azide that was converted from the alpha-amine group that is conventionally used in the peptide backbone in the triazole bridge: (N3)-Lys 1 atom 1 D-(N3)-Lys 1 atom 1 The location of the triazole in the bridge may affect the potency of the compound. In some embodiments, the location of the triazole in the bridge containing a triazole ring is closer to position X7 than position X2 once formed (i.e. the number of atoms in a linear chain from the first atom attached to the atom (carbon) adjacent to the carboxylic acid moiety of the amino acid residue (i.e. the first atom attached to the alpha carbon of the relevant residue for most amino acids) up to the triazole ring). Alternatively, in some embodiments the location of the triazole in the bridge containing a triazole ring is closer to position X2 than position X7 once formed (i.e. the number of atoms in a linear chain from the first atom attached to the atom (carbon) adjacent to the carboxylic acid moiety of the amino acid residue (i.e. the first atom attached to the alpha carbon of the relevant residue for most amino acids) up to the triazole ring). Suitable pairings of residues at positions X2 and X7 in which location of the triazole in the bridge containing a triazole ring is closer to position X2 than position X7 once formed include: X2 is (N3)-Lys and X7 is Pra; and X2 is D-(N3)-Lys and X7 is Hpg.Desirably, the length of the bridge containing a triazole ring after the formation of the trazole (not including any atoms in the peptide backbone) is 3, 4, 5, 6, 7, 8, 9, 10, or 11 atoms, such as 4, 5, 6, or 7atoms; such as 4, 5, or 6 atoms, such as 4 or 5 atoms. In some embodiments, the length of the bridge containing a triazole ring provided by the two side chains after formation of the triazole (not including any atoms in the peptide backbone) is 4 atoms. A suitable pairing of residues at positions X2 and X7 in which the bridge containing a triazole ring has a length of 4 atoms include: X2 is (N3)-Lys and X7 is Pra. In some embodiments, the length of the bridge containing a triazole ring provided by the two side chains after formation of the triazole (not including any atoms in the peptide backbone) is 5 atoms. A suitable pairing of residues at positions X2 and X7 in which the bridge containing a triazole ring has a length of 5 atoms include: X2 is D-(N3)-Lys and X7 is Hpg. Synthesis of the compounds The invention further provides a method of synthesis of a compound of the invention. The compounds (which may also be referred to as peptides) may suitably be manufactured by standard synthetic methods. Thus, the peptides may be synthesized by, e.g., methods comprising synthesizing the peptide by standard solid-phase or liquid-phase methodology, either stepwise or by fragment assembly, and optionally isolating and purifying the final peptide product. In this context, reference may be made to WO 98 / 11125 or, inter alia, Fields, G.B. et al., ^Principles and Practice of Solid-Phase Peptide Synthesis^; in: Synthetic Peptides, Gregory A. Grant (ed.), Oxford University Press (2ndedition, 2002) and the synthesis examples herein. The method typically further comprises the step of forming an amide bond between the amino acid residues at positions 2 (X2) and 11 (X11), and optionally further comprising the step of forming an amide bond or forming a triazole between the amino acid residues at positions 2 (X2) and 7 (X7), and optionally further comprising the step of forming an amide bond between the amino acid residues at positions X10 and X13, e.g. as described below. In the case of solid phase synthesis, cyclisation may be performed in situ on the solid phase (e.g. resin), i.e. before removal of the peptide from the solid phase. The synthesis of some example compounds of the invention are provided in Example 1. Generally, the method for the synthesis of said compound comprises synthesising the compound by solid-phase or liquid-phase peptide synthesis methodology, optionally isolating and / or purifying the final product, and optionally further comprising the step of forming an amide bond between the amino acid residues at positions 2 and 11, and optionally further comprising the step of forming an amide bond or forming a triazole between the amino acid residues at positions 4 and 7, and optionally further comprising the step of forming an amide bond between the amino acid residues at positions 10 and 13. The order of the steps in the synthesis of the compounds are not necessarily in the order mentioned above. For example, the order of the formation of the bridges (lactam bridge / amide bond; triazole bridge) may be in any order. In some embodiments, the bridge between the amino acid residues at positions 2 and 11 is formed first, then the bridge between the amino acid residues at positions 2 and 7 is formed second, and then the optional bridge between the amino acid residues at positions 10 and 13 is formed third. In other embodiments, the bridge between the amino acid residues at positions 2 and 7 is formed first, then the bridge between the amino acid residues positions 2 and 11 is formed second, and then the optional bridge between the amino acid residues at positions 10 and 13 is formed third. In other embodiments, the bridge between the amino acid residues at positions 2 and 11 is formed first, then the optional bridge between the amino acid residues positions 10 and 13 is formed second, and then the bridge between the amino acid residues at positions 2 and 7 is formed third. In other embodiments, the optional bridge between the amino acid residues at positions 10 and 13 is formed first, then the bridge between the amino acid residues positions 2 and 11 is formed second, and then the bridge between the amino acid residues at positions 2 and 7 is formed third. In other embodiments, the bridge between the amino acid residues at positions 2 and 7 is formed first, then the optional bridge between the amino acid residues positions 10 and 13 is formed second, and then the bridge between the amino acid residues at positions 2 and 11 is formed third. In other embodiments, the optional bridge between the amino acid residues at positions 10 and 13 is formed first, then the bridge between the amino acid residues positions 2 and 7 is formed second, and then the bridge between the amino acid residues at positions 2 and 11 is formed third. Efficacy of the compounds The compounds of the invention are interleukin-23 receptor (IL-23R) inhibitors, i.e. they are capable of binding to, and blocking signalling by, one or more receptors or receptor complexes regarded as physiological receptors for interleukin-23 (IL-23). Comparative activity may be measured by any suitable means, such as via determination of IC50 values as described below. Compounds of the present invention may exhibit a number of advantageous properties in relation to other peptide IL-23R inhibitors thereof, such as analogues described in WO 2016 / 011208, WO 2018 / 022937, WO 2018 / 136646, WO 2020 / 014646, WO 2021 / 146441, WO 2021 / 146458, WO 2023 / 288017, WO 2023 / 288019, WO 2023 / 288028, Kong et al., 2020, WO 2023 / 099669 and WO 2024 / 015958. As compared to any of these analogues, compounds of the invention may, for example, exhibit improved effects, e.g., in the form of improved in vitro potency at IL-23R. Additionally or alternatively, compounds of the invention may exhibit improved gastrointestinal (GI) stability as compared to any of the peptide inhibitors of IL-23R described in the art. The skilled person will be aware of suitable assay formats, and examples are provided below. For example, the assays may make use of employing measurements on the human IL-23R (see the examples below). Where sequences of precursor proteins are referred to, it should be understood that assays may make use of the mature protein, lacking the signal sequence. Kdvalues may be used as a numerical measure of the binding affinity at a given receptor. A Kdvalue, also termed the equilibrium dissociation constant, is a measure of how tightly a compound binds to a receptor in a particular assay. A small Kdindicates the compound binds tighter with higher affinity to the receptor as compared to a compound with a higher Kdvalue. Thus, for example, a compound having a Kd[IL-23R] value lower than the Kd[IL-23R] value of another compound inhibitor of IL-23R in a particular assay may be considered to have a stronger binding affinity (or binds more tightly) to IL-23R than that of the other compound inhibitor of IL-23R. In absence of an experimental method to directly determine the Kdof a compound for a receptor, the binding affinities for compounds may be estimated by means of determining the IC50of a compound. The IC50is determined by the compound^s ability to compete with a labelled compound for the receptor. In such a competition assay, the concentration for which half of the labelled compound is displaced from the receptor by the unlabelled compound is termed the IC50 value. The IC50 value is proportional to the affinity of the compound for the receptor (that is, its Kd value), and is assay system dependent as it depends on factors such as the concentration of the labelled compound used, the affinity of the labelled compound for the receptor, and assay incubation times. In a binding assay format an IC50 value may be used as a numerical format to measure how tightly a compound binds to a receptor in a particular assay. A small IC50 indicates the compound binds tighter with higher affinity to the receptor as compared to a compound with a higher IC50 value. Thus, for example, a compound having a IC50 [IL- 23R] value lower than the IC50 [IL-23R] value of another compound inhibitor of IL-23R in a particular assay may be considered to have a stronger binding affinity (or binds more tightly) to IL-23R than that of the other compound inhibitor of IL-23R. In some embodiments of compounds of the present invention, the IC50 towards IL-23R is below 1000 nM (e.g. 0.0001 to 1000 nM). In some embodiments of compounds of the present invention, the IC50 towards IL-23R is below 500 nM (e.g.0.0001 to 500 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 100 nM (e.g.0.0001 to 100 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 50 nM (e.g. 0.0001 to 50 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 30 nM (e.g. 0.0001 to 30 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 20 nM (e.g. 0.0001 to 20 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 10 nM (e.g. 0.0001 to 10 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 5 nM (e.g.0.0001 to 5 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23R is below 1 nM (e.g.0.0001 to 1 nM). In some embodiments of compounds of the present invention, the IC50 towards IL-23R is below 0.5 nM (e.g.0.0001 to 0.5 nM). In a functional assay format, measuring the ability of compounds to inhibit IL-23 mediated signalling in a cell-based assay, IC50 values may be used as a numerical measure of inhibitor potency. An IC50 value is a measure of the concentration of a compound required to achieve half of that compound^s maximal activity in a particular assay. Thus, for example, a compound having an IC50 [IL-23R] value lower than that of another compound inhibitor of IL-23R in a particular assay may be considered to have a stronger inhibitory potency, presumably by better blocking of the IL-23 mediated signalling, than that of the other peptide inhibitor of IL-23R. In some embodiments of compounds of the present invention, the IC50 towards IL-23 mediated signalling is below 1000 nM (e.g.0.0001 to 1000 nM). In some embodiments of compounds of the present invention, the IC50 towards IL-23 mediated signalling is below 500 nM (e.g. 0.0001 to 500 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 100 nM (e.g. 0.0001 to 100 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 50 nM (e.g.0.0001 to 50 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 30 nM (e.g.0.0001 to 30 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 20 nM (e.g.0.0001 to 20 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 10 nM (e.g.0.0001 to 10 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 5 nM (e.g.0.0001 to 5 nM). In some embodiments of compounds of the present invention, the IC50towards IL-23 mediated signalling is below 1 nM (e.g.0.0001 to 1 nM). In some embodiments of compounds of the present invention, the IC50 towards IL-23 mediated signalling is below 0.5 nM (e.g.0.0001 to 0.5 nM). In some embodiments of compounds of the present invention, the IC50 towards IL-23 mediated signalling is below 0.5 nM (e.g.0.0001 to 0.5 nM). Such assays may be performed under the conditions described in Examples 3-1 and 3-2 below. Additionally or alternatively, compounds of the invention may show gastrointestinal (GI) stability, i.e. resistance to degradation in the gastrointestinal tract. This can be measured using a simulated intestinal fluid (SIF) assay and / or a simulated gastric fluid (SGF) assay. For example, the compounds of the invention may retain at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, or at least 85%, at least 90%, at least 95%, or at least 99% of the remaining compound or peptide after incubation for 1 hour, or for 4 hours, e.g. under the conditions described in Examples 3-3 and 3-4. Preferably, the compounds retain at least 70% (or more) of the compound after incubation for 1 hour, or 4 hours, under the SIF and / or SGF assay. Pharmaceutical compositions The invention also extends to compositions, such as pharmaceutical compositions, comprising the compounds of the invention. As with all aspects of the invention, it is to be understood that reference to a compound of the invention encompasses reference to pharmaceutically acceptable salts and solvates. The compounds of the present invention may be formulated as pharmaceutical compositions which are suited for administration with or without storage, and which typically comprise a therapeutically effective amount of at least one peptide of the invention, together with a pharmaceutically acceptable carrier, excipient or vehicle. The pharmaceutical composition may be for any mode of administration common or standard in the art, e.g. oral, intravenous, intramuscular, subcutaneous, sublingual, intranasal, intradermal, suppository routes or implanting. In a preferred embodiment of the invention as described herein the pharmaceutical composition is a composition for oral administration. The term ^pharmaceutically acceptable carrier^ includes any of the standard pharmaceutical carriers. Pharmaceutically acceptable carriers for therapeutic use are well known in the pharmaceutical art and are described, for example, in ^Remington's Pharmaceutical Sciences^, 17thedition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, PA, USA, 1985. Therapeutic uses The compounds of the invention, and pharmaceutical compositions comprising said compounds, are useful in a method of prevention or treatment of various conditions. The method of prevention or treatment comprises administering to the subject a therapeutically effective amount of the compound of the invention, or the pharmaceutical composition comprising said compound. In some embodiments, the conditions may be selected from Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-I, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, ankylosing spondylitis, and graft versus host disease.In a preferred embodiment, the conditions may be selected from inflammatory bowel disease (IBD) such as Crohn^s Disease or ulcerative colitis, psoriatic arthritis, and psoriasis. In some embodiments, the conditions may be selected from inflammatory bowel disease (IBD) such as Crohn^s Disease or ulcerative colitis, and psoriasis. In some embodiments, the conditions may be selected from inflammatory bowel disease (IBD) and psoriasis. The subject or patient may be an animal subject or patient. The subject or patient may be a human subject or patient. Preferably, the subject is a human subject or patient. Dosages A typical dosage of a compound as employed in the context of the present invention may be in the range from about 0.0001 to about 100 mg / kg body weight per day, such as from about 0.0005 to about 50 mg / kg body weight per day, such as from about 0.001 to about 10 mg / kg body weight per day, e.g. from about 0.01 to about 1 mg / kg body weight per day, administered in one or more doses, such as from one to three doses. The exact dosage employed will depend, inter alia, on: the nature and severity of the disease or disorder to be treated, on the sex, age, body weight and general condition of the subject to be treated, on possible other, concomitant, disease or disorder that is undergoing or is to undergo treatment, as well as on other factors that will be known to a medical practitioner of skill in the art. The administration of the compounds described herein may be by any mode of administration common or standard in the art, e.g. oral, intravenous, intramuscular, subcutaneous, sublingual, intranasal, intradermal, suppository routes or implanting. In a preferred embodiment of the invention as described herein administration is by oral administration. EXAMPLES The following examples demonstrate certain specific embodiments of the present invention. The following examples were carried out using standard techniques that are well known and routine to those of skill in the art, except where otherwise described in detail. It is to be understood that these examples are for illustrative purposes only and do not purport to be wholly definitive as to conditions or scope of the invention. As such, they should not be construed as limiting the scope of the present invention in any way. Abbreviations employed for the amino acids and particular R2groups may be found in Tables A-C in the definitions. Other abbreviations employed in the examples include:tBuOH tert-Butanol DODT 2,2 -(Ethylenedioxy)diethanethiol Pd(PPh3)4tetrakis(triphenylphosphine)palladium(0)) PhSiH3phenylsilane PyBOP benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate) equiv. equivalents r.t. room temperature aq. Aqueous IL-23R interleukin-23 receptor hIL-23R human interleukin-23 receptor GI gastrointestinal SIF simulated intestinal fluid SGF simulated gastric fluid Nluc NanoBRET luciferase assay SD standard deviation %Eff percentage efficacy pSTAT3 phosphorylated signal transducer and activator of transcription 3 BRET Bioluminescence Resonance Energy Transfer TAMRA 5^-tetramethylrhodamine-5-carboxamide The following examples are provided to illustrate certain embodiments of the invention and are not intended to limit the scope of the invention. Example 1: Synthesis of compounds The following compounds were synthesised in Table 1-1 below. Table 1-1: Synthesised compounds Compound Structure [{d}K](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 1 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCCNC(=O)CC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NH2] 2 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H]( C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O) N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH ]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}K](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 3 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCCNC(=O)CC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 4 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCCNC(=O)CC[C@@H] (C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O) N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH ]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 5 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCCCNC(=O)CC[C@@H](C (=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[ C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c 3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Orn](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 6 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCNC(=O)CCC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 Compound Structure [{d}Dab](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino-6- carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 7 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCNC(=O)CCCC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Orn](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 8 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCNC(=O)CCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Dab](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino- 6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 9 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCNC(=O)CCCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Orn](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 10 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCNC(=O)CC[C@@H](C(=O) N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C@ @H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3cc ccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Dab](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 11 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C@@ H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3cccc c13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [bLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 12 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCNC(=O)CC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)CC(=O)N[ C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c 3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 Compound Structure [{d}bLys](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 13 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCNC(=O)CC[C@@H](C(=O) N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)CC(=O)N[C@ @H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H]( CCC(N)=O)C(=O)N2 [{d}bLys](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 14 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCNC(=O)CC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)CC(=O)N[ C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@ H](CCC(N)=O)C(=O)N2 [{d}Dab](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino-6- carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 15 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCNC(=O)CCCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H] (CCC(N)=O)C(=O)N2 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NH2] 16 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C )NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@ H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc2 3)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][Aib]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N 17 [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC(=O)C(C)(C)NC(=O) [C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H](CCC( =O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(= O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][{d}3-(3-Pyridyl)- Ala]-[NH2] 18 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)N C(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H] (CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23) NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)-Ala]- [NH2] 19 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H](CCC(=O)N2) NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H ](C(C)C)NC1=O Compound Structure K(1c)(6c)^IVWQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala]-[NH2] 20 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@H](CC3CC3)NC(=O)[C@H](CCC(=O)N2)NC( =O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C( C)C)NC1=O K(1c)(6c)^IVWQE(6c)[2-Me-Phe][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)- Ala]-[NH2] 21 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@](C)(Cc3ccccc3)NC(=O)[C@H](CCC(=O)N2)N C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H]( C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[{d}F][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)-Ala]- [NH2] 22 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H](CCC(=O)N2) NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H ](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][Cyclopropyl-Ala][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala]-[NH2] 23 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( CC3CC3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[ C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C) NC1=O K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^-[3- pyridylpropionyl] 24 Cc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)[C @@H](NC(=O)CCc4cccnc4)CCNC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc4 ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C )C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(=O)N[C@@H](CCC(N)=O)C(=O) N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^-[6- (3-pyridyl)hexanoyl] 25 Cc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)[C @@H](NC(=O)CCCCCc4cccnc4)CCNC(=O)[C@](C)(CC(C)C)NC(=O)[C@H] (Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H] (C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(=O)N[C@@H](CCC(N)=O)C (=O)N3)cc1 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-2- (pyridin-3-yl)ethyl] 26 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(= O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CC C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O Compound Structure K(1c)(6c)^IVWQ[{d}E](6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-2- (pyridin-3-yl)ethyl] 27 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(= O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@@H](CCC(=O)N2)NC(=O)[C@H]( CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1= O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-4- (pyridin-3-yl)butanyl] 28 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCCCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)N C(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H]( CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1= O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-6- (pyridin-3-yl)hexanyl] 29 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCCCCCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3 )NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@ H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC 1=O K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)-[NH-4- (pyridin-3-yl)butanyl] 30 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H]( C(=O)NCCCCc3cccnc3)NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C) C)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O) N2 K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)-[NH-4-(pyridin-3- yl)butanyl] 31 CC(C)[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCCNC(=O)CC[C@ @H](C(=O)NCCCCc3cccnc3)NC(=O)CNC(=O)[C@H](Cc3ccc4ccccc4c3)NC( =O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](C CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O K(1c)(6c)^IVWQE(6c)[Y(nPr)][2-Nal][2-Me-Leu]E(1c)-[NH-4-(pyridin-3- yl)butanyl] 32 CCCOc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(= O)CC[C@@H](C(=O)NCCCCc4cccnc4)NC(=O)[C@](C)(CC(C)C)NC(=O)[C @H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C @@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(=O)N[C@@H](CCC( N)=O)C(=O)N3)cc1 K(1c)(6c)^IVWQE(6c)[F(4-Bu)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NHMe] 33 CCCCc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(= O)CC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc4cccnc4)C(=O)N C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O) N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[n H]c4ccccc24)C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 Compound Structure K(1c)(6c)^IVWQE(6c)[Y(Bn)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NHMe] 34 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)c c3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc 2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NHMe] 35 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OC)cc3)NC(= O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3 ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 36 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@ H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C )(CC(C)C)C(=O)N1 [Dab](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 37 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H]( Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(C C(C)C)C(=O)N1 K(1c)(6c)^TWQ[hGlu](6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 38 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@ @H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@]( C)(CC(C)C)C(=O)N1 E(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]K(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 39 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCCN C(=O)CC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@ @H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@]( C)(CC(C)C)C(=O)N1 Compound Structure E(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Orn](1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 40 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCNC( =O)CC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H ](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H] (Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)( CC(C)C)C(=O)N1 [(N3)-K](1c)(6g)^TWQ[Pra](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 41 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc3c[nH]c 4ccccc34)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc3cn2nn3)C(=O)N [C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C @@](C)(CC(C)C)C(=O)N1 [{d}(N3)-K](1c)(6g)^TWQ[Hpg](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 42 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc3c[nH ]c4ccccc34)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCc3cn2nn3)C(= O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O) N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 43 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N [C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 44 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 45 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)c c2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [K(G)](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 46 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC (=O)[C@H](Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 Compound Structure K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(piconilate)]-[NH2] COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C 47 C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4ccccn4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2-pyridylacetyl)]- [NH2] 48 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ccccn4)C(N)=O)NC(=O)[C@] (C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2-pyridylpropionyl)]- [NH2] 49 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4ccccn4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(nicotinate)]-[NH2] COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C 50 C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4cccnc4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3-pyridylacetyl)]- [NH2] 51 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4cccnc4)C(N)=O)NC(=O)[C@] (C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3-pyridylpropionyl)]- [NH2] 52 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4cccnc4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(isonicotinyl)]-[NH2] COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C 53 C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4ccncc4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 Compound Structure K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridylacetyl)]- [NH2] 54 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ccncc4)C(N)=O)NC(=O)[C@] (C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridylpropionyl)]- [NH2] 55 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4ccncc4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3,5-pyrimidine)]- [NH2] 56 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4cncnc4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridyl-3- fluoroacetyl)]-[NH2] 57 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ccnc(F)c4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(Imidazoleacetyl)]- [NH2] 58 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ncc[nH]4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(Imidazolepropanoyl)]- [NH2] 59 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4ncc[nH]4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 Compound Structure K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 60 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC (=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH] c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta-hGlu](1c)[3- (3-Pyridyl)-Ala]-[NHMe] 61 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](CC(=O) N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc 3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O) N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C @H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[4- Aminopiperidin-4-carbonyl][3-(3-Pyridyl)-Ala]-[NHMe] 62 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N C3(C(=O)N[C@@H](Cc4cccnc4)C(=O)NC)CCNCC3)NC(=O)[C@](C)(CC(C) C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(= O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3 ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)P[3-(3- Pyridyl)-Ala]-[NHMe] 63 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N 3CCC[C@H]3C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C) C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(= O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3 ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[5- Aminopentanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 64 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCCCC(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C)C)NC(= O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@ H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc2 3)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta-hGlu](1c)- [NH-2-(pyridin-3-yl)ethyl] 65 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](CC(=O) NCCc3cccnc3)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)N C(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H]( CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1= O Compound Structure K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH-2- (pyridin-3-yl)ethyl] 66 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)NCCc3cccnc3)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H] (Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(= O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O) [C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH-3- (pyridin-3-yl)propyl] 67 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)NCCCc3cccnc3)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@ H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC (=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(= O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)[Dab][3-(3-Pyridyl)- Ala]-[NHMe] 68 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)CNC(=O)[C@ H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC (=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(= O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)H[3-(3- Pyridyl)-Ala]-[NHMe] 69 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN) cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C c2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H][3-(3- Pyridyl)-Ala]-[NHMe] 70 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C) (CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc 3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2 c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(3- Quinolinyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 71 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](Cc3cnc4ccccc4c3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[ C@](C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(O CCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O Compound Structure K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[(R,S)- Imidazolidin-2-carbonyl][3-(3-Pyridyl)-Ala]-[NHMe] 72 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N 3CCNC3C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C)C)N C(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[ C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3cc ccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[H(1-Me)][3- (3-Pyridyl)-Ala]-[NHMe] 73 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](Cc3cn(C)cn3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN) cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C c2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O E(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][K(Me)](1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 74 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCC(=O)N(C)CCCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)( CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3 )NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c [nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O [N-Me-Lys](1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 75 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC (=O)[C@H](CCC(=O)N2C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[n H]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][Dab](7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^ 76 CC(C)[C@@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCCNC(= O)CC[C@@H]3NC(=O)[C@H](CCNC(=O)[C@H](Cc4cccnc4)NC(=O)[C@H]( CCN)NC3=O)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCC N)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H] (Cc2c[nH]c3ccccc23)NC1=O K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal]K(7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^ 77 CC(C)[C@@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCCNC(= O)CC[C@@H]3NC(=O)[C@H](CCCCNC(=O)[C@H](Cc4cccnc4)NC(=O)[C @H](CCN)NC3=O)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc( OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc2c[nH]c3ccccc23)NC1=O Compound Structure K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3,5- Pyrimidyl)-Ala]-[NHMe] 78 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cncnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC (=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH] c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^[3-Aminopropanoyl][1-Me-Trp]QE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 79 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3cn(C)c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN) cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N 1 [N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 80 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 81 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCN(C)C2=O)C(=O)N[C@@H](Cc2ccc(OCC N)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O) N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 82 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](CC2CC2)C(=O) N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(3-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 83 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2cccnc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(2-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 84 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccccn2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(4-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 85 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccncc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)H[3-(3-Pyridyl)-Ala]-[NHMe] 86 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1 CCC(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC (=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(3-Pyridyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 87 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1cccnc1)NC(=O)[C@@H]1CC C(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(= O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(2-Pyridyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 88 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1ccccn1)NC(=O)[C@@H]1CC C(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(= O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(4-Pyridyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 89 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@@H]1CC C(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(= O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 [Orn](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 90 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H] (Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2) C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [Orn](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 91 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H] (Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2 )C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 Compound Structure [Dab](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 92 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 93 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O )N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [Dab](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 94 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C @@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [Dpr](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 95 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C c3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@ @H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[beta-hIle]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 96 CC[C@H](C)[C@H]1CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H ](CCC(N)=O)C(=O)N[C@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H]( C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN) cc3)NC2=O)C(=O)N1 K(1c)(6c)^[beta-hThr]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 97 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)C[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@ @H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@]( C)(CC(C)C)C(=O)N1 K(1c)(6c)^[4-Aminobutanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 98 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN )cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N 1 Compound Structure [beta-hLys](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 99 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2CC(=O)NCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 [beta-hLys](1c)(6c)^[beta-hTrp]QE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 100 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2CC(=O)N[C@@H](Cc3c[nH]c4ccccc34)CC(=O)N[C@@H](C CC(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [beta-hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 101 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2CC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CC C(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2) C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Lys](1c)^(6c)WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 102 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C @@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Dab](1c)^(6c)WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 103 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc 3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@ @H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Lys](1c)^(6c)GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 104 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Dab](1c)^(6c)GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 105 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc 3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 Compound Structure [iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]K(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 106 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCCN C(=O)[C@@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](C CC(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Dab](1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 107 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCNC(= O)[C@@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CCC (N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [{d}iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]K(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 108 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCCN C(=O)[C@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CC C(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2) C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [{d}iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Dab](1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 109 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCNC(= O)[C@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CCC(N )=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)W[2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 110 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2c[nH]c3cccc c23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N 1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[Q(Me)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 111 CNC(=O)CC[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCNC(=O )[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@@ H](Cc3cccnc3)C(=O)NC)NC(=O)C(C)(C)NC(=O)[C@H](Cc3ccc4ccccc4c3)N C(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2C)NC1=O K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-morpholine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 112 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(N3CCO CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 Compound Structure N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4-Diaminobutanoyl(Ac-N- Me)]E(6c)[Y(2-aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3- (3-Pyridyl)-Ala]-[NHMe] 113 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCN(C)C(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc 2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N 1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(2-aminoethoxy)][2Nal][Aib]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 114 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCNC(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2cc c(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal]{d}AE(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 115 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@H](C)C(=O)N1 {d}K(1c)(6c)^[3-Aminopropanoyl]WQ{d}E(6c)[Y(2- aminoethoxy)][2Nal][2-Me-Leu]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-Ala]-[NHMe] 116 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2NC(=O)CC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)c c2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-THP)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 117 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(C3CCO CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 118 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CH3-2-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 119 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC)cc2 F)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 120 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCNC(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2cc c(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- F)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 121 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (F)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-piperazine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 122 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(N3CCN CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-imidazole)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 123 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(- n3ccnc3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C )C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CH3-3-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 124 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC)c(F) c2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl]-[NH-2-(pyridin-3- yl)ethyl] 125 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)NCCc3cccnc3)NC1=O)C(=O)NCCC(=O)N[C@@H](Cc1c[ nH]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-piperidine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 126 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(C3CCN CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[5- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 127 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ccncc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(Ac-2-aminoethoxy)][2Nal][2- Me-Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 128 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC- CNC(C)=O)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C )C)C(=O)N1 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 129 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCN(C)C2=O)C(=O)N[C@@H](Cc2ccc(OCC N)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 130 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[6- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 131 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3cnccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 Compound Structure N-Me-Lys-oxy-propanoyl(1c)(6c)^WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 132 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)OCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(CH3)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3- Pyridyl)-Ala]-[NHMe] 133 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCNC(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2cc c(OC)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c^[3-Aminopropanoyl]WQE(6c)[F(4-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 134 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(F)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- CONH2)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 135 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (C(N)=O)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- Ala][3-Aminopropanoyl]-[NH2] 136 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NCCC(N)=O)NC1=O)C(=O) NCCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(= O)N2 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- Ala]{d}H-[NH2] 137 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)N[C@H](Cc3cnc[nH]3)C(N) =O)NC1=O)C(=O)NCCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@ H](CCC(N)=O)C(=O)N2 Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- Ala]{d}W-[NH2] 138 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)N[C@H](Cc3c[nH]c4ccccc3 4)C(N)=O)NC1=O)C(=O)NCCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[ C@@H](CCC(N)=O)C(=O)N2 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CF3)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 139 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC(F)(F )F)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O )N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 140 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQ{d}E(6c)[Y(2-aminoethoxy)][2Nal][2- Me-Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 141 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCC N)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O) N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[Q(2Me)]E(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 142 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(=O)N(C)C)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc 2c[nH]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O) N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- morpholine)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 143 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (N3CCOCC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O) N1 Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-morpholine)][2Nal][2-Me- Leu]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 144 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(N3CCO CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][Q(2Me)]E(6c)[Y(2- aminoethoxy)(N(Me)2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-alanyl]-[NHMe] 145 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N(C)C)NC(=O) [C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N 1 K(1c)(6c)^[3-Aminopropanoyl][7MeTrp][Q(2Me)]E(6c)[Y(nPentylamine) (N+(Me)3)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-alanyl]- [NHMe] 146 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N(C)C)NC(=O) [C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCCCC[N+](C)(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)( C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][Q(2Me)]E(6c)[Y(2-trimethyl- PEG2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-alanyl]- [NHMe] 147 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N(C)C)NC(=O) [C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCOC- COCC[N+](C)(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C (=O)N1 K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][K(NMePEG3)]E(6c)[Y(2- aminoethoxy)(N(Me)2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-alanyl]-[NHMe] 148 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCCCN(C)C(=O)COC- COCC[N+](C)(C)C)NC(=O)[C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O )C(=O)N[C@@H](Cc2ccc(OCCN(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c 2)C(=O)NC(C)(C)C(=O)N1 The bridging amino acid residue is the amino acid residue directly preceding the parentheses below. The square brackets indicate the bridging amino acid residues. For example, [2,11] is a bridge between amino acid residues 2 and 11. Similarly, [2,7] is a bridge between amino acid residues 2 and 7, and [10,13] is a bridge between amino acid residues 10 and 13.^denotes that the (1c), (6c), (6g), and (7c) bridges use the alpha-amine group (or beta- amine group for bLys, {d}bLys and beta-hLys, or the alpha-amine converted into an azide group for (N3)-K and {d}(N3)-K) of the amino acid in the bridge^denotes that the (1c), (6c), (6g), and (7c) bridges use the alpha-carboxylic acid group of the amino acid in the bridge (1c) denotes the [2,11] lactam bridge; (6c) denotes the [2,7] lactam bridge; (6g) denotes the [2,7] 1,4-disubstituted 1,2,3-triazole bridge; (7c) denotes the [10,13] lactam bridge. The compound numbering of Table 1-1 corresponds to the same number as the SEQ ID NO., as shown in Table 1-1a below. Table 1-1a: Sequence ID Numbers of synthesised compounds from Table 1-1 SEQ ID NO: Sequence SEQ ID NO: 1 [{d}K](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] K(1c ^ SEQ ID NO: 2 )(6c) TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 3 [{d}K](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 4 [hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 5 [{d}hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 6 [{d}Orn](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 7 [{d}Dab](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2- Amino-6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala] [{d}Orn](1c)(6c ^ SEQ ID NO: 8 ) TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala] [{d}Dab](1c)(6c ^ SEQ ID NO: 9 ) TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2- Amino-6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 10 [{d}Orn](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: Sequence SEQ ID NO: 11 [{d}Dab](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 12 [bLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 13 [{d}bLys](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 14 [{d}bLys](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 15 [{d}Dab](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino- 6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 16 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)- Ala]SEQ ID NO: 17K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][Aib]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 18 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][{d}3-(3- Pyridyl)-Ala] K(1c ^ SEQ ID NO: 19 )(6c) IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)- Ala] SEQ ID NO: 20 K(1c)(6c)^IVWQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala] SEQ ID NO: 21 K(1c)(6c)^IVWQE(6c)[2-Me-Phe][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)- Ala]SEQ ID NO: 22K(1c)(6c)^IVWQE(6c)[{d}F][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)-Ala] SEQ ID NO: 23 K(1c)(6c)^IVWQE(6c)[F(4-Me)][Cyclopropyl-Ala][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala]SEQ ID NO: 24K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^SEQ ID NO: 25K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^SEQ ID NO: 26K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 27K(1c)(6c)^IVWQ[{d}E](6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 28K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c) SEQ ID NO: SequenceSEQ ID NO: 29K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 30K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)SEQ ID NO: 31K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)SEQ ID NO: 32K(1c)(6c)^IVWQE(6c)[Y(nPr)][2-Nal][2-Me-Leu]E(1c) SEQ ID NO: 33 K(1c)(6c)^IVWQE(6c)[F(4-Bu)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 34 K(1c)(6c)^IVWQE(6c)[Y(Bn)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 35 K(1c)(6c)^IVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 36 K(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala] SEQ ID NO: 37 [Dab](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 38 K(1c)(6c)^TWQ[hGlu](6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 39 E(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]K(1c)[Dab][3-(3- Pyridyl)-Ala] SEQ ID NO: 40 E(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Orn](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 41 [(N3)-K](1c)(6g)^TWQ[Pra](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 42 [{d}(N3)-K](1c)(6g)^TWQ[Hpg](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 43 K(1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala] SEQ ID NO: 44 K(1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala] K(1c) ^ SEQ ID NO: 45 (6c) [3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 46 [K(G)](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: SequenceSEQ ID NO: 47K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(piconilate)]SEQ ID NO: 48K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2-pyridylacetyl)] SEQ ID NO: 49 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2- pyridylpropionyl)]SEQ ID NO: 50K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(nicotinate)]SEQ ID NO: 51K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3-pyridylacetyl)] SEQ ID NO: 52 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3- pyridylpropionyl)]SEQ ID NO: 53K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(isonicotinyl)]SEQ ID NO: 54K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridylacetyl)] SEQ ID NO: 55 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4- pyridylpropionyl)]SEQ ID NO: 56K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3,5-pyrimidine)] SEQ ID NO: 57 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridyl-3- fluoroacetyl)]SEQ ID NO: 58K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(Imidazoleacetyl)] K(1c) ^ SEQ ID NO: 59 (6c) TVWQE(6c)[Y(Me)][2-Nal][2-Me- Leu]E(1c)[K(Imidazolepropanoyl)] SEQ ID NO: 60 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 61 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta- hGlu](1c)[3-(3-Pyridyl)-Ala] SEQ ID NO: 62 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[4- Aminopiperidin-4-carbonyl][3-(3-Pyridyl)-Ala] K ^ SEQ ID NO: 63 (1c)(6c) IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)P[3-(3- Pyridyl)-Ala] K(1c)(6c ^ SEQ ID NO: 64 ) IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[5- Aminopentanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: SequenceSEQ ID NO: 65K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta-hGlu](1c)SEQ ID NO: 66K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]SEQ ID NO: 67K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab] SEQ ID NO: 68 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)[Dab][3-(3-Pyridyl)- Ala] K(1c) ^ SEQ ID NO: 69 (6c) IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)H[3-(3- Pyridyl)-Ala] SEQ ID NO: 70 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H][3- (3-Pyridyl)-Ala] SEQ ID NO: 71 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(3- Quinolinyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 72 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[(R,S)- Imidazolidin-2-carbonyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 73 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[H(1- Me)][3-(3-Pyridyl)-Ala] SEQ ID NO: 74 E(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][K(Me)](1c)[Dab][3-(3-Pyridyl)-Ala] 75 [N-Me-Lys] ^ SEQ ID NO: (1c)(6c) IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 76 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][Dab](7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^ SEQ ID NO: 77 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal]K(7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^ SEQ ID NO: 78 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3,5-Pyrimidyl)-Ala] SEQ ID NO: 79 K(1c)(6c)^[3-Aminopropanoyl][1-Me-Trp]QE(6c)[Y(2-aminoethoxy)][2- Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] [N-M ^ SEQ ID NO: 80 e-Lys](1c)(6c) [3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2- Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 81 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 82 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: Sequence SEQ ID NO: 83 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(3-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 84 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(2-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] K(1c) ^ SEQ ID NO: 85 (6c) [3-Aminopropanoyl]WQE(6c)[3-(4-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 86 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)H[3-(3-Pyridyl)-Ala] SEQ ID NO: 87 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(3-Pyridyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 88 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(2-Pyridyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 89 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(4-Pyridyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 90 [Orn](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 91 [Orn](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 92 [Dab](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 93 [hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ...

Claims

CLAIMS 1. A compound of the formula: Z-R2wherein R2is NHR3or C(=O)R3, wherein R3is hydrogen or C1-6 alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula I: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I) wherein X2 is selected from the group consisting of Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, (N3)-Lys, D-(N3)-Lys, (N3)-beta-Lys, (N3)-D-beta-Lys, (N3)-homo-Lys, (N3)-D-homo-Lys, (N3)-beta-homo-Lys, Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, (N3)-Dpr, D-(N3)-Dpr, (N3)-beta-Dpr, (N3)-D-beta- Dpr, (N3)-homo-Dpr, (N3)-D-homo-Dpr, (N3)-beta-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, (N3)-Dab, D-(N3)-Dab, (N3)-beta-Dab, (N3)-D- beta-Dab, (N3)-homo-Dab, (N3)-D-homo-Dab, (N3)-beta-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, (N3)-Orn, D-(N3)-Orn, (N3)-beta-Orn, (N3)-D-beta- Orn, (N3)-homo-Orn, (N3)-D-homo-Orn, (N3)-beta-homo-Orn, Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, (N3)-Asp, D-(N3)-Asp, (N3)-beta-Asp, (N3)-D-beta- Asp, (N3)-homo-Asp, (N3)-D-homo-Asp, (N3)-beta-homo-Asp,Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, (N3)-Glu, D-(N3)-Glu, (N3)-beta-Glu, (N3)-D-beta-Glu, (N3)-homo-Glu, (N3)-D-homo-Glu, (N3)-beta-homo-Glu, 2-amino-6-carboxyhexanoyl and 3-aminopropanoyl; X3 is selected from any amino acid, -hydroxy-C2-6 alkanoic acid or is absent; X4 is selected from the group consisting of Val, D-Val, beta-Val, D-beta-Val, homo-Val, D- homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo-Val, 2-Me-Val, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile or is absent; X5 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, and an optionally substituted beta- homotryptophan residue; X6 is selected from the group consisting of an optionally substituted Gln residue, an optionally substituted Lys residue, an optionally substituted Arg residue, an optionally substituted Dab residue, an optionally substituted Orn residue, an optionally substituted Phe residue, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N- Me-Ala, N-Me-homo-Ala, Cit, D-Cit, beta-Cit, D-beta-Cit, homo-Cit, D-homo-Cit, beta- homo-Cit, N-Me-Cit, N-Me-homo-Cit, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Tyr, D-Tyr, beta-Tyr, D-beta-Tyr, homo-Tyr, D-homo-Tyr, beta-homo-Tyr, N-Me-Tyr, N-Me-homo-Tyr, Val, D- Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N-Me-homo- Val or His, D-His, beta-His, D-beta-His, homo-His, D-homo-His, beta-homo-His, N-Me-His and N-Me-homo-His; X7 is selected from the group consisting of Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D- beta-Asp, homo-Asp, D-homo-Asp, beta-homo-Asp, N-Me-Asp, N-Me-homo-Asp,Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-Lys, iso-Lys, beta-Lys, D-iso-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Pra, D-Pra, beta-Pra, D-beta-Pra, homo-Pra, D-homo-Pra, beta-homo-Pra, N-Me-Pra, N- Me-homo-Pra, Hpg, D-Hpg, beta-Hpg, D-beta-Hpg, homo-Hpg, D-homo-Hpg, beta-homo-Hpg, N-Me-Hpg and N-Me-homo-Hpg; X8 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted beta- homotryptophan residue, an optionally substituted tyrosine residue, an optionally substituted phenylalanine residue, an optionally substituted homophenylalanine residue, and an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted; X9 is selected from the group consisting of an optionally substituted tryptophan residue, an optionally substituted azatryptophan residue, an optionally substituted alanine residue, an optionally substituted phenylalanine and an optionally substituted tyrosine residue; X10 is selected from the group consisting of, Val, D-Val, beta-Val, D-beta-Val, homo-Val, D-homo-Val, beta-homo-Val, N-Me-Val, N- Me-homo-Val, 2-Me-Val, Gly, beta-Gly, homo-Gly, beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab,Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Aib, D-Aib, beta-Aib, D-beta-Aib, homo-Aib, D-homo-Aib, beta-homo-Aib, N-Me-Aib, N- Me-homo-Aib, Ala, D-Ala, beta-Ala, D-beta-Ala, homo-Ala, D-homo-Ala, beta-homo-Ala, N-Me-Ala, N- Me-homo-Ala, Leu, D-Leu, beta-Leu, D-beta-Leu, homo-Leu, D-homo-Leu, beta-homo-Leu, N-Me-Leu, N-Me-homo-Leu, 2-Me-Leu, Ile, D-Ile, beta-Ile, D-beta-Ile, homo-Ile, D-homo-Ile, beta-homo-Ile, N-Me-Ile, N-Me-homo- Ile, and a carbocyclic or heterocyclic ring having an amino substituent and a carbonyl substituent; X11 is selected from the group consisting of Dpr, D-Dpr, iso-Dpr, D-iso-Dpr, beta-Dpr, D-beta-Dpr, homo-Dpr, D-homo-Dpr, beta- homo-Dpr, N-Me-Dpr, N-Me-homo-Dpr, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo-Dab, beta- homo-Dab, N-Me-Dab, N-Me-homo-Dab, Orn, D-Orn, iso-Orn, D-iso-Orn, beta-Orn, D-beta-Orn, homo-Orn, D-homo-Orn, beta- homo-Orn, N-Me-Orn, N-Me-homo-Orn, Lys, D-lys, iso-Lys, D-iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, beta-homo- Lys, N-Me-Lys, N-Me-homo-Lys, Lys(Me), Lys(Gly), Asp, D-Asp, iso-Asp, D-iso-Asp, beta-Asp, D-beta-Asp, homo-Asp, D-homo-Asp, beta- homo-Asp, N-Me-Asp, N-Me-homo-Asp, Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D-beta-Glu, homo-Glu, D-homo-Glu, beta-homo- Glu, N-Me-Glu, N-Me-homo-Glu, and 2-amino-6-carboxyhexanoyl;X12 is selected from the group consisting of an optionally substituted Phe residue, an optionally substituted Tyr residue, an optionally substituted His residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Dab, D-Dab, iso-Dab, D-iso-Dab, beta-Dab, D-beta-Dab, homo-Dab, D-homo- Dab, beta-homo-Dab, N-Me-Dab, N-Me-homo-Dab, Gly, , beta-Gly, homo-Gly, , beta- homo-Gly, N-Me-Gly, N-Me-homo-Gly, Pro, 5-aminopentanoyl,4-aminopiperidin-4- carbonyl, (R,S)-Imidazolidin-2-carbonyl, 3-aminopropanoyl, Gly-CF3, D-Gly-CF3, Nle, Gln, D-Gln, iso-Gln, D-iso-Gln, beta-Gln, D-beta-Gln, homo-Gln, D-homo-Gln, beta-homo-Gln, N-Me-Gln, N-Me-homo-Gln, THP, Ser, D-Ser, beta-Ser, D-beta-Ser, homo-Ser, D-homo- Ser, beta-homo-Ser, N-Me-Ser, N-Me-homo-Ser, Ser(OMe), 3-aminotetrahydrofuran-3- carbonyl, Arg, D-Arg, beta-Arg, D-beta-Arg, homo-Arg, D-homo-Arg, beta-homo-Arg, N- Me-Arg, N-Me-homo-Arg, , Thr, D-Thr, beta-Thr, D-beta-Thr, homo-Thr, D-homo-Thr, beta-homo-Thr, N-Me-Thr, N-Me-homo-Thr Glu, D-Glu, iso-Glu, D-iso-Glu, beta-Glu, D- beta-Glu, homo-Glu, D-homo-Glu, beta-homo-Glu, N-Me-Glu, N-Me-homo-Glu, Asn, D- Asn, beta-Asn, D-beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me- homo-Asn, 4-aminobutanoyl, 2-(trimethyl-2-aminoethoxy)ethoxy]propyl and Lys wherein the side chain -NH2of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent; and X13 is selected from the group consisting of an optionally substituted His residue, an optionally substituted Phe residue, an alanine residue substituted by a carbocyclic group or an aromatic or heteroaromatic group selected from the group consisting of phenyl, pyridyl, naphthyl and quinolinyl, each optionally substituted, Asn, D-Asn, beta-Asn, D- beta-Asn, homo-Asn, D-homo-Asn, beta-homo-Asn, N-Me-Asn, N-Me-homo-Asn, Gly, , beta-Gly, , homo-Gly, , beta-homo-Gly, N-Me-Gly, N-Me-homo-Gly, and Dab, Orn or Lys wherein the side chain -NH2is substituted with -C(=O)(CH2)nRK wherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and(iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof.

2. The compound according to claim 1, wherein X2 is selected from the group consisting of Dab, D-Dab, iso-Dab, Lys, iso-Lys, D-beta-Lys, N-Me-Lys, homo-Lys, D-Lys, D-homo-Lys, beta-Lys, beta-homo-Lys, Lys(Gly), (N3)-Lys, D-(N3)-Lys, D-iso-Glu, iso-Glu, Glu, Orn, D-Orn, Dpr, and Lys(Gly).

3. The compound according to any one of claims 1 or 2, wherein X3 is selected from the group consisting of Thr, Ile, 3-aminopropanoyl, 4-aminobutanoyl, beta-homo-Ile, beta- homo-Thr, beta-homo-Trp, Gly, N-Me-3-aminopropanoyl, Ser, Trp, Phe, N-Me-Ser, N-Me- Ala, 3-hydroxypropanoic acid or is absent.

4. The compound according to any of on claims 1 to 3, wherein X4 is absent or Val.

5. The compound according to any of claims 1 to 4, wherein X5 is selected from the group consisting of Trp, 1-Me-Trp, 7-Aza-Trp, 7-Me-Trp and beta-homo-Trp.

6. The compound according to any one of claims 1 to 5, wherein X6 is selected from the group consisting of Dab(Ac), Dab(Ac-N-Me), Gln, Gln(2Me), K(NMePEG3) and Gln(Me).

7. The compound according to any one of claims 1 to 6, wherein X7 is selected from the group consisting of Asp, D-Glu, Glu, Pra, Hpg and homo-Glu.

8. The compound according to any one of claims 1 to 7, wherein X8 is selected from the group consisting of Y(2-aminoethoxy), Y(2-aminoethoxy)(N(Me)2), Y(nPentylamine) (N+(Me)3), Y(2-trimethyl-PEG2), homo-Phe, 7-AzaTrp, beta-homo-Trp, 7-F-Trp, F(4- morpholine), 3-quinolinylalanine, Y(Me), Y(nPr), Y(Bn), Trp, D-Phe, 2-Me-Phe, F(4-Me), F(4-Bu), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, Cyclopropyl-Ala, F(4-THP), Y(CH3-2-F), F(4-F), F(4-piperazine), F(4-imidazole), F(4-piperidine), Y(CH3-3-F), 5- AzaTrp, Y(Ac-2-aminoethoxy), 6-AzaTrp and F(4-CONH2).

9. The compound accoridng to any one of claims 1 to 8, wherein X9 is selected from the group consisting of 2NaI and cyclopropyl-Ala. 10 The compound according to any one of claims 1 to 9, wherein X10 is selected from the group consisting of Dab, 2-Me-Leu, 2-Me-Val, Aib, D-Ala, Gly and Lys.

11. The compound according to any one of claims 1 to 10, wherein X11 is selected from the group consisting of Dab, 2-amino-6-carboxyhexanoyl, beta-homo-Glu, Glu, homo-Glu, iso-Dab, Lys, Orn and Lys(Me).

12. The compound according to any one of claims 1 to 11, wherein X12 is selected from the group consisting of Dab, His, D-His, His(1-Me), 3-(2-Pyridyl)-Ala, 3-(3-Pyridyl)- Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, Gly, Pro, Ser(OCH3), 5-aminopentanoyl, 4- aminopiperidin-4-carbonyl, (R,S)-Imidazolidin-2-carbonyl, and Lys wherein the side chain - NH2 of the Lys is substituted with -C(=O)(CH2)nRKwherein n is 0-2 and RKis imidazolyl, pyrimidyl, or pyridyl optionally substituted with F, or X12 is absent.

13. The compound according to any one of claims 1 to 12, wherein X13 is selected from the group consisting of 3-(3-Pyridyl)-Ala, D-3-(3-Pyridyl)-Ala, and 3-(3,5-Pyrimidyl)- Ala, or is absent.

14. The compound according to any one of claims 1 to 13, wherein: Z-R2wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl optionally substituted with a pyridyl ring, or is absent; and Z is an amino acid sequence of formula Ia: X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (Ia) wherein X2 is selected from the group consisting of Lys, D-Lys, iso-Lys, beta-Lys, D-beta-Lys, homo-Lys, D-homo-Lys, , beta-homo-Lys, N-Me-Lys, Dab, D-Dab, Glu, iso-Glu, Orn, D- Orn, Lys(Gly), (N3)-Lys and D-(N3)-Lys; X3 is selected from the group consisting of Thr, Trp, Ile, 3-aminopropanoyl, 4- aminobutanoyl, beta-homo-Ile, beta-homo-Thr, Gly, and N-Me-3-aminopropanoyl, 3- hydroxypropanoic acid or is absent; X4 is Val or is absent; X5 is Trp or 1-Me-Trp;X6 is Gln, Gln(Me), Dab(Ac-N-Me), Dab(Ac) or Gln(2Me); X7 is selected from the group consisting of Glu, homo-Glu, Asp, Pra, and Hpg; X8 is selected from the group consisting of Y(2-aminoethoxy), Y(Me), Y(Bn), Y(2- aminoethoxy)(N(Me)2), Y(nPentylamine)(N+(Me)3), Y(2-trimethyl-PEG2), F(4-Me), F(4- Bu), Cyclopropyl-Ala, F(4-morpholine), F(4-THP), Y(CH3-2-F), F(4-F), F(4-piperazine), F(4-imidazole), Y(CH3-3-F), F(4piperidine), 5-AzaTrp, Y(Ac-2-aminoethoxy), 7-AzaTrp, 6- AzaTrp, F(4-CONH2); X9 is 2-Nal; X10 is selected from the group consisting of 2-Me-Leu, 2-Me-Val, D-Ala, Dab, Gly, and Aib; X11 is selected from the group consisting of Glu, homo-Glu, Lys, Lys(Me), Orn, and 2- amino-6-carboxyhexanoyl; X12 is selected from the group consisting of Dab, His, S(OCH3), D-His, His(1-Me), 3-(3- Quinolinyl)-Ala, and 4-aminopiperidin-4-carbonyl; and X13 is 3-(3-Pyridyl)-Ala, 3-(3,5-Pyrimidyl)-Ala, or is absent; wherein (i) X2 and X11 are amino acid residues who together form a lactam bridge; (ii) X2 and X7 are amino acid residues who together form a lactam bridge or a bridge containing a triazole ring; and (iii) optionally, when X13 is present, X10 and X13 are amino acid residues who together form a lactam bridge; or a pharmaceutically acceptable salt or solvate thereof.

15. The compound according to any one of claims 1 to 14, wherein the lactam bridge between X2 and X11 uses the side chain of the amino acid residue at X2, and the bridge between X2 and X7 uses the N-terminus of the amino acid residue at X2.

16. The compound according to any one of the preceding claims, wherein X2 is Lys; optionally wherein X3 is selected from the group consisting of Thr, Ile, and 3- aminopropanoyl, or is absent. optionally wherein X4 is absent.

17. The compound according to any one of the preceding claims, wherein X5 is Trp; optionally wherein X7 is Glu; optionally wherein X8 is Y(2-aminoethoxy), Y(Me), or F(4-Me); optionally wherein X8 is Y(2-aminoethoxy).

18. The compound according to any one of the preceding claims, wherein X9 is 2-Nal; optionally wherein X10 is 2-Me-Leu or 2-Me-Val; optionally wherein X10 is 2-Me-Leu; optionally wherein X11 is Glu.

19. The compound according to any one of the preceding claims, wherein X12 is Dab; optionally wherein X13 is 3-(3-Pyridyl)-Ala or is absent; optionally wherein X13 is 3-(3- Pyridyl)-Ala.

20. The compound according to any one of the preceding claims, wherein R2is NHR3wherein R3is hydrogen or C1-6alkyl; optionally wherein R2is NH2or NHMe.

21. The compound according to any one of the preceding claims, wherein: X2 is Lys; X5 is Trp; X9 is 2-Nal; and X10 is 2-Me-Leu; or X2 is Lys; X5 is Trp; X9 is 2-Nal; X10 is 2-Me-Leu; and R2is NH2or NHMe; orX2 is Lys; X5 is Trp; X9 is 2-Nal; X10 is 2-Me-Leu; X13 is 3-(3-Pyridyl)-Ala or is absent, and R2is NH2 or NHMe; or X2 is Lys; X5 is Trp; X7 is Glu; X9 is 2-Nal; X10 is 2-Me-Leu; X13 is 3-(3-Pyridyl)-Ala or is absent, and R2is NH2 or NHMe.

22. The compound according to claim 1 wherein Z is an amino acid sequence selected from the group consisting of: SEQ ID NO: Sequence [{d}K] ^ SEQ ID NO: 1 (1c)(6c) TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 2 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 3 [{d}K](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 4 [hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 5 [{d}hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 6 [{d}Orn](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 7 [{d}Dab](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2- Amino-6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala] [{d}Orn](1c ^ SEQ ID NO: 8 )(6c) TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala] [{d}Dab]( ^ SEQ ID NO: 9 1c)(6c) TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2- Amino-6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 10 [{d}Orn](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 11 [{d}Dab](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 12 [bLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 13 [{d}bLys](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]SEQ ID NO: Sequence SEQ ID NO: 14 [{d}bLys](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 15 [{d}Dab](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino- 6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 16 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)- Ala]SEQ ID NO: 17K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][Aib]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 18 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][{d}3-(3- Pyridyl)-Ala] SEQ ID NO: 19 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)- Ala] SEQ ID NO: 20 K(1c)(6c)^IVWQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala] SEQ ID NO: 21 K(1c)(6c)^IVWQE(6c)[2-Me-Phe][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)- Ala]SEQ ID NO: 22K(1c)(6c)^IVWQE(6c)[{d}F][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)-Ala] K(1c)(6 ^ SEQ ID NO: 23 c) IVWQE(6c)[F(4-Me)][Cyclopropyl-Ala][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala]SEQ ID NO: 24K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^SEQ ID NO: 25K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^SEQ ID NO: 26K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 27K(1c)(6c)^IVWQ[{d}E](6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 28K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 29K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)SEQ ID NO: 30K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)SEQ ID NO: 31K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)SEQ ID NO: SequenceSEQ ID NO: 32K(1c)(6c)^IVWQE(6c)[Y(nPr)][2-Nal][2-Me-Leu]E(1c) SEQ ID NO: 33 K(1c)(6c)^IVWQE(6c)[F(4-Bu)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 34 K(1c)(6c)^IVWQE(6c)[Y(Bn)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 35 K(1c)(6c)^IVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 36 K(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala] SEQ ID NO: 37 [Dab](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 38 K(1c)(6c)^TWQ[hGlu](6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] ^ SEQ ID NO: 39 E(1c)(6c) TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]K(1c)[Dab][3-(3- Pyridyl)-Ala] E(1c)(6c)^ SEQ ID NO: 40 TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Orn](1c)[Dab][3-(3-Pyridyl)-Ala] [(N3)-K](1c)(6g ^ SEQ ID NO: 41 ) TWQ[Pra](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] [{d}(N3)-K](1 ^ SEQ ID NO: 42 c)(6g) TWQ[Hpg](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] K(1c)(6c)^ SEQ ID NO: 43 WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala] SEQ ID NO: 44 K(1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala] SEQ ID NO: 45 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 46 [K(G)](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]SEQ ID NO: 47K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(piconilate)]SEQ ID NO: 48K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2-pyridylacetyl)] SEQ ID NO: 49 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2- pyridylpropionyl)]SEQ ID NO: SequenceSEQ ID NO: 50K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(nicotinate)]SEQ ID NO: 51K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3-pyridylacetyl)] SEQ ID NO: 52 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3- pyridylpropionyl)]SEQ ID NO: 53K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(isonicotinyl)]SEQ ID NO: 54K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridylacetyl)] SEQ ID NO: 55 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4- pyridylpropionyl)]SEQ ID NO: 56K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3,5-pyrimidine)] SEQ ID NO: 57 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridyl-3- fluoroacetyl)]SEQ ID NO: 58K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(Imidazoleacetyl)] SEQ ID NO: 59 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me- Leu]E(1c)[K(Imidazolepropanoyl)] SEQ ID NO: 60 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 61 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta- hGlu](1c)[3-(3-Pyridyl)-Ala] SEQ ID NO: 62 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[4- Aminopiperidin-4-carbonyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 63 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)P[3-(3- Pyridyl)-Ala] SEQ ID NO: 64 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[5- Aminopentanoyl][3-(3-Pyridyl)-Ala]SEQ ID NO: 65K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta-hGlu](1c)SEQ ID NO: 66K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]SEQ ID NO: 67K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]SEQ ID NO: Sequence SEQ ID NO: 68 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)[Dab][3-(3-Pyridyl)- Ala] SEQ ID NO: 69 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)H[3-(3- Pyridyl)-Ala] SEQ ID NO: 70 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H][3- (3-Pyridyl)-Ala] SEQ ID NO: 71 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(3- Quinolinyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 72 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[(R,S)- Imidazolidin-2-carbonyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 73 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[H(1- Me)][3-(3-Pyridyl)-Ala] SEQ ID NO: 74 E(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][K(Me)](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 75 [N-Me-Lys](1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 76 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][Dab](7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^SEQ ID NO: 77 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal]K(7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^SEQ ID NO: 78 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3,5-Pyrimidyl)-Ala] SEQ ID NO: 79 K(1c)(6c)^[3-Aminopropanoyl][1-Me-Trp]QE(6c)[Y(2-aminoethoxy)][2- Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 80 [N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2- Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 81 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 82 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 83 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(3-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 84 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(2-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 85 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(4-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]SEQ ID NO: Sequence SEQ ID NO: 86 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)H[3-(3-Pyridyl)-Ala] SEQ ID NO: 87 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(3-Pyridyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 88 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(2-Pyridyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 89 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(4-Pyridyl)-Ala][3-(3-Pyridyl)-Ala] SEQ ID NO: 90 [Orn](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] [Orn](1c ^ SEQ ID NO: 91 )(6c) [3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 92 [Dab](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 93 [hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 94 [Dab](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 95 [Dpr](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 96 K(1c)(6c)^[beta-hIle]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] K(1c)( ^ SEQ ID NO: 97 6c) [beta-hThr]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 98 K(1c)(6c)^[4-Aminobutanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 99 [beta-hLys](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] EQ ID NO: 100 [beta-hLys](1c)(6c)^[beta-hTrp]QE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] EQ ID NO: 101 [beta-hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] EQ ID NO: 102 [iso-Lys](1c)^(6c)WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] EQ ID NO: 103 [iso-Dab](1c)^(6c)WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]SEQ ID NO: Sequence SEQ ID NO: 104 [iso-Lys](1c)^(6c)GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 105 [iso-Dab](1c)^(6c)GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 106 [iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]K(1c)[Dab][3-(3-Pyridyl)-Ala] [iso-Glu](1c)^(6c)^ SEQ ID NO: 107 WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Dab](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 108 [{d}iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]K(1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 109 [{d}iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Dab](1c)[Dab][3-(3-Pyridyl)-Ala] SEQ ID NO: 110 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)W[2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala] SEQ ID NO: 111 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[Q(Me)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 112 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-morpholine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 113 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4-Diaminobutanoyl(Ac-N- Me)]E(6c)[Y(2-aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-Ala] SEQ ID NO: 114 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(2-aminoethoxy)][2Nal][Aib]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 115 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal]{d}AE(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 116 {d}K(1c)(6c)^[3-Aminopropanoyl]WQ{d}E(6c)[Y(2-aminoethoxy)][2Nal][2- Me-Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]SEQ ID NO: Sequence SEQ ID NO: 117 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-THP)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 118 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 119 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CH3-2-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 120 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 121 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- F)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 122 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-piperazine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 123 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-imidazole)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 124 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CH3-3-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 125 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl] SEQ ID NO: 126 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-piperidine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 127 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[5- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]SEQ ID NO: Sequence SEQ ID NO: 128 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(Ac-2-aminoethoxy)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 129 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 130 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 131 N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[6- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 132 N-Me-Lys-oxy-propanoyl(1c)(6c)^WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 133 N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(CH3)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3- Pyridyl)-Ala] SEQ ID NO: 134 K(1c)(6c^[3-Aminopropanoyl]WQE(6c)[F(4-F)][2Nal][2-Me-Leu]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 135 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- CONH2)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 136 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- alanyl][3-Aminopropanoyl] SEQ ID NO: 137 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]{d}H SEQ ID NO: 138 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- Ala]{d}WSEQ ID NO: Sequence SEQ ID NO: 139 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CF3)][2Nal][2-Me-Leu]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 140 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 141 K(1c)(6c)^[3-Aminopropanoyl]WQ{d}E(6c)[Y(2-aminoethoxy)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala] SEQ ID NO: 142 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[Q(2Me)]E(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 143 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- morpholine)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 144 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-morpholine)][2Nal][2-Me- Leu]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala] SEQ ID NO: 145K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][Q(2Me)]E(6c)[Y(2- aminoethoxy)(N(Me)2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-alanyl]-[NHMe] SEQ ID NO: 146K(1c)(6c)^[3-Aminopropanoyl][7MeTrp][Q(2Me)]E(6c)[Y(nPentylamine) (N+(Me)3)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-alanyl]- [NHMe] SEQ ID NO: 147 K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][Q(2Me)]E(6c)[Y(2-trimethyl- PEG2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-alanyl]-[NHMe] SEQ ID NO: 148K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][K(NMePEG3)]E(6c)[Y(2- aminoethoxy)(N(Me)2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-alanyl]-[NHMe] wherein:^denotes that the (1c), (6c), (6g), and (7c) bridges use the alpha-amine group (or beta- amine group for bLys, {d}bLys and beta-hLys, or the alpha-amine converted into an azide group for (N3)-K and {d}(N3)-K) of the amino acid in the bridge^denotes that the (1c), (6c), (6g), and (7c) bridges use the alpha-carboxylic acid group of the amino acid in the bridge (1c) denotes the [2,11] lactam bridge; (6c) denotes the [2,7] lactam bridge; (6g) denotes the [2,7] 1,4-disubstituted 1,2,3-triazole bridge; (7c) denotes the [10,13] lactam bridge.

23. A compound according to claim 1 which is selected from: Compound Structure [{d}K](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 1 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCCNC(=O)CC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NH2] 2 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H]( C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O) N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH ]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}K](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 3 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCCNC(=O)CC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 4 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCCNC(=O)CC[C@@H] (C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O) N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH ]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2Compound Structure [{d}hLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 5 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCCCNC(=O)CC[C@@H](C (=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[ C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c 3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Orn](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 6 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCNC(=O)CCC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Dab](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino-6- carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 7 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCNC(=O)CCCC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Orn](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][hGlu](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 8 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCNC(=O)CCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Dab](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino- 6-carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 9 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCNC(=O)CCCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3 ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}Orn](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 10 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCNC(=O)CC[C@@H](C(=O) N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C@ @H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3cc ccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2Compound Structure [{d}Dab](1c)(6c)^TVWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 11 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C@@ H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c3cccc c13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [bLys](1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NH2] 12 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCNC(=O)CC[C@@H](C( =O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)CC(=O)N[ C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c 3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 [{d}bLys](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 13 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCCNC(=O)CC[C@@H](C(=O) N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)CC(=O)N[C@ @H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H]( CCC(N)=O)C(=O)N2 [{d}bLys](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 14 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@H](CCCNC(=O)CC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)CC(=O)N[ C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@ H](CCC(N)=O)C(=O)N2 [{d}Dab](1c)(6c)^TWQD(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][2-Amino-6- carboxyhexanoyl](1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] 15 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CC(=O)N[C@H](CCNC(=O)CCCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC1=O)C(=O)N[C @@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H] (CCC(N)=O)C(=O)N2 K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NH2] 16 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C )NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@ H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc2 3)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][Aib]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2] CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N 17 [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(N)=O)NC(=O)C(C)(C)NC(=O) [C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H](CCC( =O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(= O)[C@H](C(C)C)NC1=OCompound Structure K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)[Dab][{d}3-(3-Pyridyl)- Ala]-[NH2] 18 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)N C(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H] (CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23) NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)-Ala]- [NH2] 19 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H](CCC(=O)N2) NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H ](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala]-[NH2] 20 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@H](CC3CC3)NC(=O)[C@H](CCC(=O)N2)NC( =O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C( C)C)NC1=O K(1c)(6c)^IVWQE(6c)[2-Me-Phe][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)- Ala]-[NH2] 21 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@](C)(Cc3ccccc3)NC(=O)[C@H](CCC(=O)N2)N C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H]( C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[{d}F][2-Nal][2-Me-Val]E(1c)G[{d}3-(3-Pyridyl)-Ala]- [NH2] 22 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( Cc3ccc4ccccc4c3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H](CCC(=O)N2) NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H ](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[F(4-Me)][Cyclopropyl-Ala][2-Me-Val]E(1c)G[{d}3-(3- Pyridyl)-Ala]-[NH2] 23 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CC(=O)N[C@H](Cc3cccnc3)C(N)=O)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H]( CC3CC3)NC(=O)[C@H](Cc3ccc(C)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[ C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C) NC1=OCompound Structure K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^-[3- pyridylpropionyl] 24 Cc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)[C @@H](NC(=O)CCc4cccnc4)CCNC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc4 ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C )C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(=O)N[C@@H](CCC(N)=O)C(=O) N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][iso-Dab](1c)^-[6- (3-pyridyl)hexanoyl] 25 Cc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)[C @@H](NC(=O)CCCCCc4cccnc4)CCNC(=O)[C@](C)(CC(C)C)NC(=O)[C@H] (Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H] (C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(=O)N[C@@H](CCC(N)=O)C (=O)N3)cc1 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-2- (pyridin-3-yl)ethyl] 26 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(= O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CC C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQ[{d}E](6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-2- (pyridin-3-yl)ethyl] 27 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(= O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@@H](CCC(=O)N2)NC(=O)[C@H]( CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1= O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-4- (pyridin-3-yl)butanyl] 28 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCCCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)N C(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H]( CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1= O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)-[NH-6- (pyridin-3-yl)hexanyl] 29 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCCCCCc3cccnc3)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3 )NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@ H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC 1=O K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)-[NH-4- (pyridin-3-yl)butanyl] 30 CC(C)C[C@]1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(O CCN)cc2)NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H]( C(=O)NCCCCc3cccnc3)NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C) C)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O) N2Compound Structure K(1c)(6c)^SVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)-[NH-4-(pyridin-3- yl)butanyl] 31 CC(C)[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCCNC(=O)CC[C@ @H](C(=O)NCCCCc3cccnc3)NC(=O)CNC(=O)[C@H](Cc3ccc4ccccc4c3)NC( =O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](C CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O K(1c)(6c)^IVWQE(6c)[Y(nPr)][2-Nal][2-Me-Leu]E(1c)-[NH-4-(pyridin-3- yl)butanyl] 32 CCCOc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(= O)CC[C@@H](C(=O)NCCCCc4cccnc4)NC(=O)[C@](C)(CC(C)C)NC(=O)[C @H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C @@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(=O)N[C@@H](CCC( N)=O)C(=O)N3)cc1 K(1c)(6c)^IVWQE(6c)[F(4-Bu)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NHMe] 33 CCCCc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(= O)CC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc4cccnc4)C(=O)N C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O) N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[n H]c4ccccc24)C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^IVWQE(6c)[Y(Bn)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NHMe] 34 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)c c3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc 2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]- [NHMe] 35 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OC)cc3)NC(= O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3 ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 36 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@ H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C )(CC(C)C)C(=O)N1 [Dab](1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 37 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H]( Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(C C(C)C)C(=O)N1Compound Structure K(1c)(6c)^TWQ[hGlu](6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 38 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@ @H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@]( C)(CC(C)C)C(=O)N1 E(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]K(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 39 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCCN C(=O)CC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@ @H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@]( C)(CC(C)C)C(=O)N1 E(1c)(6c)^TWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Orn](1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 40 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCNC( =O)CC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H ](Cc3c[nH]c4ccccc34)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H] (Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)( CC(C)C)C(=O)N1 [(N3)-K](1c)(6g)^TWQ[Pra](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 41 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc3c[nH]c 4ccccc34)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc3cn2nn3)C(=O)N [C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C @@](C)(CC(C)C)C(=O)N1 [{d}(N3)-K](1c)(6g)^TWQ[Hpg](6g)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 42 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc3c[nH ]c4ccccc34)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCc3cn2nn3)C(= O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O) N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 43 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N [C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 44 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 45 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)c c2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [K(G)](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 46 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC (=O)[C@H](Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(piconilate)]-[NH2] COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C 47 C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4ccccn4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2-pyridylacetyl)]- [NH2] 48 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ccccn4)C(N)=O)NC(=O)[C@] (C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(2-pyridylpropionyl)]- [NH2] 49 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4ccccn4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(nicotinate)]-[NH2] COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C 50 C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4cccnc4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3-pyridylacetyl)]- [NH2] 51 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4cccnc4)C(N)=O)NC(=O)[C@] (C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1Compound Structure K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3-pyridylpropionyl)]- [NH2] 52 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4cccnc4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(isonicotinyl)]-[NH2] COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C 53 C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4ccncc4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridylacetyl)]- [NH2] 54 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ccncc4)C(N)=O)NC(=O)[C@] (C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridylpropionyl)]- [NH2] 55 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4ccncc4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(3,5-pyrimidine)]- [NH2] 56 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)c4cncnc4)C(N)=O)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([C@ @H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24)C(= O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(4-pyridyl-3- fluoroacetyl)]-[NH2] 57 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ccnc(F)c4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(Imidazoleacetyl)]- [NH2] 58 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)Cc4ncc[nH]4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1Compound Structure K(1c)(6c)^TVWQE(6c)[Y(Me)][2-Nal][2-Me-Leu]E(1c)[K(Imidazolepropanoyl)]- [NH2] 59 COc1ccc(C[C@@H]2NC(=O)[C@@H]3CCC(=O)N[C@@H](CCCCNC(=O)C C[C@@H](C(=O)N[C@@H](CCCCNC(=O)CCc4ncc[nH]4)C(N)=O)NC(=O)[C @](C)(CC(C)C)NC(=O)[C@H](Cc4ccc5ccccc5c4)NC2=O)C(=O)N[C@@H]([ C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2c[nH]c4ccccc24) C(=O)N[C@@H](CCC(N)=O)C(=O)N3)cc1 K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 60 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC (=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH] c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta-hGlu](1c)[3- (3-Pyridyl)-Ala]-[NHMe] 61 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](CC(=O) N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc 3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O) N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C @H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[4- Aminopiperidin-4-carbonyl][3-(3-Pyridyl)-Ala]-[NHMe] 62 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N C3(C(=O)N[C@@H](Cc4cccnc4)C(=O)NC)CCNCC3)NC(=O)[C@](C)(CC(C) C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(= O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3 ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)P[3-(3- Pyridyl)-Ala]-[NHMe] 63 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N 3CCC[C@H]3C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C) C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(= O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3 ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[5- Aminopentanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 64 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N CCCCC(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C)C)NC(= O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@ H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc2 3)NC(=O)[C@H](C(C)C)NC1=OCompound Structure K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][beta-hGlu](1c)- [NH-2-(pyridin-3-yl)ethyl] 65 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](CC(=O) NCCc3cccnc3)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)N C(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H]( CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1= O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH-2- (pyridin-3-yl)ethyl] 66 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)NCCc3cccnc3)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H] (Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(= O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O) [C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH-3- (pyridin-3-yl)propyl] 67 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)NCCCc3cccnc3)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@ H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC (=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(= O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal]GE(1c)[Dab][3-(3-Pyridyl)- Ala]-[NHMe] 68 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)CNC(=O)[C@ H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC (=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(= O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)H[3-(3- Pyridyl)-Ala]-[NHMe] 69 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN) cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C c2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H][3-(3- Pyridyl)-Ala]-[NHMe] 70 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C) (CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc 3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2 c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=OCompound Structure K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(3- Quinolinyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 71 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](Cc3cnc4ccccc4c3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[ C@](C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(O CCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[(R,S)- Imidazolidin-2-carbonyl][3-(3-Pyridyl)-Ala]-[NHMe] 72 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N 3CCNC3C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC(C)C)N C(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[ C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3cc ccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[H(1-Me)][3- (3-Pyridyl)-Ala]-[NHMe] 73 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](Cc3cn(C)cn3)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN) cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C c2c[nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O E(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][K(Me)](1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 74 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCC(=O)N(C)CCCC[C@@H](C(= O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)( CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3 )NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c [nH]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O [N-Me-Lys](1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 75 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC (=O)[C@H](CCC(=O)N2C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[n H]c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal][Dab](7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^ 76 CC(C)[C@@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCCNC(= O)CC[C@@H]3NC(=O)[C@H](CCNC(=O)[C@H](Cc4cccnc4)NC(=O)[C@H]( CCN)NC3=O)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCC N)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H] (Cc2c[nH]c3ccccc23)NC1=OCompound Structure K(1c)(6c)^TVWQE(6c)[Y(2-aminoethoxy)][2-Nal]K(7c)E(1c)[Dab][3-(3- Pyridyl)-Ala](7c)^ 77 CC(C)[C@@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCCNC(= O)CC[C@@H]3NC(=O)[C@H](CCCCNC(=O)[C@H](Cc4cccnc4)NC(=O)[C @H](CCN)NC3=O)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc( OCCN)cc3)NC(=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc2c[nH]c3ccccc23)NC1=O K(1c)(6c)^IVWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3,5- Pyrimidyl)-Ala]-[NHMe] 78 CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N [C@@H](CCN)C(=O)N[C@@H](Cc3cncnc3)C(=O)NC)NC(=O)[C@](C)(CC( C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN)cc3)NC (=O)[C@H](CCC(=O)N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH] c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O K(1c)(6c)^[3-Aminopropanoyl][1-Me-Trp]QE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 79 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3cn(C)c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN) cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N 1 [N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 80 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2- Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 81 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCN(C)C2=O)C(=O)N[C@@H](Cc2ccc(OCC N)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O) N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Cyclopropyl-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 82 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](CC2CC2)C(=O) N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(3-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 83 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2cccnc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(2-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 84 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccccn2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[3-(4-Pyridyl)-Ala][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 85 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccncc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)H[3-(3-Pyridyl)-Ala]-[NHMe] 86 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1 CCC(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC (=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(3-Pyridyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 87 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1cccnc1)NC(=O)[C@@H]1CC C(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(= O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(2-Pyridyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 88 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1ccccn1)NC(=O)[C@@H]1CC C(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(= O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[3-(4-Pyridyl)-Ala][3-(3-Pyridyl)-Ala]-[NHMe] 89 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@@H]1CC C(=O)NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(= O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 [Orn](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 90 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H] (Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2) C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1Compound Structure [Orn](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 91 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H] (Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2 )C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [Dab](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 92 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 93 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O )N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [Dab](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 94 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C @@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [Dpr](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 95 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C c3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@ @H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[beta-hIle]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 96 CC[C@H](C)[C@H]1CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H ](CCC(N)=O)C(=O)N[C@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H]( C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NC)NC(=O)[C@]( C)(CC(C)C)NC(=O)[C@H](Cc3ccc4ccccc4c3)NC(=O)[C@H](Cc3ccc(OCCN) cc3)NC2=O)C(=O)N1 K(1c)(6c)^[beta-hThr]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 97 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)C[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@ @H](Cc2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@]( C)(CC(C)C)C(=O)N1Compound Structure K(1c)(6c)^[4-Aminobutanoyl]WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 98 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN )cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N 1 [beta-hLys](1c)(6c)^GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 99 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2CC(=O)NCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc( OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C) C(=O)N1 [beta-hLys](1c)(6c)^[beta-hTrp]QE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 100 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2CC(=O)N[C@@H](Cc3c[nH]c4ccccc34)CC(=O)N[C@@H](C CC(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [beta-hLys](1c)(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 101 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2CC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CC C(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2) C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Lys](1c)^(6c)WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 102 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C @@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Dab](1c)^(6c)WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 103 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc 3c[nH]c4ccccc34)NC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(=O)N[C@ @H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Lys](1c)^(6c)GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 104 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]( Cc3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1Compound Structure [iso-Dab](1c)^(6c)GWQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 105 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) N[C@H]2CCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc 3c[nH]c4ccccc34)NC(=O)CNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]K(1c)[Dab][3- (3-Pyridyl)-Ala]-[NHMe] 106 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCCN C(=O)[C@@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](C CC(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc 2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Dab](1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 107 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCNC(= O)[C@@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CCC (N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [{d}iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu]K(1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 108 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCCCN C(=O)[C@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CC C(N)=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2) C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 [{d}iso-Glu](1c)^(6c)^WQE(6c)[Y(2-aminoethoxy)][2-Nal][2-Me- Leu][Dab](1c)[Dab][3-(3-Pyridyl)-Ala]-[NHMe] 109 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCNC(= O)[C@H]2CCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CCC(N )=O)C(=O)N[C@@H](CCC(=O)N2)C(=O)N[C@@H](Cc2ccc(OCCN)cc2)C(= O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)W[2-Nal][2-Me-Leu]E(1c)[Dab][3-(3- Pyridyl)-Ala]-[NHMe] 110 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2c[nH]c3cccc c23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N 1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[Q(Me)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 111 CNC(=O)CC[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCNC(=O )[C@@H]2CCCCNC(=O)CC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@@ H](Cc3cccnc3)C(=O)NC)NC(=O)C(C)(C)NC(=O)[C@H](Cc3ccc4ccccc4c3)N C(=O)[C@H](Cc3ccc(OCCN)cc3)NC(=O)[C@H](CCC(=O)N2C)NC1=OCompound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-morpholine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 112 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(N3CCO CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4-Diaminobutanoyl(Ac-N- Me)]E(6c)[Y(2-aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3- Pyridyl)-Ala]-[NHMe] 113 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCN(C)C(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc 2ccc(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N 1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4-Diaminobutanoyl(Ac)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 114 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCNC(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2cc c(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal]{d}AE(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 115 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@H](C)C(=O)N1 {d}K(1c)(6c)^[3-Aminopropanoyl]WQ{d}E(6c)[Y(2-aminoethoxy)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 116 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2NC(=O)CC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCCN)c c2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-THP)][2Nal][2-Me-Leu]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 117 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(C3CCO CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1Compound Structure N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 118 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CH3-2-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 119 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC)cc2 F)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[2,4-Diaminobutanoyl(Ac)]E(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 120 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCNC(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2cc c(OCCN)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-F)][2Nal][Aib]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 121 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (F)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-piperazine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 122 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(N3CCN CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-imidazole)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 123 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(- n3ccnc3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C )C(=O)N1Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CH3-3-F)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 124 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC)c(F) c2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl]-[NH-2-(pyridin-3-yl)ethyl] 125 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)NCCc3cccnc3)NC1=O)C(=O)NCCC(=O)N[C@@H](Cc1c[ nH]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(=O)N2 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-piperidine)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 126 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(C3CCN CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[5- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 127 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ccncc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(Ac-2-aminoethoxy)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 128 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC- CNC(C)=O)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C )C)C(=O)N1 K(1c)(6c)^[N-Me-3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]- [NHMe] 129 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCN(C)C2=O)C(=O)N[C@@H](Cc2ccc(OCC N)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1Compound Structure N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 130 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]WQE(6c)[6- AzaTrp][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 131 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3cnccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys-oxy-propanoyl(1c)(6c)^WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 132 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)OCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 N-Me-Lys](1c)(6c)^[3-Aminopropanoyl]W[2,4- Diaminobutanoyl(Ac)]E(6c)[Y(CH3)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3- Pyridyl)-Ala]-[NHMe] 133 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCNC(C)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2cc c(OC)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c^[3-Aminopropanoyl]WQE(6c)[F(4-F)][2Nal][2-Me-Leu]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] 134 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(F)cc2)C (=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O)N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- CONH2)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 135 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (C(N)=O)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1Compound Structure K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala][3- Aminopropanoyl]-[NH2] 136 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)NCCC(N)=O)NC1=O)C(=O) NCCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCC(N)=O)C(= O)N2 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]{d}H- [NH2] 137 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)N[C@H](Cc3cnc[nH]3)C(N) =O)NC1=O)C(=O)NCCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@ H](CCC(N)=O)C(=O)N2 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(2- aminoethoxy)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]{d}W- [NH2] 138 CC1(C)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccc(OCCN)cc2) NC(=O)[C@@H]2CCC(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C @@H](CCN)C(=O)N[C@@H](Cc3cccnc3)C(=O)N[C@H](Cc3c[nH]c4ccccc3 4)C(N)=O)NC1=O)C(=O)NCCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[ C@@H](CCC(N)=O)C(=O)N2 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[Y(CF3)][2Nal][2-Me-Leu]E(1c)[2,4- Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 139 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OC(F)(F )F)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O )N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] 140 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2c[n H]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl]WQ{d}E(6c)[Y(2-aminoethoxy)][2Nal][2-Me- Leu]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 141 NCCCC[C@@H]2NC(=O)CC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C @H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(OCC N)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C(=O) N1Compound Structure N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]W[Q(2Me)]E(6c)[7- AzaTrp][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O 142 )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(=O)N(C)C)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc 2c[nH]c3ncccc23)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O) N1 N-Me-Lys(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4- morpholine)][2Nal][Aib]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O 143 )NCCCC[C@H]2C(=O)NCCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C @@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)N2C)C(=O)N[C@@H](Cc2ccc (N3CCOCC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O) N1 K(1c)(6c)^[3-Aminopropanoyl]WQE(6c)[F(4-morpholine)][2Nal][2-Me- Leu]E(1c)[Ser(OCH3)][3-(3-Pyridyl)-Ala]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](COC)NC(=O)[C@@H]1CCC(=O 144 )NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@ H](Cc3c[nH]c4ccccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc(N3CCO CC3)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@](C)(CC(C)C)C( =O)N1 K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][Q(2Me)]E(6c)[Y(2- aminoethoxy)(N(Me)2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- alanyl]-[NHMe] 145 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N(C)C)NC(=O) [C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCN(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C(=O)N 1 K(1c)(6c)^[3-Aminopropanoyl][7MeTrp][Q(2Me)]E(6c)[Y(nPentylamine) (N+(Me)3)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-alanyl]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 146 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N(C)C)NC(=O) [C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCCCC[N+](C)(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)( C)C(=O)N1 K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][Q(2Me)]E(6c)[Yr(2-trimethyl- PEG2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)-alanyl]-[NHMe] CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) 147 NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N(C)C)NC(=O) [C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O)C(=O)N[C@@H](Cc2ccc( OCCOC- COCC[N+](C)(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NC(C)(C)C (=O)N1Compound Structure K(1c)(6c)^[3-Aminopropanoyl][7-Me-Trp][K(NMePEG3)]E(6c)[Y(2- aminoethoxy)(N(Me)2)][2Nal][Aib]E(1c)[2,4-Diaminobutanoyl][3-(3-Pyridyl)- alanyl]-[NHMe] 148 CNC(=O)[C@H](Cc1cccnc1)NC(=O)[C@H](CCN)NC(=O)[C@@H]1CCC(=O) NCCCC[C@@H]2NC(=O)CC[C@H](NC(=O)[C@H](CCCCN(C)C(=O)COC- COCC[N+](C)(C)C)NC(=O)[C@H](Cc3c[nH]c4c(C)cccc34)NC(=O)CCNC2=O )C(=O)N[C@@H](Cc2ccc(OCCN(C)C)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c 2)C(=O)NC(C)(C)C(=O)N1 or a pharmaceutically acceptable salt or solvate thereof; wherein:^denotes that the (1c), (6c), (6g), and (7c) bridges use the alpha-amine group (or beta- amine group for bLys, {d}bLys and beta-hLys, or the alpha-amine converted into an azide group for (N3)-K and {d}(N3)-K) of the amino acid in the bridge^denotes that the (1c), (6c), (6g), and (7c) bridges use the alpha-carboxylic acid group of the amino acid in the bridge (1c) denotes the [2,11] lactam bridge; (6c) denotes the [2,7] lactam bridge; (6g) denotes the [2,7] 1,4-disubstituted 1,2,3-triazole bridge; (7c) denotes the [10,13] lactam bridge.

24. A pharmaceutical composition comprising a compound according to any one of the preceding claims in combination with a pharmaceutically acceptable carrier, excipient or vehicle.

25. The pharmaceutical composition according to claim 24, wherein said pharmaceutical composition is for oral administration.

26. A method for the synthesis of a compound according to any one of claims 1 to 23, comprising synthesising the analogue by solid-phase or liquid-phase peptide synthesis methodology, optionally isolating and / or purifying the final product, and optionally further comprising the step of forming an amide bond between the amino acid residues at positions X2 and X11, and optionally further comprising the step of forming an amide bondor forming a triazole between the amino acid residues at positions X2 and X7, and optionally further comprising the step of forming an amide bond between the amino acid residues at positions X10 and X13.

27. A compound according to any one of claims 1 to 23, or a pharmaceutical composition according to any of claims 24-25, for use in a method of medical treatment.

28. A compound according to any one of claims 1 to 23, or a pharmaceutical composition according to any of claims 24-25, for use in a method of prevention or treatment of a disease or condition selected from inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, and combinations thereof.

29. The compound or pharmaceutical composition for use according to claim 28, wherein the IBD is selected from Crohn^s Disease or ulcerative colitis.

Images